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Abbreviations 
 
 
 
ACP    Acyl carrier protein 
AT   Acyl transferase 
BLAST   Basic Local Alignment Search Tool 
CoA   Coenzyme A 
CD   Circular dichroism 
Cryo-EM  Single-particle cryo-electron microscopy 
DEBS   6-Deoxyerythronolide B synthase 
DH   Dehydratase 
E.   Escherichia 
ECH   Enoyl-CoA-hydratase 
ER   Enoyl reductase 
FAS   Fatty acid synthase 
FDA    Food and Drug Administration 
GNAT   GCN5-related N-acetyltransferase 
GTP   Guanosine triphosphate 
HCS   Hydroxylmethylglutaryl-ACP-synthase 
HEPES   2-[4-(2-Hydroxyethyl) piperazin-1-yl] ethanesulfonic acid 
HMG-CoA  3-Hydroxy-3-methylglutaryl-coenzyme A 
HMGS   Hydroxymethylglutaryl synthase 
HR   Highly-reducing 
HRMS   High resolution mass spectrometry 
KR   Ketoreductase 
KS   Ketosynthase 
LC-ESI-MS  Liquid chromatography-electrospray ionization-mass spectrometry 
MALDI  Matrix-assisted laser desorption/ionization 
MCoA   Malonyl-CoA 
MS   Mass spectrometry 
MT   Methyl transferase 
MWCO  Molecular weight cut-off 
NMR   Nuclear Magnetic Resonance 
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NR   Non-reducing 
NRPS   Nonribosomal peptide synthetase 
PDB   Protein data bank 
PKS   Polyketide synthase 
PPant   Phosphopantetheine 
PPTase  4'-Phosphopantetheinyl transferase 
PR   Partially-reducing 
R & D   Research and Development 
SAH   S-Adenosyl-L-homocysteine 
SAM   S-Adenosyl-L-methionine 
SAXS   Small-angle X-ray scattering 
SNAC   N-acetylcysteamine 
TE   Thioesterase 
TOF   Time of flight 
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1 Introduction 
 
1.1 Natural products in drug discovery 
Nature has long been a definitive resource for basic human needs, especially for medicinal 
purposes. Natural products, with a history dating back to 2600 BC, serve as ingredients of 
traditional indigenous medicine in treating common ailments like colds, coughs and 
inflammation.1 With their intrinsic pharmacophore conformations and biological activities, 
natural products also function as excellent starting points to tailor them into drugs, and hence 
hold high value in the drug discovery process.1-3 About one-third of the FDA-approved drugs in 
use today belong to natural products and their derivatives.4 These compounds include most of 
the known classes of antibiotics including the β-lactams, aminoglycosides, tetracyclines, 
macrolides, glycopeptides and lipopeptides.5 Natural products are mainly produced by plants, 
bacteria and fungi and broadly belong to the structural classes of polyketides, nonribosomal 
peptides, terpenes, ribosomally synthesized and posttranslationally modified peptides and 
alkaloids. They target a wide variety of proteins (enzymes) and function as inhibitors or 
modulators of protein-protein interactions.6 Consequently, they display diverse biological 
activities, acting as antibiotics, antiparasitics, antimalarials, statins, immunosuppressants, and 
anticancer agents, among others.7  
The use of antibiotics puts selective pressure on microbes to develop multidrug resistance, 
which is compounded by their indiscriminate use. Therefore, there is an ongoing need for the 
discovery and development of new antibiotics. Despite this growing need, there exists marked 
gap in the discovery of new class of antimicrobial compounds over the past 30 years. This 
innovation gap is partly due to the decline of natural product research in many pharmaceutical 
companies. The diminished interest in natural product-based drug discovery could be 
attributed to several reasons.6, 8-10 First, the commonly practiced strategy of screening chemical 
libraries against defined targets in a high-throughput assay is not amenable to natural 
products of low natural abundance as they are often synthetically intractable on the required 
scale. Second, the growing interest in combinatorial chemistry resulted in synthetic 
combinations of compounds rather than natural product-based libraries and finally, the 
pressure for a short-time discovery of new leads precludes products from natural sources. 
However, with the emerging trends on genome mining and other R & D approaches, there is a 
renewed interest in using natural products as sources for lead identification and 
development.11, 12 
Natural products have been the target for synthetic chemists and synthetic biologists alike, 
with a focus on developing analogues with enhanced activity.13 Some of the examples of natural 
products and their derivatives are shown in figure 1.1.  
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Figure 1.1 Natural products and their derivatives in clinical use 
Avermectin B1a (1) belongs to the group of polyketides isolated from Streptomyces avermitilis 
that exhibit potent anthelmintic and insecticidal properties.14 Ivermectin (2), the synthetic 
dihydro derivative of avermectin B1a, has led to a significant reduction of river blindness in 
Africa and of scabies in India and Southeast Asia.15 Being a broad spectrum antiparasitic agent, 
ivermectin is also effective against human parasitic worm infestations including lymphatic 
filariasis.16 Hence it may come as no surprise that the discovery of ivermectin has been 
awarded a Nobel prize in 2015 and it is on the WHO’s list of essential medicines.17 
Pneumocandin B0 (3) is a lipohexapeptide isolated from the fungus Glarea lozoyensis and 
belongs to the class of echinocandins.18 Caspofungin (4), a semisynthetic derivative of 
pneumocandin B0, is the first glucan-inhibiting antifungal drug approved by the FDA against 
the human pathogen Candida albicans.19 Selective chemical modifications of natural products 
have also resulted in reduced cytotoxicity of the anticancer agents such as the β-tubulin-
binding epothilone B (5). The epothilones are effective microtubule disruptors initially isolated 
from the Myxobacterium Sorangium cellulosum.20 Ixabepilone (6) is one of the synthetic 
analogous of epothilone B with substitution in its macrolide ring. This drug has been approved 
by the FDA to treat metastatic or advanced localized breast cancer.21  
Semisynthetic strategies have also been employed towards addressing the problem of drug 
supply shortage. Artemisinin (7) is a sesquiterpene endoperoxide with a unique 
pharmacophore (1, 2, 4-trioxane peroxide), initially isolated from the plant Artemisia annua.22 
Artemisinin and its derivatives have played an effective role in combating the deadly malaria 
caused by Plasmodium falciparum and Plasmodium vivax worldwide. A recent assessment 
shows that artemisinin combination therapies have averted nearly 22% of the 663 million 
clinical cases in the period 2000-2015.23 As an alternative for extracting artemisinin from huge 
plant cultures, an engineered Saccharomyces cerevisiae strain produces its precursor, 
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artemisinic acid in very high yields.24 Semi-synthetic artemisinin is now routinely derived from 
artemisinic acid in a two-step reaction.25 The research on artemisinin has not only led to a 
Nobel prize, but also to a new direction for the synthesis of peroxide-based antimalarial 
drugs.26 The alkaloid trabectedin (8) is an example for a product isolated from a symbiont of 
the sea squirt Ecteinascidia turbinata27 which is in clinical use for soft tissue sarcoma and 
relapsed ovarian cancer.28 The supply problem of this compound was met by a semisynthetic 
strategy commencing with a precursor, cyanosafracin B from Pseudomonas fluorescens.29  
 
Paclitaxel (9) is a complex diterpene isolated from the Pacific yew Taxus brevifolia.30 It is a 
microtubule-stabilizing drug and is in clinical use for the treatment of a number of cancers 
including ovarian, breast, pancreatic and lung cancers.31 Synthetic approaches towards the 
production of paclitaxel led to the development of several analogues including cabazitaxel. 
This semi-synthetic drug is being used for the treatment of hormone-refractory metastatic 
prostate cancer in combination with prednisone.26 The polyketide lovastatin (10) isolated from 
Aspergillus terreus was the first commercialized HMG-CoA reductase inhibitor of the 
cholesterol biosynthesis.32 Further biotransformation experiments with an esterase (LovD) to 
convert the 2-methylbutanoate side chain to 2, 2-dimethylbutanoate led to an improved drug, 
simvastatin (11).10 The statin family of drugs are easily one of the best-selling pharmaceutical 
drugs to date in treating hypercholesterolaemia.33 
Clearly, natural products are being extensively useful in drug discovery efforts. However, only a 
miniscule of the earth’s soil surface has been screened for antibiotic production,9 leaving 
plenty of room for exploration, also pertaining to sources other than soil. In addition to the 
discovery of new compounds, combinatorial biosynthesis (i.e. reprogramming natural product 
biosynthetic pathways to produce novel compounds) holds great promises in lead 
development. The enzymes that constitute natural product biosynthetic pathways have 
emerged as excellent biocatalysts to create novel natural product analogues with increased 
bioactivity.34 Therefore, studying the biosynthesis of natural products becomes highly 
imperative to generate compounds with defined stereochemistry that might be difficult to 
generate using synthetic chemistry. 
The building blocks for polyketides, nonribosomal peptides and terpenes are most often their 
simple monomer constituents – acyl-CoA thioesters, amino acids and isoprenyl-
pyrophosphates, respectively. In the following sections, the biosynthesis of natural products 
with an emphasis on polyketides is explained in detail. 
 
1.2 Polyketide biosynthesis 
1.2.1 Basic mechanisms 
Polyketides belong to a structurally diverse class of natural products, encompassing 
macrolides, polyphenols, polyethers, enediynes and many more.35 The structural diversity of 
polyketides mirrors the myriad biological activities including, but not limited to, antimicrobial, 
antiproliferative and immunosuppressive effects.10, 36, 37 
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Equally astonishing as the diversity of polyketides are the enzymatic machineries that 
assemble them, with a stark similarity to the fatty acid synthases.38 Typically, polyketides are 
synthesized by polyketide synthases (PKSs) via the successive coupling of esters through a 
Claisen condensation.35 The starter units add to the chemical complexity of the polyketides 
which ranges from the common isobutyryl- or isovaleryl-CoA, to the unusual p-nitrobenzoate, 
glycolate, glycyl moieties and so on.39, 40 Aside from malonyl-, the extender units can also be 
their 2-substituted methyl-, methoxy-, ethyl- or chloroethyl-derivatives.41 A typical reaction 
cycle in the biosynthesis of polyketides involves an acyl carrier protein (ACP), to which the 
growing intermediates are tethered to the thiol group of its 18 Å swinging phosphopantetheine 
(PPant) arm, an acyl transferase (AT) that selectively activates and loads simple or substituted 
malonyl-extender units on the ACP and a ketosynthase (KS) which then decarboxylates the 
extender unit and condenses with the acyl-intermediate (or a starter unit). The growing chain 
is therefore extended by two carbon atoms in each cycle. The nascent formed β-keto group can 
be processed further by optional enzymes such as ketoreductases (KRs), dehydratases (DHs) 
and enoylreductases (ERs) to afford β-hydroxyl, α,β double bond and fully-reduced methylene 
moieties, respectively (Figure 1.2a).35   
 
Figure 1.2 a) Schematic of polyketide biosynthesis.35 Wavy bond in ACP refers to its 
phosphopantetheine arm. b) Examples of bioactive polyketides. 
In most characterized PKSs, the thioester linkage attaching the polyketide intermediate to the 
terminal ACP is cleaved by a thioesterase (TE) by simple hydrolysis with bulk solvent or 
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intramolecular cyclization with a nucleophile on the polyketide;42-44 however, other offloading 
mechanisms are known.45, 46 Several tailoring modifications might follow the offloading step 
including acylation, alkylation, hydroxylation, oxygenation, halogenation and glycosylation.47 
Together with the modifications introduced by the post-PKS tailoring enzymes, the structural 
diversity of polyketides can be attributed to the chain size, diversity of starter and extender 
units, alterations in the oxidation state, configuration of the β-keto groups and offloading 
mechanisms (Figure 1.2b).35  
1.2.2 The ketosynthase domain 
The ~430 residue β-ketoacyl-S-ACP synthase, or the KS domain, catalyzes the core carbon-
carbon bond formation that result in the chain elongation in polyketide and fatty acid 
biosynthesis.48 The KS domain is highly conserved and possesses a thiolase fold with 
alternating layers of 2α-5β-2α-5β-2α architecture (Figure 1.3a). The KS forms a dimer and its 
dimeric interface largely contributes to the dimerization of the entire PKS module. Typically, 
KS domains have a Cys-His-His catalytic triad found in the TACSSS, EAHGTG and KSNIGHT 
motifs.48 Although the reaction mechanism catalyzed by the KS is not fully understood, studies 
of the KS domains from bacterial and mammalian fatty acid synthases have provided insights 
into the role of the conserved amino acids.49-51 The cysteine nucleophile is located at the KS 
dimer interface and its nucleophilicity is enhanced by the helix dipole effect. Mutational 
experiments revealed that Cys is pivotal for the transthioesterification, where it attacks the 
thioester of an acyl-ACP upon its entry into the substrate channel. The negative charge on the 
thioester carbonyl is stabilized by the backbone amides of the Cys164 and Phe396 residues that 
constitute the oxyanion hole (Figure 1.3b).49  
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Figure 1.3 a) KS dimer of the DEBS KS module 5 (PDB code: 2hg4)52 with the active site cysteine 
shown as spheres. The figure was generated using Pymol.53 b) Proposed mechanism of chain 
elongation catalyzed by a typical KS domain exemplified by the FabF KS49 c) Active center of 
FabF of fatty acid biosynthesis from Streptococcus pneumoniae.49 Pink ball refers to the 
oxyanion hole; pink dots represent the backbone amide interactions; and red dots refer to the 
hydrogen bonds. 
Following acylation of the KS active site cysteine, the ACP is released and the extender unit 
(malonyl or substituted malonyl) is loaded to the upstream ACP. At this stage, the KS catalyzes 
the decarboxylation of the extender unit. One of the histidines activates a structured water 
molecule to attack the malonyl-ACP C3 carboxylate, to release bicarbonate. The resulting 
negatively charged enolate oxygen is stabilized by the other histidine. Notably, this 
decarboxylation reaction is independent of Cys acylation as KS domains in which the Cys is 
mutated to Ala or Gln retained the ability to decarboxylate the extender units.54, 55 In the 
condensation step, the enolate attacks the acyl-thioester to afford a tetrahedral intermediate 
stabilized by the oxyanion hole (Figure 1.3b). After resolution of the tetrahedral intermediate, 
the β-ketoacyl-ACP product dissociates from the active site and associates with either the β-
keto reductive domains (if they are present) or to the downstream module for further 
elongation/modification. Apart from the residues that comprise the critical catalytic triad, 
other residues with notable functions include Lys332 that contributes to the hydrogen bond 
network and Phe396 located on a hairpin turn that functions as a ‘gatekeeper’ that controls the 
order of the substrate addition, (residue numbers correspond to FabF KS from S. pneumoniae) 
(Figure 1.3c).49 A proper orientation of the KS active site residues is essential for its substrate 
selectivity, and therefore the decarboxylative condensation reaction.  
The mechanism described above corresponds to KS I and KS II-type of enzymes.49, 56 The KS 
III-type enzymes utilize distinct substrates and catalytic residues.57 They are present across 
different types of PKSs, as described in the following section.  
1.2.3 Classification of PKSs 
Owing to the varied structure and mode of action, PKSs are classified into three distinct types 
–type I, type II and type III PKSs, analogous to the fatty acid synthases (FASs).58, 59 Although 
the reaction chemistry of PKSs is similar to FASs, PKSs have evolved to use a broader range of 
building blocks leading to the formation of diverse products.59 Type I PKSs are multifunctional 
megaenzymes (up to ~10 MDa) with covalently fused catalytic domains arranged on a large 
polypeptide.60 Type I PKSs are mainly found in prokaryotes and are subdivided into two major 
groups: modular and iterative (Figure 1.4a).61 The classical example for a bacterial modular 
type I PKS is the 6-deoxyerythronolide B synthase (DEBS) responsible for the synthesis of the 
agylcone core of the antibiotic erythromycin.62 In this case, each PKS ‘module’, where all the 
catalytic ‘domains’ are grouped, is involved in a single round of incorporation and reductive 
processing of a C2 unit. Therefore, the number of modules can directly be translated to the 
number of precursors incorporated and therefore the expected product structure, a principle 
defined as ‘colinearity’.63, 64 Iterative type I PKSs possess the same core catalytic domains as the 
modular PKSs, but the domains are arranged on a single polypeptide that functions in an 
iterative fashion to form the entire product.58, 65 Fungal iterative PKSs generate aromatic 
polyketides such as lovastatin, with varying degrees of reduction and are further classified into 
nonreducing (NR), partially reducing (PR) and highly reducing (HR) PKSs.66 In recent years, 
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bacterial iterative PKSs have been characterized that produce highly complex molecules such 
as enediynes and tetramate macrolactams.67  
Type II PKSs are dissociable complexes of discrete enzymes typically with single functions. 
They are present only in bacterial systems and contain the same core catalytic domains found 
in type I PKSs. The exception is the presence of two KS domains, KSα which catalyzes iterative, 
decarboxylative extension of the starter unit and KSβ, which controls the length of the 
polyketide intermediate (Figure 1.4b).68 There is little or no reductive processing of the β-keto 
group but subsequent cyclizations generate aromatic molecules such as the anticancer drugs 
daunorubicin and doxorubicin.69, 70  
Both type I and type II PKSs rely on the thiotemplate mechanism where the substrates and the 
growing intermediates are covalently attached to the PPant arm of the ACP domain. In 
contrast, type III PKSs utilize free CoA-linked thioester substrates and a single enzyme 
catalyzes acyl group transfers (Figure 1.4c).71 Type III PKSs are present mainly in plants but 
also in fungi and bacteria (for example, 3, 5-dihydroxyphenylglycine synthase).72, 73 
In addition to these PKSs, integrated NRPS-PKS hybrids are also responsible for the synthesis 
of many active compounds like epothilone and FK-506.74, 75  
 
Figure 1.4  Representation of PKS systems from76 a) type I PKS (modular and iterative) b) type II 
PKS and c) type III PKS 
 
1.2.4 Trans-AT PKSs 
The colinearity of type I PKSs described above is limited to the class of cis-AT PKSs, in which 
the AT domains are integral parts of the modules (figure 1.4a). Recently, the complexity of 
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polyketides has been further expanded by a second class of modular system termed as trans-
AT PKSs.77-81 A recent analysis of PKS-specific genes in bacterial genomes revealed that almost 
38% of the modular PKSs belong to the trans-AT type, suggesting that trans-AT PKS-generated 
polyketides contribute to a major class of natural products.82 One prominent feature of trans-
AT PKSs is the absence of integrated AT domains within their modules. Instead, stand-alone 
AT domains activate and load malonyl or substituted-malonyl units on the ACP.78 The complex 
diversity of this class of polyketides can be attributed to the presence of inactive domains, 
module skipping, unusual domain orders, split modules (divided on two proteins) and the 
presence of other trans-acting enzymes such as ERs.83, 84 Phylogenetic analysis of trans-AT 
PKSs revealed that these enzymes have evolved by horizontal gene transfer that allowed 
recombination of PKS genes. In contrast to the phylogeny of cis-AT PKSs where the enzymes 
are grouped according to the polyketide types, trans-AT PKSs are grouped based on the 
substrate selectivity of KSs.85 Several non-canonical modules are housed in the trans-AT PKSs 
such as GNAT loading modules,86 non-elongating modules with inactive KS domains,87 
modules that perform double bond migration88 and modules that generate a β-branch and/or 
rings. Due to their inherent mosaic architectures, the trans-AT PKSs are attractive targets for 
engineering and reprogramming strategies.89 Among the trans-AT-derived polyketides, 
compounds with α- or β-branches represent an interesting class, as the alkyl branches serve as 
precursors for chemical diversification of functional groups in polyketides. 
 
1.2.5 Structures of PKSs – opportunities for synthetic biology 
The mechanisms of cis-AT and trans-AT PKSs are remarkably complex in that each catalytic 
domain must communicate with many others throughout the modular architecture. 
Understanding how these domains work in concert would greatly facilitate the engineering of 
the PKSs to generate novel metabolites. However, it is extremely challenging to generate a 
crystal structure of an intact PKS module mainly due to the inherent flexibility of the domains. 
Owing to the conserved homology between the FASs and PKSs, the first reported high 
resolution crystal structure of porcine FAS90, 91 propelled generation of several models of the 
cis-AT PKS modular architecture. These models were built on the mammalian FAS as well as 
based on the structures of individual domains and didomains.48, 92-94 Nevertheless, marked 
differences were observed in the oligomeric state of the domains and the domain interfaces 
between FASs and PKSs. In 2014, the first structures of an intact PKS module were reported for 
the pikromycin PKS module 5 (KS-AT-KR-ACP) by single-particle cryo-EM and for the DEBS 
module 3-TE (KS-AT-KR-ACP-TE) and the bimodules 5 and 6 by SAXS.95, 96 The structures 
revealed that the domains undergo extensive conformational changes adopting up to seven 
functional states in a single step of biosynthesis. The interdomain linkers play a massive role in 
allowing free movement of ACP to and from neighboring domains and also function as 
structural motifs. 
However, understanding the structure-function relationships of linkers is incomplete without 
a high-resolution structure. Very recently, hybrid crystal structures have been reported for the 
condensing (KS-AT) and modifying (DH-ΨKR-ER-KR) regions of the Mycobacterium 
smegmatis drug target mycerosic acid synthase (MAS), a fully reducing iterative PKS. The 
modifying region revealed a linker-based dimeric architecture that could be exploited for PKS 
engineering approaches.97 Although the reported structures advance the basic understanding 
Introduction  Polyketide biosynthesis 
 
  11 
 
of the dynamic cis-AT PKS architecture, we are only beginning to understand how the domain 
arrangement and intersubunit communication occurs in case of the complex trans-AT PKSs. In 
contrast to a number of high resolution structures of the cis-AT PKS domains,48 very few 
structures of trans-AT PKSs are available. The only available structure of an intact module 
from the trans-AT family is the low resolution structure of module 5 (KS-ACP-ACP) from 
virginiamycin PKS.98 In light of the very few high resolution structures available from the 
trans-AT family, the AT from disorazole synthase, the solution structure of a tandem ACP from 
the mupirocin β-branching cassette, the KS of module 2 from bacillaene PKS are some 
examples for structures from individual domains.99-101  
Knowledge on the structure of PKSs would propel the genetic engineering approaches further. 
The first example of combinatorial biosynthesis surfaced in 1989 where a carbomycin 
biosynthetic gene from Streptomyces thermotolerans produced isovalerylspiramycin in S. 
ambofaciens.102 Since then, several strategies have been implemented to selectively insert, 
exchange or delete domains and modules to generate hybrid compounds.103, 104 One of the well-
established examples for combinatorial biosynthesis of complex polyketides is the synthesis of 
structural and functional variants of erythromycin.105, 106 In recent years, thanks to the 
advanced genetic and molecular biology techniques now available, it is possible to identify, 
express and manipulate diverse biosynthetic pathways in heterologous hosts. This ‘synthetic 
biology’ approach, geared towards the specific modification of individual PKS domains, is 
gaining attention either as an alternative or a parallel approach to combinatorial 
biosynthesis.107  
 
As more structures of individual domains or subunit domains are obtained, the boundaries of 
domains within the assembly line are coming into focus. Especially for the trans-AT PKSs, 
considerable progress has been made in understanding their function by studying individual 
domains using in vitro biochemical techniques.89 Such in vitro analyses depend on the 
availability of suitable substrates, production of functional proteins and the usage of high 
resolution techniques such as mass spectrometry, NMR and X-ray crystallography. Only if the 
domain junctions and the linker regions of PKSs are better defined, can the true potential of 
PKS engineering to produce novel compounds be realized. 
 
This thesis focusses on a trans-AT derived macrolide with a pharmacophoric moiety formed as 
a result of an unusual C-C bond forming mechanism. The biosynthesis of this macrolide has 
been mentioned in detail in the following section. 
 
 
 
Introduction  Rhizoxin 
 
  12 
 
1.3 Rhizoxin  
1.3.1 Isolation, mode of action and biosynthesis 
Compounds that target the microtubules either to block their depolymerization or to inhibit 
their assembly belong to the most effective class of chemotherapeutics.108 Rhizoxin (15), a 16-
membered macrolide (Figure 1.5a), was first isolated from the pathogenic fungus Rhizopus 
microsporus in 1984, and shown to be the causative agent of rice seedling blight.109 The 
structure of rhizoxin features 11 stereogenic centers, two epoxides, an oxazole and the 
pharmacophoric δ-lactone.110 Rhizoxin alone was shown to induce abnormal swelling and 
malformation of the rice seedling roots, by binding to the rice cell β-tubulin and thereby 
inhibiting cell division.111 Rhizoxin and its derivatives inhibit tubulin-dependent GTP 
hydrolysis, microtubule assembly (IC50 – 5μM) and caused extensive depolymerisation of the 
microtubules in human and murine tumor cell lines.111, 112 Although rhizoxin entered clinical 
trials as an antitumor agent, poor in vivo efficacy prevented the compound and derivatives 
from progressing beyond phase II trials.113, 114 The unique structure of rhizoxin nevertheless 
triggered several total synthetic approaches with the aim to generate stable derivatives; 
however, these studies have not resulted in a clinically successful compound.115, 116 Stable 
isotope labeling experiments with 13C labeled acetate, methionine, serine and glycine 
demonstrated that the biosynthesis of rhizoxin involved a PKS.117 However, failure to identify 
fungal-specific PKS genes led to the unexpected finding that the actual producer of rhizoxin is 
not the rice-plant residing fungus Rhizopus microsporus, but a bacterial endosymbiont, 
Burkholderia rhizoxinica that lives in the fungal cytosol.118 The bacterium isolated from the 
fungus was amenable to genetic manipulation and produced several rhizoxin derivatives in 
pure culture, with enhanced antiproliferative activities.119 This example was the first of its kind 
to establish a metabolite connection in a plant-bacterial-fungal symbiotic association. The 
Burkholderia-Rhizopus symbiosis spreads across diverse ecological niches throughout the 
world.120 The report parallels the endosymbiotic metabolites isolated from other eukaryotes 
like tunicates, sponges or insects.121  
By cloning and gene inactivation experiments, the gene cluster responsible for rhizoxin 
biosynthesis was subsequently identified to be a type I trans-AT PKS-NRPS hybrid gene 
cluster. The proteins that comprise this PKS-NRPS hybrid are encoded by five open reading 
frames, rhi A-F and are arranged into modules that uses serine and malonate as the building 
blocks. The compound released from the assembly line is devoid of the C2-C3 and C11-C12 
epoxide moieties and the C17 O-methyl group (Figure 1.5a). The C11-C12 epoxidation and C17 
O-methylation are part of the post-PKS tailoring reactions catalysed by RhiH and RhiI, 
respectively.122 The second epoxidation is carried out by the fungal host by an unidentified 
enzyme. Although not required for bioactivity, the epoxidation at C2-C3 makes the molecule 
more potent. The Rhi PKS exhibits rare features typical of a trans-AT system, with a disrupted 
NRPS module 1 and PKS module 3, a silent KS-ACP divided between modules 8 and 9, an 
acetate-derived C5 β-branching between modules 10 and 11.122 An identical but silent gene 
cluster was also found in Pseudomonas fluorescens, a biocontrol agent present in plant 
rhizosphere.123 P. fluorescens produces several rhizoxin analogues that are toxic to fungal and 
oomycete plant pathogens.124 This revealed the ecological role of rhizoxin to be dependent on 
the tolerance or sensitivity of the plant itself. In case of Rhizopus-sensitive rice plants, the 
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bacterium, in return for the nutrients from fungus, produces rhizoxin which the fungus then 
uses to kill the rice seedling.125 However, for rhizoxin-tolerant plants, P. fluorescens can 
associate with the plant and produce rhizoxin that protects the plant against fungal pathogens.  
Although the discovery of rhizoxin failed to make a clinical impact, it nevertheless led to the 
identification of a novel druggable site on β-tubulin. The crystal structure of tubulin and the 
2,3-desepoxy rhizoxin derivative (rhizoxin F) shows that the compound shares a distinct 
binding site from that of the vinca alkaloid, vinblastine.126 The key interactions of rhizoxin F 
and the β-tubulin were made by hydrophobic contacts between 8a methyl- and Asn 101, Asn 
102, Val 182, Phe 404 and Tyr 408 and hydrogen bonds between the hydroxyl oxygen at 
position 13 and Val 181 and between the 5b carbonyl- and Asn 102 of the β-tubulin (Figure 1.5b 
and 1.5c).126, 127 Mutational analysis shows that the Asn 102 (or Asn 100 in some homologues127) 
is the residue that determines sensitivity or resistance to rhizoxin.128, 129 From the tubulin 
binding experiments, the δ-lactone has been proven to be pivotal for the biological activity of 
rhizoxin. An open form of the δ-lactone had 4-fold decreased activity whereas the deletion of 
C5b carbonyl group resulted in complete loss of activity.114, 130 Modifications on the C5b 
carbonyl also resulted in a set of 16 amide and ester analogues, of which the glycerol ester 
exhibited the best antiproliferative activity.131 
 
Figure 1.5 a) Structure of rhizoxin (15) b) Rhizoxin F (orange) bound to the β2 subunit of the 
tubulin (grey) c) Interactions between the functional groups and side chains of rhizoxin F 
(orange sticks) and the β-tubulin (grey ribbon). Adapted from126 
 
1.3.2 Polyketide-chain branching 
Installation of alkyl branches at the α-position is frequently observed in polyketides and is 
introduced by ATs that are specific for substituted-CoA extender units.41 An alternate way to 
generate α-methyl-branched intermediates is by the activity of C-methyl transferases (MTs) 
with S-adenosyl methionine (SAM) as a methyl donor (Figure 1.6a).132 These SAM-dependent 
methyl transferases are commonly seen embedded in the assembly line of trans-AT PKSs and 
function as a primary source for generating gem-dimethyl functionalities in polyketides.133 
Some examples of polyketides containing MT-generated branches are bacillaene,134 
mupirocin135 and bongkrekic acid136 (16). Branches at the β-position are introduced by 3-
hydroxymethylglutaryl synthase137 (HMGS) cassettes that work in an analogous fashion to 
mevalonate biosynthetic enzymes.138 Typically, the hydroxylmethylglutaryl-ACP-synthase 
(HCS) catalyzes the aldol condensation of acyl donors to the β-keto polyketide intermediate. 
In select pathways, this intermediate is further processed by cis or trans-acting enoyl-CoA-  
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Figure 1.6 a) α- branching by SAM-dependent methyl transferases b) General mechanism of β-
branching by HCS cassette enzymes. The branches are highlighted. 
 
hydratases (ECH1 and ECH2) which catalyze the dehydration and decarboxylation of the 
growing chain, respectively (Figure 1.6b). The HMGS cassette has been shown to incorporate 
β-branches in curacin139, bacillaene140 and pederin79 (17). The ACP of this cassette typically 
contains the motif DSxxxxxW that is specific for β-branching.100  
 
The absence of HMGS cassette-specific genes in the rhizoxin PKS122 suggested that an 
alternative β-branching reaction could be a starting point to generate its δ-lactone moiety. To 
understand the exact timing and mechanism of the pivotal C5 branch in rhizoxin (15), the TE 
domain at the C-terminus of the 
megasynthase was deleted to 
prematurely release the pathway 
intermediates. Using rigorous MS 
and NMR analyses, it was found 
that the β-branch is introduced in 
the so called, ‘branching module’ 
(Figure 1.7) that is comprised of a 
KS, an ACP and a cryptic 530 amino 
acid branching (B) domain.141 
Unlike the HMGS cassette, these 
enzymes are hosted within a single 
module. The substrate for the β-
branch was a δ-hydroxy-α,β-
unsaturated thioester rather than a β-keto thioester as seen for the mevalonate-like branching.  
Based on these results, a new mechanism of β-branching has been proposed. According to this 
proposal, the β-branch is formed by a novel Michael addition of a malonyl extender unit to the 
α,β-unsaturated thioester intermediate bound to the KS (Figure 1.7).141  
 
Figure 1.7 Mechanism of β-branching in rhizoxin PKS 
involves Michael addition of an acetate unit to the α,β-
unsaturated thioester intermediate 
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A detailed biochemical insight into the β-branching reaction has been made possible by in 
vitro reconstitution of the entire branching module. Using purified proteins (KS-B didomain, 
ACP and AT) and N-acetylcysteamine (SNAC) thioester 18 as the substrate mimic, malonyl-
acetate was added to the α,β-unsaturated thioester by a decarboxylative Michael addition. 
NMR analysis of the in vitro assay performed with 13C-malonate revealed that the δ-hydroxyl 
group of the substrate further attacks the C1 carbonyl of the KS-bound chain to form the δ-
lactone (figure 1.8a). The ACP-bound lactone (19) and hydrolysed product (20) were observed 
by MALDI-MS and HRMS, respectively.142 The KS-B didomain of the rhizoxin branching 
module is the first reported structure of a KS domain from a trans-AT PKS (figure 1.8b).142 
Point mutations on the catalytic residues of the KS domain completely abolished the 
branching activity proving that these residues are crucial for the β-branching. The B domain 
resembles a regular DH domain with a double-hotdog fold. However, the conserved DH 
catalytic dyad, His-Asp is altered to Tyr-Asp in the active site of the B domain. The B domain, 
when produced as a stand-alone protein, was not capable of catalyzing the branching reaction, 
suggesting that it might only have a structural role. Moreover, point mutation of the conserved 
Asp residue of the B domain also did not affect the branching activity. In addition to these 
observations, using a substrate mimic that lacks the δ-hydroxy group, an unprecedented 
covalent complex of the polyketide intermediate with the KS-B and ACP domains was 
observed. Taken together, the Rhi KS represents a novel β-carbon branching KS which is 
distinct from the regular linear chain-forming KSs, that could be exploited for generating 
specific branches in polyketides.  
 
 
 
Figure 1.8 a) In vitro reconstitution setup of the branching reaction.142 b) Structure of the 
dimeric KS-B didomain of the rhizoxin branching module. PDB code: 4kc5 
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2 Aims of the research 
 
Enzymes from natural product biosynthetic pathways are attractive biocatalysts for synthetic 
biology. Deeper understanding of the biochemistry of these enzymes would facilitate their use 
in the generation of ‘non-natural’ natural products. The non-canonical branching module (KS-
B-ACP) of the rhizoxin PKS catalyzes δ-lactone formation via a two-step Michael addition and 
lactonization reaction. As this mechanism of δ-lactone formation is unprecedented, the 
rhizoxin branching module represents an excellent candidate for product diversification or 
pathway engineering.  
The branching module generates the δ-lactone which is pivotal for the antimitotic activity of 
rhizoxin. The first aim of this thesis was to determine the substrate tolerance of the branching 
module. As a first step to generate 6-membered heterocycles, a series of N-acetylcysteamine 
thioesters with varied δ-substituents should be synthesized and tested in vitro. This study will 
not only diversify the product-forming capabilities of the branching module but also provide a 
model for the biosynthesis of natural products with hitherto unknown β-branched 
architectures. In addition to the use of polyketide SNAC thioester mimics, the second aim was 
to find out the tolerance of the module towards α-substituted malonyl extender units. These 
results would address the feasibility of introducing more than one branch in a single reaction. 
Third, this research also aimed to generate lactones with varied ring sizes, in addition to the 6-
membered heterocycles. This should be demonstrated with chemically-synthesized thioester 
mimics with shorter or longer methylene chains. Generating lactones with increased ring sizes 
will expand the scope of this complex enzymatic cyclization reaction, especially when such 
reactions are difficult or not accessible by synthetic chemistry.  
Finally, the major aim of the thesis was to understand the mechanistic details of the 
branching-KS and the cryptic B domain. Although the B domain has been proposed to have a 
structural role in the branching reaction, to provide direct biochemical proof, chimeric 
modules should be generated in which the B domain is substituted with similar domains from 
other PKSs. This analysis would reveal whether the B domain is needed for the structural 
stability of the KS-B didomain or if it directly participates in the β-branching-lactonization 
reactions. To decipher the exact mechanism of KS domain in the branching reaction, the role 
of its conserved amino acid residues should be investigated. Site-specific mutations on selected 
residues should be performed to observe their impact on each step of the branching reaction. 
To complement the mutational analysis, KS domain substitution experiments should be 
performed to understand the role of the entire KS in catalysis. The study would also reveal the 
key determinants for the construction of a successful hybrid didomain. Taken together, the 
results from this research would establish the substrate promiscuity of the branching module 
with a detailed understanding of the mechanism of its key enzyme components. 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Manuscripts  List of manuscripts 
 
  19 
 
3 Manuscripts 
 
3.1 List of manuscripts 
 
Manuscript A 
 
Enzymatic polyketide chain branching to give substituted lactone, lactam, and 
glutarimide heterocycles 
Daniel Heine, Tom Bretschneider, Srividhya Sundaram, Christian Hertweck: Enzymatic 
polyketide chain branching to give substituted lactone, lactam, and glutarimide heterocycles, 
Angewandte Chemistry International Edition 53 (43), 11645-11649, 2014. 
Polyketides typically result from head-to-tail condensation of acyl thioesters to produce highly 
functionalized linear chains. The biosynthesis of the phytotoxin rhizoxin, however, involves a 
polyketide synthase (PKS) module that introduces a δ-lactone chain branch through Michael 
addition of a malonyl extender to an α,β-unsaturated intermediate unit. To evaluate the scope 
of the branching module, polyketide mimics were synthesized and their biotransformation by 
the reconstituted PKS module from the Rhizopus symbiont Burkholderia rhizoxinica was 
monitored in vitro. The impact of the type and configuration of the δ-substituents was probed 
and it was found that amino-substituted surrogates yield the corresponding lactams. A 
carboxamide analogue was transformed into a glutarimide unit, which can be found in many 
natural products. Our findings illuminate the biosynthesis of glutarimide-bearing polyketides 
and also demonstrate the utility of this branching module for synthetic biology. 
 
Daniel Heine Experiment design, Substrate and reference compounds 
synthesis, Data analysis, Manuscript writing 
 
Tom Bretschneider Experiment design, Genetic and biochemical 
experiments, Data analysis, Manuscript writing 
 
Srividhya Sundaram Genetic and biochemical experiments, Data analysis 
(20%) 
 
Christian Hertweck  Experiment design, Manuscript writing 
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Manuscript B 
Twofold polyketide branching by a stereoselective enzymatic Michael addition 
 
Daniel Heine, Srividhya Sundaram, Tom Bretschneider, Christian Hertweck: Twofold 
polyketide branching by a stereoselective enzymatic Michael addition, Chemical 
Communications 51 (48), 9872-9875, 2015.  
 
The versatility of the branching module of the rhizoxin polyketide synthase was tested in an in 
vitro enzyme assay with a polyketide mimic and branched (di) methylmalonyl-CoA extender 
units. Comparison of the products with synthetic reference compounds revealed that the 
module is able to stereoselectively introduce two branches in one step by a Michael addition–
lactonisation sequence, thus expanding the scope of previously studied PKS systems. 
 
 
Daniel Heine Experiment design, Substrate and reference compounds 
synthesis, Data analysis, Manuscript writing 
 
Srividhya Sundaram Genetic and biochemical experiments, Data analysis 
(20%) 
 
Tom Bretschneider Experiment design, Genetic and biochemical 
experiments, Data analysis, Manuscript writing 
 
Christian Hertweck  Experiment design, Manuscript writing 
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Manuscript C 
Polyketide synthase chimeras reveal key role of ketosynthase domain in chain 
branching 
Srividhya Sundaram, Daniel Heine, Christian Hertweck: Polyketide synthase chimeras reveal 
key role of ketosynthase domain in chain branching, Nature Chemical Biology 11 (12), 949-951, 
2015.  
 
Biosynthesis of rhizoxin in Burkholderia rhizoxinica affords an unusual polyketide synthase 
module with ketosynthase and branching domains that install the δ-lactone, conferring 
antimitotic activity. To investigate their functions in chain branching, we designed chimeric 
modules with structurally similar domains from a glutarimide-forming module and a 
dehydratase. Biochemical, kinetic and mutational analyses reveal a structural role of the 
accessory domains and multifarious catalytic actions of the ketosynthase. 
 
 
Srividhya Sundaram Experiment design, Genetic and biochemical 
experiments, Data analysis, Manuscript writing (70%) 
 
Daniel Heine  Substrate and reference compounds synthesis 
 
Christian Hertweck  Experiment design, Manuscript writing 
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Manuscript D 
On-line enzymatic tailoring of polyketides and peptides in thiotemplate systems 
(Review) 
Srividhya Sundaram, Christian Hertweck: On-line enzymatic tailoring of polyketides and 
peptides in thiotemplate systems, Current Opinion in Chemical Biology 31, 82-94, 2016.  
 
Nonribosomal peptide synthetases (NRPS) and type I polyketide synthases (PKS) are versatile 
thiotemplate systems for the programmed assembly of biosynthetic building blocks. Typically, 
the post-PKS/NRPS enzymes tailor the resulting chains to yield the bioactive natural product 
scaffolds. However, more and more examples have surfaced showing that important structural 
modifications take place while the intermediates are still bound to the assembly line. A 
growing number of enzymatic domains and trans-acting enzymes as well as their recruiting 
areas in the modules have been identified and characterized. In addition to the widespread on-
line alkylations, hydroxylations and heterocyclizations into oxazole/thiazole residues, on-line 
modifications lead to a variety of ring systems such as cycloethers, lactones, lactams, 
glutarimides, cyclopropanes, decalins and cyclic biaryls.  
 
 
Srividhya Sundaram Literature research, Manuscript writing (60%) 
 
Christian Hertweck  Literature research, Manuscript writing 
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Manuscript E 
Investigation of a non-canonical chain-branching ketosynthase by site-directed 
mutagenesis and domain swaps  
 
Srividhya Sundaram, Ruth Bauer, Hak Joong Kim, Tawatchai Thongkongkaew; Christian 
Hertweck, Investigation of a non-canonical chain-branching ketosynthase by site-directed 
mutagenesis and domain swaps, in preparation, 2017. 
 
 
Ketosynthase (KS) domains of modular type I polyketide synthases (PKSs) typically catalyze 
Claisen condensation of simple acyl and malonyl units to form linear chains that eventually 
make bioactive polyketides. The KS domain of the branching module of rhizoxin PKS installs a 
β-branch in the otherwise linear polyketide intermediate which is then cyclized to form the 
pharmacophoric δ-lactone moiety. To know the exact role of KS domain in the branching-
cyclization sequence, we performed targeted mutagenesis of 10 of the conserved amino acids. 
Biochemical and kinetic analysis revealed that the C3228A and T3290Y mutations completely 
abolished the β-branch formation. The H3364A, H3404A S3141D, I3478F and S3409A mutants 
exhibited low turnover activity with attenuated rate for lactonization. Complementing the 
mutational analyses, we generated chimeras of the branching-KS domain with elongating-KSs 
and show that a canonical linear chain is formed. These results reveal the mechanistic details 
of a complex branching reaction catalyzed solely by a KS domain. 
 
 
Srividhya Sundaram Experiment design, Genetic and biochemical 
experiments, Data analysis, Manuscript writing (50%) 
 
Ruth Bauer  Genetic and biochemical experiments 
 
Hak Joong Kim  Reference compounds synthesis 
 
Tawatchai Thongkongkaew  Substrate synthesis 
 
Christian Hertweck  Experiment design, Manuscript writing 
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Manuscript F 
Versatile polyketide-chain lactonization by a non-canonical ketosynthase of the 
rhizoxin megasynthase 
 
Srividhya Sundaram, Tawatchai Thongkongkaew, Hak Joong Kim, Ruth Bauer, Daniel Heine, 
Christian Hertweck: Versatile polyketide-chain lactonization by a non-canonical ketosynthase 
of the rhizoxin megasynthase, in preparation, 2017. 
 
 
In vitro reconstitution of a branching module from the rhizoxin PKS revealed a non-canonical 
β-branching mechanism that forms its pharmacophoric δ-lactone moiety. The branching 
module is tolerant towards substrates with varied δ substituents that yield 6-membered rings 
like lactam and glutarimide structures. Here, we expand the range of products and show that 
that the branching module lactonizes substrates with different chain lengths to yield an array 
of 5- to 10-membered lactones. The ability of KS to promote lactone formation complements 
the thioesterase- (TE) catalyzed cyclizations. It further sets the stage to generate ring-
containing molecular architectures with potential bioactivities, especially when large-
membered rings are challenging to produce by synthetic chemistry.  
 
 
Srividhya Sundaram Experiment design, Genetic and biochemical 
experiments, Data analysis, Manuscript writing (40%) 
 
Tawatchai Thongkongkaew  Substrate synthesis 
 
Hak Joong Kim  Reference compounds synthesis 
 
Ruth Bauer Substrate synthesis 
 
Daniel Heine  Substrate synthesis 
 
Christian Hertweck  Experiment design, Manuscript writing 
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Manuscript G 
A widespread bacterial phenazine forms S-conjugates with biogenic thiols and 
crosslinks proteins 
 
Daniel Heine, Srividhya Sundaram, Matthias Beudert, Karin Martin, Christian Hertweck: A 
widespread bacterial phenazine forms S-conjugates with biogenic thiols and crosslinks 
proteins, Chemical Science 7, 4848-4855, 2016. 
 
 
Phenazines are redox-active compounds produced by a range of bacteria, including many 
pathogens. Endowed with various biological activities, these ubiquitous N-heterocycles are 
well known for their ability to generate reactive oxygen species by redox cycling. Phenazines 
may lead to an irreversible depletion of glutathione, but a detailed mechanism has remained 
elusive. Furthermore, it is not understood why phenazines have so many protein targets and 
cause protein misfolding as well as their aggregation. Here we report the discovery of 
unprecedented conjugates (panphenazines A, B) of pantetheine and phenazine-1-carboxylic 
(PCA) acid from a Kitasatospora sp., which prompted us to investigate their biogenesis. We 
found that PCA reacts with diverse biogenic thiols under radical-forming conditions, which 
provides a plausible model for irreversible glutathione depletion. To evaluate the scope of the 
reaction in cells we designed biotin and rhodamine conjugates for protein labelling and 
examined their covalent fusion with model proteins (ketosynthase, carbonic anhydrase III, 
albumin). Our results reveal important, yet overlooked biological roles of phenazines and show 
for the first time their function in protein conjugation and crosslinking. 
 
 
Daniel Heine Experiment design, Compound isolation, Chemical 
synthesis, Data analysis, Manuscript writing 
 
Srividhya Sundaram Experiment design, Protein crosslinking assays, Data 
analysis (20%) 
 
Matthias Beudert Chemical synthesis   
 
Karin Martin Strain handling and fermentation    
 
Christian Hertweck  Experiment design, Manuscript writing 
 
 
This manuscript results from an unrelated side project undertaken. The complete manuscript is 
shown in the Appendix section (9.3). 
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3.2 Manuscript A 
 
Enzymatic polyketide chain branching to give substituted lactone, lactam, and 
glutarimide heterocycles 
 
Daniel Heine, Tom Bretschneider, Srividhya Sundaram, Christian Hertweck: Enzymatic 
polyketide chain branching to give substituted lactone, lactam, and glutarimide heterocycles, 
Angewandte Chemistry International Edition 53 (43), 11645-11649, 2014. 
 
 
 
 
 
The branching module of the rhizoxin PKS is tolerant towards substrates with varied δ-
substituents. An amine-substituted substrate yields a lactam moiety whereas a carboxamide 
surrogate results in a glutarimide moiety.  
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Abstract: Polyketides typically result from head-to-tail con-
densation of acyl thioesters to produce highly functionalized
linear chains. The biosynthesis of the phytotoxin rhizoxin,
however, involves a polyketide synthase (PKS) module that
introduces a d-lactone chain branch through Michael addition
of a malonyl extender to an a,b-unsaturated intermediate unit.
To evaluate the scope of the branching module, polyketide
mimics were synthesized and their biotransformation by the
reconstituted PKS module from the Rhizopus symbiont
Burkholderia rhizoxinica was monitored in vitro. The impact
of the type and configuration of the d-substituents was probed
and it was found that amino-substituted surrogates yield the
corresponding lactams. A carboxamide analogue was trans-
formed into a glutarimide unit, which can be found in many
natural products. Our findings illuminate the biosynthesis of
glutarimide-bearing polyketides and also demonstrate the
utility of this branching module for synthetic biology.
Polyketides encompass an impressive range of natural
products, many of which are in clinical use. Their structural
diversity primarily emerges from simple head-to-tail conden-
sations of activated acyl and malonyl building blocks. The
resulting polyketide chains are enzymatically processed and
may undergo enzymatic tailoring, for example, cyclization,
oxygenation, halogenation, and glycosylation.[1] With respect
to the assembly of the carbon backbone, it is remarkable that
only a few variations to the unidirectional 1,2-condensation
scheme have been observed. However, noncanonical sub-
structures can be crucial for the biological activity of the
polyketide, as exemplified by the remarkably potent anti-
mitotic agent rhizoxin (1, Figure 1).[2] This phytotoxin is
employed in a symbiosis of the plant-pathogenic fungus
Rhizopus microsporus and its bacterial endosymbiont, Bur-
kholderia rhizoxinica.[3] The structure of the macrolide is
highly unusual because it features a d-lactone ring that is
tethered to the polyketide backbone. Notably, this chain
branch is essential for the binding of rhizoxin to the b-tubulin
subunit,[4] through which it efficiently halts cell division in the
picomolar range.[3b] Isotope-labeling experiments have
showed that the d-lactone ring integrates an acetyl unit that
branches off at a b-position relative to a former acetyl
carbonyl in the polyketide chain (Figure 1).[5]
Whereas alkyl substitutions at a-positions result from
methylation or the incorporation of substituted malonyl
units,[6] branches at b-positions typically involve enzymes
that resemble those of the isoprenoid enzymatic machinery.[7]
Surprisingly, genes for such components could not be found in
the genome of the rhizoxin producer.[8] Instead, the architec-
ture of the rhizoxin (rhi) type I polyketide synthase (PKS)[9]
and the structures of isolated pathway intermediates[10] have
suggested that the chain branch is introduced through
a Michael addition. To shed light on the enzyme mechanism,
we reconstituted the designated “branching module” of the
rhi PKS, which consists of ketosynthase (KS), branching (B),
and acyl carrier (ACP) domains, and a trans-acting acyl
transferase (AT). By means of an in vitro enzyme assay, we
successfully transformed a synthetic surrogate of the poly-
ketide intermediate into the corresponding d-lactone deriv-
ative. We thus confirmed that the pharmacophoric side chain
Figure 1. A) The structure of rhizoxin (1) and a model for vinylogous
chain branching catalyzed by a specialized PKS module; 1) Michael
addition, 2) lactonization. B) The structures of isomigrastatin (2) and
cycloheximide (3) with the glutarimide motif highlighted. KS, keto-
synthase; B, branching domain; ACP, acyl carrier domain; AT, acyl-
transferase.
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is introduced through a vinylogous addition of a malonyl unit
to an a,b-unsaturated thioester, followed by lactonization
(Figure 1).[11] Notably, similar PKS modules are encoded in
the biosynthetic gene clusters for glutarimide-bearing natural
products such as isomigrastatin (2),[12] an important cell
migration inhibitor (Figure 1). As in the structurally related
antibiotic cycloheximide (3), the glutarimide residue is
important for the biological activity of these compounds.[13]
Although it had been proposed that an enzymatic Michael
addition could give rise to the glutarimide structure, the roles
of these PKS modules have remained elusive and the
proposed mechanism still needs to be experimentally con-
firmed. Herein, we show that the chain-branching rhi PKS
module is more versatile than expected. Through an in vitro
multienzyme assay with synthetic polyketide mimics, we have
demonstrated that the unusual KS–B–ACP module is also
capable of forming lactams and even glutarimides.
To test the substrate specificity of the rhizoxin PKS
branching module and to explore the scope of potential
applications, we synthesized various polyketide analogues for
in vitro multienzyme biotransformation experiments. Specif-
ically, a series of d-functionalized, a,b-unsaturated N-acetyl
cysteamine thioester (SNAC) derivatives that mimic the
activated intermediates were prepared. First, we explored the
impact of the configuration of the d-hydroxy group on the
course of the reaction. For this purpose, we synthesized the R
and S enantiomers of the 5-hydroxyhexenoic acid SNAC
thioester from the corresponding protected hydroxybuta-
noates through a reduction–olefination sequence. The ste-
reoisomers 4 and 5 were individually subjected to the in vitro
enzyme assay, and the products were analyzed by HPLC–
HRMS, with the synthetic d-lactone as reference (Figure 2).
Surprisingly, in both cases formation of the branched product
was detected in only one diastereoisomeric form. From
retention-time comparisons and deductions from the natural
biosynthetic pathway, we inferred that in both cases the syn-
substituted lactone was formed.
To shed light on the preferences of the KS, we determined
the kinetic parameters of the branching reaction. For the R
enantiomer, we found a KM value of (2694 627) mm and
a vmax value of (20.9 2.4) mmmin1. By contrast, using the S
enantiomer gave a KM value of (1348 315) mm and a vmax
value of (2.1 0.3) mmmin1. Binding of the non-natural R
enantiomer to the KS is thus only lowered twofold, whereas
the transformation rate of this substrate is ten times lower
compared to the S enantiomer. This result indicates that the
KS basically does not differentiate between the configura-
tions of the d-hydroxy groups, but lactone ring formation is
drastically reduced when the non-natural isomer is applied. It
appears that this sequence of Michael addition and lactoniza-
tion exclusively yields syn-substituted lactones and that the
configuration of the hydroxy group determines the stereo-
chemical course of the reaction.
To verify the proposed course of the reaction and to
corroborate the idea that non-covalent interactions between
the substrate and the malonyl unit define the stereochemical
course of the reaction, we synthesized and tested the d-
hydroxy-substituted dihydro surrogate 8, which cannot
undergo a branching reaction because of the missing double
bond. Furthermore, a phenol analogue (10) was prepared
(Figure 3). The activated malonyl units and the rhizoxin
polyketide chain mimics were individually added to the
enzyme mixture that constitutes the functional PKS module
in vitro. The reactions were monitored by MALDI analysis of
the ACP with potentially bound products, as well as by high-
resolution mass spectrometry (HRMS) of the hydrolyzed
products. Unsurprisingly, the saturated alcohol 8 did not
undergo any chain branching reaction, thus demonstrating
once again that the Michael addition precedes ester bond
formation. Furthermore, this experiment showed that the KS
does not catalyze Claisen condensation with this substrate
when a vinylogous attack is hampered. Changing the aliphatic
alcohol to a phenol nucleophile did not give rise to the
hypothetical product 11. These results indicate a high degree
of specificity for the KS–B–ACP module.
Next, we explored the possibility of replacing the nucle-
ophilic d-hydroxy substituent of the polyketide chain. It
should be highlighted that this OH group is required for the
release of the KS-bound intermediate by lactonization, which
allows the propagation of the intermediate. Nonetheless, it is
conceivable that other nucleophilic residues could also cleave
the thioester bond, which would result in the formation of
Figure 2. Vinylogous chain branching of pure R and S enantiomers of
the N-acetyl cysteamine thioester of 5-hydroxyhexenoic acid, and
subsequent lactone formation. A) Michaelis–Menten kinetics of the
biotransformation. B) MALDI analysis of ACP-bound products (peak in
middle relates to decarboxylated malonylated ACP species). C) SIM-
LC–HRMS analysis of hydrolyzed products, and comparison with the
racemic synthetic reference. SIM=selected ion monitoring.
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alternative heterocyclic systems. If the surrogate was accepted
as a substrate for the Michael addition, aminolysis of the
thioester would give a lactam ring. To evaluate the effect of an
amino group in lieu of the hydroxy group, we synthesized the
corresponding d-amino-substituted surrogate of the natural
polyketide precursor. To this end, N-Boc-protected ethyl d,l-
3-aminobutanoate was reduced with DibalH. The amino-
aldehyde was immediately subjected to a Horner–Wads-
worth–Emmons (HWE) olefination, and subsequent depro-
tection gave the desired amine 12 (see the Supporting
Information). This synthetic surrogate of the growing poly-
ketide chain was employed in the in vitro assay and product
formation was monitored by HRMS. The formation of a new
compound with m/z= 172.0966 and a molecular formula of
C8H14O3N [M+H]
+ as deduced from LC–HRMS suggested
that the desired lactam compound was produced. To confirm
the identity of the lactam, we prepared a synthetic reference.
In brief, a protected d,l-b-aminoacid ester was subjected to
a reductive Horner–Wadsworth–Emmons olefination to
obtain the substituted a,b-unsaturated ester. A cesium
carbonate catalyzed Michael addition of diethylmalonate
followed by hydrolysis yielded the lactam as a diastereoiso-
meric mixture (see the Supporting Information). Comparison
of the high-resolution mass spectra andHPLC retention times
of the enzyme products and the synthetic reference confirmed
the successful conversion of 12 into the d-lactam 13
(Figure 4). Furthermore, only the (late-eluting) syn-diaste-
reomer is formed, thus confirming that the enzymatic reaction
is highly selective, yielding only one diastereoisomer from
a mixture of enantiomeric d-amino-substituted precursors, as
has been observed for the d-lactones.
The successful biotransformation of the amino analogue
encouraged an expansion of this approach to carbonyl
substituents such as carboxylic acid and amide residues. In
principle, a carboxylate could give rise to an anhydride moiety
or the respective dicarboxylic acid, whereas the carboxyamide
would lead to the glutarimide moiety, which is found in many
natural products. Unexpectedly, the synthesis of carboxy- and
carboxamide-substituted SNAC derivatives proved to be
highly challenging. Despite many attempts, the functionaliza-
tion of glutaconic acid and HWE olefination were not
feasible, possibly owing to the highly reactive a-proton at
the allylic position. Finally, we succeeded in preparing the
desired polyketide surrogates 14 and 16 (see the Supporting
Information) through alkene metathesis of propenyl SNAC
with but-3-enoic acid and but-3-enamide, respectively. Addi-
tion of the carboxy-substituted SNAC derivative 14 to the
enzyme assay resulted in protein precipitation, and no
biotransformation took place. To exclude the possibility of
a pH effect, we repeated the experiment after accurately
adjusting the pH value to 7.0 with Tris buffer. However,
neither the respective anhydride 15 nor the hydrolyzed
product could be detected.
By contrast, the carboxamide-substituted polyketide sur-
rogate 16 was accepted as a substrate by the branching
module. Through analysis of the enzyme mixture, we detected
a MALDI signal corresponding to the ACP-bound glutari-
mide product (Figure 5). Moreover, acidic workup released
the expected product with m/z= 172.0610 and a molecular
formula of C7H10O4N (HRMS). The identity of the glutari-
mide 17 was rigorously confirmed through comparison of the
HPLC retention times and high-resolution mass signals of the
reaction product and a synthetic reference (Figure 5). A
negative control experiment with a heat-inactivated KS–B
didomain confirmed that the reaction is indeed enzyme-
catalyzed.
Our results unequivocally show that the unusual KS–B–
ACP module of the rhi PKS is not limited to lactone
formation but is also capable of introducing branches that
Figure 3. Probing the substrate tolerance of the branching module
towards dihydro and phenol variants by using synthetic polyketide
surrogates.
Figure 4. In vitro biotransformation of an amino-substituted polyketide
surrogate into a lactam moiety. A) General Scheme of the enzyme
assay. B) MALDI analysis of the ACP-bound product. C) SIM-LC–
HRMS analysis of the hydrolyzed product and comparison with the
synthetic reference (as a mixture of diastereoisomers); only one
enantiomer is shown.
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constitute lactam and glutarimide moieties. The latter are
particularly noteworthy since related modules (KS–“X”–
ACP, or KS–B–ACP) were found in PKS complexes involved
in the biosynthesis of the glutarimide-bearing polyketides
such as 9-methylstreptimidone,[14] isomigrastatin[12] and cyclo-
heximide.[15] The successful enzymatic synthesis of a glutari-
mide with the rhi PKS module for the first time confirms the
proposed pathway involving Michael addition and hetero-
cyclization.
In conclusion, we have shed light on the scope and
versatility of a specialized PKS module that catalyzes the
noncanonical vinylogous addition of a C2 extender unit to
generate polyketide chain branches. Through the synthesis of
a series of thioester surrogates with different d-substituents,
in vitro biotransformation experiments, and product analyses
with synthetic references, we showed that the branching
module generates lactone, lactam, and glutarimide hetero-
cycles. We found that this set of domains exhibits a marked
stereochemical substrate preference and that exclusively syn-
substituted lactones and lactams are formed. However, there
is a degree of flexibility that leaves room for various
alternative conversions. Among these, the enzymatic forma-
tion of glutarimide provides first experimental support for
postulated biosynthetic pathways to known glutarimide-
bearing natural products. Although corresponding d-lactam
substructures have not yet been observed in natural poly-
ketide structures, we postulate that the biosynthesis of
polyketides with d-lactam branches would be feasible and
that such natural products await discovery. From a practical
point of view, our findings are an important addition to our
current understanding of non-terpenoid polyketide branch-
ing. Furthermore, the use of this branching module in
synthetic biology or the engineering of enzymatic pathways
could provide unique opportunities for compound diversifi-
cation.
Received: July 16, 2014
Published online: September 11, 2014
.Keywords: beta-branching · biotransformation · macrolides ·
Michael addition · polyketide synthases
[1] C. Hertweck, Angew. Chem. Int. Ed. 2009, 48, 4688 – 4716;
Angew. Chem. 2009, 121, 4782 – 4811.
[2] J. Hong, J. D. White, Tetrahedron 2004, 60, 5653 – 5681.
[3] a) L. P. Partida-Martinez, C. Hertweck, Nature 2005, 437, 884 –
888; b) K. Scherlach, L. P. Partida-Martinez, H.-M. Dahse, C.
Hertweck, J. Am. Chem. Soc. 2006, 128, 11529 – 11536; c) L. P.
Partida-Martinez, I. Groth, M. Roth, I. Schmitt, K. Buder, C.
Hertweck, Int. J. Syst. Evol. Microbiol. 2007, 57, 2583 – 2590;
d) K. Scherlach, B. Busch, G. Lackner, U. Paszkowski, C.
Hertweck, Angew. Chem. Int. Ed. 2012, 51, 9615 – 9618;
Angew. Chem. 2012, 124, 9753 – 9756.
[4] a) M. Takahashi, S. Iwasaki, H. Kobayashi, S. Okuda, T. Murai,
Y. Sato, Biochim. Biophys. Acta Gen. Subj. 1987, 926, 215 – 223;
b) I. Schmitt, L. P. Partida-Martinez, R. Winkler, K. Voigt, A.
Einax, J. Wçstemeyer, C. Hertweck, ISME J. 2008, 2, 632 – 641;
c) B. Kusebauch, K. Scherlach, H. Kirchner, H. M. Dahse, C.
Hertweck, ChemMedChem 2011, 6, 1998 – 2001.
[5] H. Kobayashi, S. Iwasaki, E. Yamada, S. Okuda, J. Chem. Soc.
Chem. Commun. 1986, 1702 – 1703.
[6] a) Y. A. Chan, A. M. Podevels, B. M. Kevany, M. G. Thomas,
Nat. Prod. Rep. 2009, 26, 90 – 114; b) M. C. Wilson, B. S. Moore,
Nat. Prod. Rep. 2012, 29, 72 – 86.
[7] a) C. T. Calderone, W. E. Kowtoniuk, N. L. Kelleher, C. T.
Walsh, P. C. Dorrestein, Proc. Natl. Acad. Sci. USA 2006, 103,
8977 – 8982; b) C. T. Calderone, Nat. Prod. Rep. 2008, 25, 845 –
853.
[8] a) G. Lackner, N. Moebius, L. P. Partida-Martinez, C. Hertweck,
J. Bacteriol. 2011, 193, 783 – 784; b) G. Lackner, N.Moebius, L. P.
Figure 5. In vitro biotransformation of the amide-functionalized poly-
ketide surrogate into a glutarimide moiety. A) General Scheme of the
enzyme assay. B) MALDI analysis of the ACP-bound product. C) SIM-
LC–HRMS analysis of hydrolyzed product and comparison with the
reference. D) Proposed model for the biosynthesis of glutarimide-
bearing polyketides such as 2 and 3 (see Figure 1).
.Angewandte
Communications
11648 www.angewandte.org  2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2014, 53, 11645 –11649
 
ͣ͠
Partida-Martinez, S. Boland, C. Hertweck, BMC Genomics
2011, 12, 210.
[9] a) L. P. Partida-Martinez, C. Hertweck, ChemBioChem 2007, 8,
41 – 45; b) T. Nguyen, K. Ishida, H. Jenke-Kodama, E. Dittmann,
C. Gurgui, T. Hochmuth, S. Taudien, M. Platzer, C. Hertweck, J.
Piel, Nat. Biotechnol. 2008, 26, 225 – 233.
[10] a) B. Kusebauch, B. Busch, K. Scherlach, M. Roth, C. Hertweck,
Angew. Chem. Int. Ed. 2009, 48, 5001 – 5004; Angew. Chem.
2009, 121, 5101 – 5104; b) B. Kusebauch, B. Busch, K. Scherlach,
M. Roth, C. Hertweck, Angew. Chem. Int. Ed. 2010, 49, 1460 –
1464; Angew. Chem. 2010, 122, 1502 – 1506.
[11] a) T. Bretschneider, J. B. Heim, D. Heine, R. Winkler, B. Busch,
B. Kusebauch, T. Stehle, G. Zocher, C. Hertweck, Nature 2013,
502, 124 – 128; related highlight articles: b) C. A. Townsend,
Nature 2013, 502, 44 – 45, c) R. J. Cox, ChemBioChem 2014, 15,
27 – 29.
[12] S. K. Lim, J. Ju, E. Zazopoulos, H. Jiang, J. W. Seo, Y. Chen, Z.
Feng, S. R. Rajski, C. M. Farnet, B. Shen, J. Biol. Chem. 2009,
284, 29746 – 29756.
[13] S. R. Rajski, B. Shen, ChemBioChem 2010, 11, 1951 – 1954.
[14] B. Wang, Y. Song, M. Luo, Q. Chen, J. Ma, H. Huang, J. Ju, Org.
Lett. 2013, 15, 1278 – 1281.
[15] M. Yin, Y. Yan, J. R. Lohman, S. X. Huang, M. Ma, G. R. Zhao,
L. H. Xu, W. Xiang, B. Shen, Org. Lett. 2014, 16, 3072 – 3075.
Angewandte
Chemie
11649Angew. Chem. Int. Ed. 2014, 53, 11645 –11649  2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
 
ͣ͡
Supporting Information
 Wiley-VCH 2014
69451 Weinheim, Germany
Enzymatic Polyketide Chain Branching to Give Substituted Lactone,
Lactam, and Glutarimide Heterocycles**
Daniel Heine, Tom Bretschneider, Srividhya Sundaram, and Christian Hertweck*
anie_201407282_sm_miscellaneous_information.pdf
 
ͣ͢
 
 
Supporting Information for 
 
 
 
 
1. Instrumentation ..................................................................................................................... 2 
2. General Methods .................................................................................................................. 3 
3. Protein Production ................................................................................................................ 3 
4. In vitro Enzymatic Biotransformations .................................................................................. 4 
5. Synthetic Protocols and Analytical Data .............................................................................. 5 
6. NMR Spectra ...................................................................................................................... 19 
7. Original HRMS Data ........................................................................................................... 32 
8. Original MALDI Data .......................................................................................................... 39 
9. Supplemental References .................................................................................................. 43 
 
 
 
 
ͣͣ
 
1. Instrumentation 
 
NMR measurements were performed on a Bruker AVANCE II 300, AVANCE III 500 or 
600 MHz spectrometer, equipped with a Bruker Cryo platform. Chemical shifts are reported 
in parts per million (ppm) relative to the solvent residual peak of chloroform-d1 (
1H: 
7.24 ppm, singlet; 13C: 77.00 ppm, triplet), methanol-d4 (
1H: 3.30 ppm, quintet; 13C: 
49.00 ppm, septet) or DMSO-d6 (
1H: 2.50 ppm, quintet; 13C: 39.52 ppm, septet). MALDI 
measurements were performed with a Bruker UltrafleXtreme machine. HRESI-MS was 
carried out on an Accela UPLC-system (Thermo Scientific) combined with an Exactive mass 
spectrometer (Thermo Scientific) equipped with an electrospray ion source. Solid phase 
extraction was carried out using Chromabond C18 ec Cartridges filled with 2,000 mg of 
octadecyl-modified silica gel (Macherey-Nagel). HPLC-MS measurements were performed 
on a HPLC 1100 System connected to a 1100 Series LC/MSD Trap using an Zorbax Eclipse 
XDB-C8, 4.6 x 150 mm column, particle size 5 μm (Agilent Technologies). Semi-preparative 
HPLC was performed on a 1260 Infinity System (Agilent Technologies) using the following 
columns: Zorbax Eclipse XDB-C8, 9.5 x 250 mm, particle size 5 μm (Agilent Technologies), 
Zorbax Eclipse XDB-C18, 9.5 x 250 mm, particle size 5 μm (Agilent Technologies) and EC 
250/4 Nucleodur Sphinx RP, particle size 5 μm (Macherey-Nagel). All solvents for analytical 
and preparative HPLC measurements were obtained commercially at least in gradient grade 
and were filtered prior to use. To avoid microbial growing 0.1 % formic acid was added to the 
water, used for analytical and preparative HPLC. IR-spectra were recorded on an FT/IR-4100 
ATR spectrometer (Jasco). 
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2. General Methods 
 
All reagents and glutarimide reference 17 were obtained from commercial suppliers (Sigma 
Aldrich and Acros Organics) and were used without further purification except where 
reported. All solvents were at least obtained in HPLC grade. Reactions were performed under 
inert atmosphere (Argon) using the common Schlenk technique. Solvents were dried prior to 
use by the following procedures: N,N-dimethylformamide (DMF) and dichloromethane 
(DCM) were distilled from a calcium hydride suspension. Tetrahydrofurane (THF) was pre-
dried over potassium hydroxide and then freshly distilled from lithum aluminium hydride. 
Methanol, dichloromethane, chloroform and ethyl acetate were distilled prior to use. For thin-
layer chromatography TLC aluminum sheets silica gel 60 F254 (MERCK) were used. Open 
column chromatography was performed on silica gel 60; particle size 0.015 - 0.04 mm 
(Macherey-Nagel) and on Sephadex® LH-20 (Sigma-Aldrich). 
 
3. Protein Production 
 
Recombinant RhiE*, consisting of the KS-B-bidomain, was produced and purified as 
described previously.[1] Briefly, 5 mg of Escherichia coli BL21 cells containing the expression 
plasmids (pTB57, pTB41 and pTB39 respectively) were dissolved in 50 mL of 20 mM Tris 
(pH 7.5) supplemented with 200 M NaCl and 50 mM imidazole. After disrupting the cells by 
sonication (sonotrode, 20% power), and removing the cell debris by centrifugation at 
10,000 rpm for 20 min, the supernatant was loaded onto a 5 mL Ni-NTA matrix (Machery 
Nagel) connected to a FPLC machine (Äkta Explorer, Amersham Biosciences). The 
recombinant protein was eluted using the same buffer with 500 mM imidazole. The protein 
was diluted twice with 20 mM Tris (pH 7.5) and further purified using an ion-exchange 
column (5 ml HiTrap Q-HP, GE Healthcare). Elution was carried out with 30 column 
volumes of 20 mM Tris (pH 7.5) supplemented with 1 M NaCl. The fractions containing the 
target protein were concentrated using a vivaspin column (MWCO 5 & 10 kDa - Sartorius) 
and stored at 4 °C until use.  
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4. In vitro Enzymatic Biotransformations 
 
In vitro biotransformations were conducted in analogy to the method established for the 
functional analysis of the branching module.[1] At a 40 μL scale, 167 μM ACP, 3 μM RhiE*, 
0.2 μM RhiG , 733 μM malonyl-CoA  and 2,000 μM of the N-acetylcysteamine congeners 
were incubated in 20 mM Tris buffer (pH 7.0) at 23 °C with shaking at 400 rpm.  After 2 h, 2 
μL of the sample was mixed with 2 μL of 100 mM 2,5-dihydroxyacetophenone 
(containing 2.5 mM diammonium hydrogen citrate) and spotted onto an anchor chip 800/384 
T F target (Bruker) to analyze products. For mass spectrometric measurements, the enzyme 
reaction was stopped by either adding 200 μL of ethyl acetate or an equal volume of methanol 
(in case of substrate 12). The organic phase was recovered and concentrated to dryness under 
a stream of nitrogen gas. The residue was dissolved in 60 μL methanol and analyzed by 
HRMS (Exactive). 
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5. Synthetic Protocols and Analytical Data 

 
 
 
Scheme S1. a) 3,4-dihydro-2H-pyran, pyridinium p-toluenesulfonate, CH2Cl2, 0 °C then RT; b) 1. 
DIBAL-H, toluene, −78 °C; 2. LiCl, iPr2NEt, S-(2-Acetamidoethyl)2-diethoxyphosphoryl)ethanethioate, 
acetonitrile, 0 °C then RT; c) p-toluenesulfonic acid, CH3OH, RT. DIBAL-H = diisobutyl aluminium 
hydride. 
 
 
(S)-Ethyl 3-((tetrahydro-2H-pyran-2-yl)oxy)butanoate 18[1] 
To a solution of 3,4-dihydro-2H-pyran (1.9 g, 22.7 mmol) and 3-hydroxybutyric acid (2 g, 
15.2 mmol) was slowly added pyridinium p-toluenesulfonate (380 mg, 1.52 mmol) in 
dichloromethane (5 mL). The solution was allowed to warm room temperature and stirred for 
additional 24 h. A saturated solution of sodium hydrogen carbonate (5 mL) was added and the 
aqueous phase was extracted with dichloromethane (3×10 mL). The combined organic phases 
were dried with sodium sulfate. After evaporation of the solvent and bulb to bulb distillation 
at 125 °C and 13 mbar, a  colorless liquid (3.12 g) was obtained.  
Yield: 95 %. 1H NMR (300 MHz, CDCl3): δ 4.71 (1H, m), 4.66 (1H, m), 4.25-4.05 (2H, m), 
4.17 (4H, q, 3J = 6.3 Hz), 3.86 (2H, m), 3.48 (2H, m), 2.71-2.34 (4H, m), 1.81-1.47 (12 H, m), 
1.27 (6H, d, 3J = 7.1 Hz), 1.22 ppm (6H, t, 3J = 6.3 HZ);  = +14.29 (7.7 mg mL-1, 
MeOH). 
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(R)-Ethyl 3-((tetrahydro-2H-pyran-2-yl)oxy)butanoate 19 
The synthesis of 19 was performed by the same procedure as for compound 18 by using 
(R)-(+)-ethyl-3-hydroxybutyrate (2 g, 15.2 mmol). After workup and bulb to bulb distillation, 
2.99 g of a colorless liquid could be obtained.  
Yield: 91 %. NMR data are identical to those of compound 18;  = −15.48 (5.8 mg mL−1, 
MeOH).  
 
(S)-(E)-S-(2-Acetamidoethyl)-5-((tetrahydro-2H-pyran-2-yl)oxy)hex-2-enethioate 20[1] 
A stirred solution of 18 (60 mg, 0.28 mmol) in dry toluene (1 mL) was cooled to 78 °C and 
diisobutylaluminium hydride (DIBAL-H) (1 M in n-hexane, 7.5 mL) was added slowly. A 
mixture of methanol/1 M HCl (2:1; 4 mL) was added after 3 h, and the solution was filtered 
through celite. The filtrate was extracted with ethyl acetate (3×10 mL) and the combined 
organic phases were dried with sodium sulfate and concentrated under reduced pressure. The 
aldehyde could be used for the next step without further purification steps.  
LiCl (13 mg, 0.3 mmol) was suspended together with 2 (50 mg, 0.16 mmol) in dry acetonitrile 
(2 mL). After addition of N,N-diisopropylethylamine (50 µl, 0.3 mmol) the mixture was 
cooled to 0 °C and the aldehyde, dissolved in acetonitrile (2 mL), was added. After warming 
to room temperature, the solution was stirred for 17 h. Saturated ammonium chloride solution 
(20 mL), water (20 mL) and diethyl ether (20 mL) were added, and the aqueous phase was 
extracted with diethyl ether (3×20 mL). The combined organic phases were dried with sodium 
sulfate and concentrated under reduced pressure. After column chromatography 
(chloroform/methanol 100:0 to 95:5) a colorless oil (72 mg) was obtained.  
Yield: 81 %. 1H NMR (300 MHz, CDCl3): δ 6.97 (1H, dt, 
3J = 15.6 Hz, 4J = 7.3), 6.88 (1H, 
dt, 3J = 15.6 Hz, 4J = 7.3), 6.18 (1H, dt, 3J = 15.6 Hz, 4J = 1.4 Hz), 6.14 (1H, dt, 3J = 15.6 Hz, 
4J = 1.4 Hz), 5.90 (2H, br s), 4.69 (1H, dd, 3J1 = 4.4 Hz, 
3J2 = 2.9 Hz), 4.61 (1H, dd, 
3J1 = 4.4 Hz, 
3J2 = 2.9 Hz), 4.00-3.80 (4H, m), 3.49-3.45 (2H, m), 3.44 (4H, m), 3.07 (4H, t, 
3J = 6.4 Hz), 2.49-2. 31 (4H, m), 1.94 (3H, s), 1.94 (3H, s), 1.71-1.48 (12H, m), 1.23 (3H, d, 
3J = 6.3 Hz), 1.12 ppm (3H, d, 3J = 6.3 Hz);  = +7.05 (c = 4.2 mg mL−1, MeOH). 
 
(R)-(E)-S-(2-Acetamidoethyl)-5-((tetrahydro-2H-pyran-2-yl)oxy)hex-2-enethioate 21 
Compound 21 was prepared by the same procedure used for the synthesis of compound 20 by 
using 19 (60 mg, 0.28 mmol). Purification by column chromatography (chloroform/methanol 
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100/0 to 95/5) gave 46 mg of a colorless oil. Yield: 52 %. NMR data are identical to those of 
compound 20; Yield: 52 %.  = −8.48 (c = 4.7 mg mL−1, MeOH). 
 
(S)-(E)-S-(2-Acetamidoethyl) 5-hydroxyhex-2-enethioate 4[1] 
The protected ester 20 (63 mg, 0.2 mmol) was dissolved in methanol (2 mL) and 
p-toluenesulfonic acid monohydrate (4 mg, 0.02 mmol) in methanol (1 mL) was added 
dropwise. After 16 h saturated sodium hydrogen carbonate solution (3 mL) and water (3 mL) 
were added. The aqueous phase was extracted with ethyl acetate (3×5 mL) and the combined 
organic fractions were dried with sodium sulfate and concentrated under reduced pressure. 
Column chromatography over silica gel (chloroform/methanol 95:5) gave a colorless oil 
(37 mg).  
Yield: 80 %. 1H NMR (600 MHz, CDCl3): δ 6.92 (1H, dt, 
3J = 15.6 Hz, 4J = 7.5 Hz), 6.20 
(1H, dt, 3J = 15.6 Hz, 4J = 1.4 Hz), 3.97 (1H, m), 3.45 (2H, q, 3J = 6.3), 3.08 (2H, t, 
3J = 6.4 Hz), 2.36-2.33 (2H, m), 1.97 (3H, s), 1.23 ppm (3H, d, 3J = 6.3 Hz);  = +8.66 
(c = 1 mg mL−1, MeOH). 
 
(R)-(E)-S-(2-Acetamidoethyl) 5-hydroxyhex-2-enethioate 5 
Compound 5 was synthesized from 22 (4.7 mg, 0.015 mmol) by the same procedure as 
described for the S-enantiomer 4. Isolation of the product gave a colorless oil (2.4 mg). 
Yield: 71 %. NMR data are identical to those of compound 4;  = −6.77 (c = 1 mg mL−1, 
MeOH). 
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General Procedure for the Synthesis of SNAC-Thioesters 
The free carboxylic acid (2 mmol) was dissolved or suspended in 15 mL of dry 
dichloromethane, and the mixture was cooled to 0 °C. Subsequently N-acetylcysteamine 
(2 mmol), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (2.5 mmol) and 
4-dimethylaminopyridine (0.2 mmol) were added. The solution was slowly allowed to warm 
to room temperature and stirred for 12 hours. Water (20 mL) and dichloromethane (20 mL) 
were added to the solution, and the aqueous phase was extracted with dichloromethane 
(2×20 mL). The combined organic phases were dried over sodium sulfate and concentrated 
under reduced pressure. The product was subsequently purified by column chromatography 
on silica gel (gradient elution: chloroform/methanol: 98:2 to 90:10).  
 
(E)-S-(2-Acetamidoethyl) 3-(2-hydroxyphenyl)prop-2-enethioate 10 
 
 
 
Yield: 84 %. Yellow solid; m.p. 150.4 – 151.2 °C; 1H NMR (500 MHz, MeOD): δ 7.88 (1H, 
d; 3J = 3.1 Hz), 7.49 (1H, dd, 3J1 = 8.0 Hz, 
3J2 = 1.6 Hz), 7.22 (1H, m), 6.93 (1H, d, 
3Jtrans = 15.9 Hz), 6.84 (2H, m), 3.37 (2H, t, 
3J = 6.7 Hz), 3.11 (2H, t, 3J = 6.7 Hz), 1.93 ppm 
(3H, s); 13C NMR (125 MHz, MeOD): δ 191.6, 173.5, 158.9, 138.4, 133.0, 130.5, 125.5, 
122.2, 120.8, 117.1, 40.4, 29.1, 22.5 ppm; IR (film): 3363, 1641, 1600, 1446, 1263, 1020, 
973, 743 cm–1; HRMS: (ESI+): m/z calculated for C13H16O3NS: 266.0845, found 266.0845 
[M+H]+. 
 
S-(2-Acetamidoethyl) 5-oxohexanethioate 22 
 
 
 
Yield: 90 %. Colorless liquid; 1H NMR (500 MHz, CDCl3): δ 6.26 (1H, bs), 3.40 (2H, q, 
3J = 6.4 Hz), 3.00 (1H, t, 3J = 6.4 Hz), 2.57 (2H, t, 3J = 7.1 Hz), 2.48 (2H, t, 3J = 7.1 Hz), 2.11 
(3H, s), 1.98 (3H, s), 1.90 ppm (2H, quint, 3J = 7.1 Hz); 13C NMR (125 MHz, CDCl3): δ 
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207.8, 199.4, 170.8, 42.9, 42.1, 39.6, 29.9, 28.4, 22.9, 19.4 ppm; IR (film): 3289, 3097, 2951, 
1705, 1679, 1636, 1557, 1441, 1362, 1295, 987 cm–1; HRMS: (ESI+): m/z calculated for 
C10H18O3NS: 232.1002, found 232.0999 [M+H]
+. 
 
 
 
Scheme S2. a) N-acetylcysteamine, DMAP, EDCl, CH2Cl2, 0 °C then RT, 90 %; b) NaBH4, CeCl3, 
THF, 0 °C, 66 %. DMAP = 4-dimethylaminopyridine, EDCl = N-(3-dimethylaminopropyl)-N-ethylcarbo 
diimide hydrochloride. 
 
S-(2-Acetamidoethyl) 5-hydroxyhexanethioate 8 
 
 
 
To an ice-cooled, stirred suspension of S-(2-acetamidoethyl) 5-oxohexanethioate 22 (35 mg, 
0.15 mmol) and CeCl3 (100 mg, 0.4 mmol, 1.5 equivalents) in dry THF (0.5 mL) was given 
NaBH4 (10 mg, 0.27 mmol). After 2 hours, the reaction mixture was cooled to −78 °C and 
methanol (0.2 mL) was added. After 30 minutes water (1 mL) and ethyl acetate (1 mL) were 
added. The aqueous layer was extracted with ethyl acetate (2×1 mL). The combined organic 
fractions were dried with Na2SO4 and the solvent evaporated under reduced pressure. After 
silica gel column chromatography (CHCl3/MeOH 98:2) a colorless liquid oil (23 mg) was 
obtained.  
Yield: 66 %. Colorless oil; 1H NMR (500 MHz, MeOD): δ 7.87 (1H, s), 3.64-3.75 (1H, m), 
3.29 (3H, m), 2.98 (2H, t, 3J = 6.7 Hz), 2.58 (2H, t, 3J = 7.5 Hz), 1.89 (3H, s), 1.69 (2H, m), 
1.38-1.45 (2H, m), 1.12 ppm (3H, d, 3J = 6.1 Hz); 13C NMR (125 MHz, MeOD): δ 200.5, 
173.4, 68.1, 44.7, 40.1, 39.1, 29.1, 23.5, 23.0, 22.5 ppm; IR (film): 3304, 2944, 2832, 1658, 
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1558, 1448, 1023 cm–1; HRMS: (ESI+): m/z calculated for C10H20O3NS: 234.1158, found 
234.1159 [M+H]+. 
 
 
 
 
Scheme S3. a) (Boc)2O, THF, RT, 73 %; b) 1. DIBAL-H, toluene, −78 °C; 2. S-(2-acetamidoethyl) 2-
(diethoxyphosphoryl) ethanethioate, LiCl, Et3N, acetonitrile, 0 °C then RT, 2 steps 90 %; c) TFA, THF, 
RT, 96 %. Boc = tertbutoxycarbonyl, TFA = trifluoroacetic acid. 
 
 
Ethyl 3-((tert-butoxycarbonyl)amino)butanoate 25 
 
 
 
To a stirred solution of (R,S)-ethyl 3-aminobutanoate (131 mg, 1 mmol) in dry THF di-t-butyl 
dicarbonate (240 mg, 1.1 mmol) was added in small portions. After 12 h, the solvent was 
removed under reduced pressure, and the product was purified by column chromatography on 
silica gel (CHCl3/MeOH 98:2) to give 170 mg of a colorless oil.  
Yield: 73 %. Colorless oil; 1H NMR (500 MHz, CDCl3): δ 4.90 (1H, bs), 4.12 (2H, q, 
3J = 7.1 Hz), 4.01 (1H, bs), 2.40-2.52 (2H, m), 1.41 (9H, s), 1.24 (3H, t, 3J = 7.1 Hz), 
1.19 ppm (3H, d, 3J = 6.8 Hz). 
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S-(2-acetamidoethyl) (E)-5-((tert-butoxycarbonyl)amino)hex-2-enethioate 26 
 
 
 
A solution of (R,S)-ethyl 3-((tert-butoxycarbonyl)amino)butanoate 25 (50 mg, 0.2 mmol) in 
dry toluene (1.5 mL) was cooled to −78 °C, and DibalH solution (1 mL, 1 M in cyclohexane) 
was added dropwise. After 2 h the reaction was stopped by adding a mixture of methanol and 
HCl (1 M) (2:1, 4 mL). After warming to room temperature, the solution was filtered through 
Celite and washed thoroughly with ethyl acetate. The aqueous phase was extracted with ethyl 
acetate (2×25 mL), and the combined organic fractions were dried over sodium sulfate. After 
removal of the solvent under reduced pressure, the crude product was directly used for the 
next step. 
Phosphonate 1 (50 mg, 0.17 mmol) was dissolved in dry acetonitrile (1 mL) and given to a 
suspension of LiCl (8 mg, 0.2 mmol) in dry acetontrile (5 mL). The mixture was cooled to 
0 °C, and N,N-diisopropylethylamine (80 μL) was added dropwise. After the crude product of 
the first previous step was given to the mixture, the stirred solution was allowed to warm to 
room temperature. The reaction was quenched by adding a saturated ammonium chloride 
solution (5 mL), and the crude product was extracted with ethyl acetate (3×20 mL). The 
combined organic fractions were washed with water (50 mL) and dried over sodium sulfate. 
The product (60 mg) was obtained after column chromatography over silica gel 
(CHCl3/MeOH 95:5). 
Yield: 90 %. Colorless liquid; 1H NMR (300 MHz, MeOD): δ 6.83 (1H, dt, 3J1 = 15.5 Hz,
 
3J2 = 7.7 Hz ), 6.30 (1H, bs), 6.12 (1H, d, 
3J = 15.5 Hz), 4.41 (1H, bs), 4.14(1H, m), 3.42 (2H, 
m), 3.06 (2H, d, 3J = 6.3 Hz), 2.33 (2H, t, 3J = 6.8 Hz), 1.96 (3H, s), 1.40 (9H, s), 1.14 ppm 
(3H, d, 3J = 7.2 Hz); 13C NMR (75 MHz, MeOD): δ 190.0, 170.4, 155.7, 141.9, 130.5, 79.5, 
58.9, 39.7, 28.2, 23.1, 21.0, 20.9, 18.9 ppm; IR (film): 3305, 2938, 2828, 1661, 1538, 1367, 
1168, 1025 cm–1; HRMS: (ESI+): m/z calculated for C15H27O4N2S: 331.17, found 331.17 
[M+H]+. 
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S-(2-Acetamidoethyl) (E)-5-aminohex-2-enethioate 12 
 
 
 
To a stirred solution of (R,S)-S-(2-acetamidoethyl) (E)-5-((tert-butoxycarbonyl)amino)hex-2-
enethioate 26 (17 mg, 0.05 mmol) in dry THF trifluoracetic acid (24 μL, 0.3 mmol) was 
added at room temperature. After stirring for 48 h the solvent was removed under reduced 
pressure, and the product was purified by column chromatography (CHCl3/MeOH 95:5) in a 
Pasteur pipette to give 11 mg of colorless oil.  
Yield: 96 %. Colorless liquid; 1H NMR (300 MHz, MeOD): δ 6.83 (1H, dt; 3J = 15.5 Hz; 
3J = 7.4 Hz), 6.33 (1H, d, 3J1 = 15.5 Hz), 3.62-3.82 (1H, m), 3.35 (2H, m), 3.07 (2H, t, 
3J = 6.70 Hz), 2.40-2.65 (2H, m), 1.90 (3H, s), 1.30 ppm (3H, d, 3J = 6.70 Hz); 13C NMR 
(75 MHz, MeOD): δ 190.4, 173.5, 139.5, 133.1, 59.6, 40.0, 38.0, 29.1, 22.5, 18.6 ppm; IR 
(film): 3315, 2945, 2834, 1679, 1427, 1203, 1141, 1021 cm–1; HRMS: (ESI+): m/z calculated 
for C10H19O2N2S: 231.1162, found 231.1163 [M+H]
+. 
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Scheme S4. a) (Boc)2O, THF, RT, 73 %; b) 1. DIBAL-H, toluene, 78 °C; 2. LiCl, triethyl phosphono- 
acetate, iPr2NEt, acetonitrile, 0 °C then RT, 2 steps, 80 %; c) diethyl malonate, Cs2CO3, acetonitrile, 
80 °C, 91 %; d) TFA, CH3OH, RT, 88 %; e) 2 M HCl, 100 °C, 74 %. 
 
 
tert-Butyl (E)-(6-ethoxy-6-oxohex-4-en-2-yl)-l2-azanecarboxylate (27) 
 
 
Ethyl 3-((tert-butoxycarbonyl)amino)butanoate (941 mg, 4 mmol) was dissolved in toluene 
(5 mL) and cooled to −78 °C. Dibal (1 M in cyclohexane, 6 mL) was added dropwise, and the 
mixture was stirred for additional 2 h. After adding a solution of methanol and HCl (1 M) 
(2:1, 6 mL) the solution was warmed to room temperature and filtered through Celite and 
washed with diethyl ether (3×40 mL). The combined organic phases were dried over sodium 
sulfate and concentrated under reduced pressure. LiCl (168 mg, 4 mmol) and triethyl 
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phosphonoacetate (896 mg, 4 mmol) were suspended in dry acetonitrile (10 mL) and N,N-
diisopropylethylamine (680 μL, 4 mmol) was added to the mixture. After cooling to 0 °C, a 
solution of the freshly prepared aldehyde in acetonitrile (1 mL) was added. The mixture was 
allowed to warm to room temperature and stirred for 12 h. Saturated ammonium chloride  
solution  (10 mL),  water  (10 mL)  and diethyl ether (30 mL) were added, and the aqueous 
phase was extracted with diethyl ether (3×40 mL). The combined organic phases were dried 
over sodium sulfate and concentrated under reduced pressure. Column chromatography 
(chloroform/methanol 100:0 to 95:5) gave 822 mg of viscous oil. 
Yield: 80 %. Colorless oil; 1H NMR (300 MHz, MeOD): δ 6.86-6.96 (1H, dt, 3J = 15.6 Hz, 
3J = 7.5 Hz), 5.85 (1H, d, 3J = 15.6 Hz), 4.15 (2H, q, 3J = 7.1 Hz), 3.64-3.75 (1H, m), 3.29-
3.31 (1H, m), 2.32 (2H, q, 3J = 7.5 Hz), 1.41 (9H, s), 1.26 (3H, t, 3J = 7.1 Hz), 1.12 ppm (3H, 
d, 3J= 6.7 Hz); 13C NMR (75 MHz, CDCl3): δ 166.6, 156.4, 145.8, 122.8, 78.5, 60.0, 45.5, 
39.1, 27.3, 19.6, 13.1 ppm; IR (film): 3333, 2942, 2832, 1688, 1528, 1448, 1368, 1272, 1119 
cm–1; HRMS: (ESI+): m/z calculated for C13H24O4N: 258.1700, found 258.1697 [M+H]
+. 
 
Triethyl 2-(2-((tert-butoxycarbonyl)amino)propyl)propane-1,1,3-tricarboxylate 28  
 
 
Tert-butyl (E)-(6-ethoxy-6-oxohex-4-en-2-yl)-l2-azanecarboxylate (27) (26 mg, 0.1 mmol) 
was dissolved in dry acetonitrile (0.5 mL). Diethyl malonate (32 mg, 0.2 mmol) and cesium 
carbonate (16 mg, 0.05 mmol) were added, and the mixture was stirred for 10 h at 80 °C. 
Non-dissolved components were filtered off, and the filtrate was concentrated under reduced 
pressure. Column chromatography (n-hexane/ethyl acetate 90:10) gave 38.5 mg of clear oil. 
Yield: 91 %. Colorless oil; 1H NMR (500 MHz, CDCl3): δ 4.2-4.08 (8H, m), δ 3.67 (1H, d, 
3J = 6.0 Hz), 2.66-2.51 (2H, m), 1.62 (1H, bs), 1.55-1.45 (2H, m), 1.42 (9H, s), 1.26-1.22 (9H, 
m), 1.11 ppm (3H, d, 3J = 6.4 Hz); 13C NMR (125 MHz, CDCl3): δ 172.0, 168.5, 168.4, 155.5, 
62.6, 61.2, 60.3, 53.8, 39.4, 35.9, 31.6, 28.3, 21.6, 16.2, 14.1, 14.0 ppm (data given for the 
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main stereoisomer); IR (film): 2978, 1729, 1520, 1448, 1367, 1247, 1158 cm–1; HRMS: 
(ESI+): m/z calculated for C20H36O8N: 418.2435, found 418.2437 [M+H]
+. 
 
Triethyl 2-(2-aminopropyl)propane-1,1,3-tricarboxylate 29 
 
Compound 28 (12 mg, 0.029 mmol) was dissolved in dichloromethane (0.5 mL), and 
trifluoroacetic acid (20 μL) was added cautiously. After 5 h the solvent was removed under a 
stream of nitrogen gas, and the product was purified by small-scale column chromatography 
(CHCl3/MeOH 98:2 to 95:5) to give 8 mg of a viscous liquid. 
Yield: 88 %. Colorless oil; 1H NMR (500 MHz, MeOD): δ 4.24-4.12 (6H, m), 3.66 (1H, d, 
3J = 5.6 Hz), 3.36 (1H, m), 2.67 (1H, m), 2.65-2.56 (1H, m), 2.51-2.45 (1H, m), 1.83-1.74 
(1H, m), 1.71-1.60 (1H, m), 1.31 (3H, d, 3J = 6.5 Hz) 1.28-1.24 ppm (9H, m); 13C NMR 
(125 MHz, MeOD): δ 174.0, 173.6, 169.9, 169.8, 169.8, 169.7, 62.8, 62.7, 62.0, 61.9, 55.7, 
55.3, 47.2, 47.0, 38.7, 38.3, 37.2, 37.0, 37.0, 32.3, 32.3, 19.3, 18.5, 14.5, 14.4, 14.4 ppm; IR 
(film): 3335, 2949, 2836, 1672, 1402, 1203, 1142 cm–1; HRMS: (ESI+): m/z calculated for 
C15H28O6N: 318.1911, found 318.1905 [M+H]
+. 
 
2-(2-Methyl-6-oxopiperidin-4-yl)acetic acid 13 
 
Compound 29 (7.8 mg, 0.025 mmol) was suspended in HCl (2 M, 400 μL) and heated to 
100 °C in a clear glass vial (1.5 mL) closed with a screw cap. After 28 hours the solution was 
cooled to room temperature and water (1 mL) was added. After washing with ethyl acetate 
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(3×1 mL) the aqueous phase was concentrated in an argon flow to give 3.1 mg (0.018 mmol) 
of clear oil.  
Yield: 74 %. Colorless liquid; mixture of diastereoisomers, NMR signals are given for the 
main diastereoisomer, 1H NMR (600 MHz, D2O): δ 3.32-3.26 (1H, m), 2.39-2.33 (3H, m), 
2.32-2.23 (2H, m), 1.61-1.44 (2H, m), 1.17 ppm (3H, d, 3J = 6.6 Hz); 13C NMR (150 MHz, 
D2O): δ 174.5, 173.2, 47.0, 43.7, 36.7, 36.4, 35.7, 26.3, 15.8 ppm; IR (film): 3320, 2945, 
2832, 1447, 1415, 1022 cm–1; HRMS: (ESI+): m/z calculated for C8H14O3N: 172.0968, found 
172.0969 [M+H]+. 
 
 
 
Scheme S5. a) 1. SOCl2, CH2Cl2, RT; 2. NH3 in MeOH, −78 °C, 2 steps, 84 %; b) N-acetylcysteamine, 
DMAP, EDC, CH2Cl2, 0 °C then RT, 66 %, c) Grubbs II, CH2Cl2, RT. 
 
 
But-3-enamide 31 
 
 
But-3-enoic acid (516 mg, 6 mmol) was suspended in dry dichloromethane (10 mL), and 
thionyl chloride was added dropwise. The solution was stirred for 4 h after the addition of 
DMF (50 μL). The solution was cooled to −78 °C, and a solution of ammonia in MeOH (7 N, 
6 mL) was added. The solution was allowed to warm to room temperature. After 15 hours it 
was concentrated under reduced pressure. Column chromatography over silica gel 
(CHCl3/MeOH 98:2 to 7:1) gave pure amide 31 (426 mg). All analytical data were identical to 
those reported earlier.[2] 
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Yield: 84 %. Colorless liquid, 1H NMR (300 MHz, CDCl3): δ 5.92 (1H, m), 5.89 (2H, bs), 
5.25 (1H, m), 5.21 (1H, m), 3.02 ppm (2H, dt, 3J1 = 7.1 Hz, 
4J2 = 1.2 Hz); HRMS: (ESI+): m/z 
calculated for C8H15O2N2: 171.1128, found 171.1127 [2M+H]
+. 
 
S-(2-Acetamidoethyl) prop-2-enethioate 33 
 
 
Acrylic acid (288 mg, 4 mmol), N-acetylcysteamine (476 mg, 4 mmol) and DMAP (48 mg, 
0.4 mmol) were dissolved in dry dichloromethane under argon. The solution was cooled to 
0 °C, and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (840 mg, 
4.4 mmol) was added. The solution was stirred for 15 h at room temperature. The white slurry 
was concentrated under reduced pressure, and the residue was subjected to column 
chromatography using silica gel (CHCl3/MeOH 95:5) to give 453 mg of a viscous liquid. 
Yield: 66 %. Colorless liquid, 1H NMR (600 MHz, CDCl3): δ 6.38 (1H, dd, 
3J1 = 17.2 Hz, 
3J2 = 10.0 Hz), 6.31 (1H, dd, 
3J = 17.2 Hz, 2J = 1.0 Hz), 5.88 (1H, bs), 5.72 (1H, dd, 
3J = 10.0 Hz, 2J = 1.0 Hz), 3.46 (2H, q, 3J = 6.20 Hz), 3.10 (2H, t, 3J = 6.20 Hz), 1.95 ppm 
(3H, s); 13C NMR (75 MHz, MeOD): δ 190.8, 170.6, 134.7, 127.2, 39.7, 28.3, 23.1 ppm; IR 
(film): 3304, 2946, 2835, 1658, 1559, 1399, 1021 cm–1; HRMS: (ESI+): m/z calculated for 
C7H12O2NS: 174.0583, found 174.0583 [M+H]
+. 
 
 
(E)-5-((2-acetamidoethyl)thio)-5-oxopent-3-enoic acid 14 
 
 
 
But-3-enoic acid (2.5 mg, 0.029 mmol) and thioester 33 (5 mg, 0.029 mmol) were dissolved 
in dry dichloromethane (0.5 mL) under argon. After addition of Hoveyda-Grubbs catalyst 2nd 
generation (7 mg, 0.01 mmol) the solution was stirred for 3 h. The solvent was evaporated 
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under reduced pressure, and the residue subjected to column chromatography on silica gel 
(CHCl3/MeOH 100:0 to 90:10) to give a white solid.  
Yield: 48 % (based on recovered starting material 33). Compound 16a appears as a mixture 
with its isomer 16b. All attempts to obtain the pure compound 16a failed due to a fast 
equilibrium at room temperature. White solid, 1H NMR (500 MHz, MeOD): δ 6.91-6.70 (1H, 
m), 6.27 (1H, dt, 3J = 15.6 Hz, 3J = 1.6 Hz), 3.31-3.35 (2H, m), 3.30 (2H, m), 3.07 (2H, t, 
3J = 6.6 Hz), 1.91 ppm (3H, s); 13C NMR (125 MHz, MeOD): δ 196.8, 190.6, 173.5, 140.8, 
138.8, 40.0, 29.4, 29.0, 22.5 ppm; IR (film): 3325, 2948, 2835, 1660, 1449, 1412, 1112 cm–1; 
HRMS: (ESI+): m/z calculated for C9H14O4NS: 232.0644, found 232.0631 [M+H]
+. 
 
S-(2-Acetamidoethyl) (E)-5-amino-5-oxopent-2-enethioate 16 
 
 
 
But-3-enamide (8.5 mg, 0.1 mmol) and thioester 33 (17 mg, 0.1 mmol) were dissolved in dry 
dichloromethane (0.5 mL) under argon. After addition of Hoveyda-Grubbs catalyst 2nd 
generation (24 mg, 0.04 mmol) the solution was stirred for 3 h. The solvent was evaporated 
under reduced pressure, and the residue subjected to column chromatography on silica gel 
(CHCl3/MeOH 100:0 to 80:20) to give a white solid.  
Yield: 70 % (based on recovered starting material 33). 1H NMR (600 MHz, CDCl3): δ 6.96 
(1H, dt, 3J = 15.5 Hz, 3J = 7.2 Hz), 6.28 (1H, dt, 3J = 15.5 Hz, 4J = 1.5 Hz), 3.34 (2H, t, 
3J = 6.7 Hz), 3.15 (2H, dd, 3J = 7.2 Hz, 4J = 1.5 Hz), 3.07 (2H, t, 3J = 6.7 Hz), 1.91 ppm (3H, 
s); 13C NMR (150 MHz, CDCl3):  δ 190.6, 174.4, 173.5, 139.5, 131.8, 40.1, 39.3, 29.0, 22.5 
ppm; IR (film): 3310, 2947, 2831, 1663, 1407, 1111, 1020 cm–1; m/z calculated for 
C9H15O3N2S: 231.0798, found 231.0793 [M+H]
+. 
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6. NMR Spectra 
 
Figure S1. 1H NMR spectrum (MeOD, 500 MHz) of 8. 
 
 
Figure S2. 13C NMR spectrum (MeOD, 125 MHz) 8.  
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Figure S3. 1H NMR spectrum (MeOD, 500 MHz) of 10. 
 
Figure S4. 13C NMR spectrum (MeOD, 125 MHz) of 10. 
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Figure S5. 1H NMR spectrum (MeOD, 300 MHz) of 12. 
 
 
Figure S6. 13C NMR spectrum (MeOD, 75 MHz) of 12. 
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Figure S7. 1H NMR spectrum (D2O, 600 MHz) of 13. 
Figure S8. 13C NMR spectrum (D2O, 150 MHz) of 13. 
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Figure S9. 1H NMR spectrum (CDCl3, 500 MHz) of 14. 
 
 
Figure S10. 13C NMR spectrum (CDCl3, 125 MHz) of 14.  
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Figure S11. 1H NMR spectrum (CDCl3, 600 MHz) of 16. 
 
Figure S12. 13C NMR spectrum (CDCl3, 150 MHz) of 16. 
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Figure S13. 1H NMR spectrum (CDCl3, 600 MHz) of 22. 
 
Figure S14. 13C NMR spectrum (CDCl3, 125 MHz) of 22. 
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Figure S15. 1H NMR spectrum (CDCl3, 500 MHz) of 25. 
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Figure S16. 1H NMR spectrum (CDCl3, 300 MHz) of 26. 
 
Figure S17. 13C NMR spectrum (CDCl3, 75 MHz) of 26. 
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Figure S18. 1H NMR spectrum (CDCl3, 300 MHz) of 27. 
 
Figure S19. 13C NMR spectrum (CDCl3, 75 MHz) of 27. 
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Figure S20. 1H NMR spectrum (CDCl3, 500 MHz) of 28. 
Figure S21. 13C NMR spectrum (CDCl3, 125 MHz) of 28. 
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Figure S22. 1H NMR spectrum (MeOD, 500 MHz) of 29. 
Figure S23. 1H NMR spectrum (MeOD, 125 MHz) of 29. 
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Figure S24. 1H NMR spectrum (CDCl3, 600 MHz) of 33. 
 
Figure S25. 13C NMR spectrum (CDCl3, 150 MHz) of 33. 
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7. Original HRMS Data 
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Figure S26. EIC (m/z = 171.0646-171.0664, negative mode) and mass spectrum after in vitro 
enzymatic biotransformation of 4. 
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Figure S27. EIC (m/z = 171.0646-171.0664, negative mode) and mass spectrum after in vitro 
enzymatic biotransformation of 5. 
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Figure S28. EIC (m/z = 171.0646-171.0664, negative mode) mass spectrum of reference compounds 
6 and 7. 
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Figure S29. EIC (m/z = 172.0957-172.0975, positive mode) and mass spectrum after in vitro 
enzymatic biotransformation of 12. 
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Figure S30. EIC (m/z = 172.0957-172.0975, positive mode) and mass spectrum of reference 
compound 13. 
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Figure S31. EIC (m/z = 170.0438-170.0456, negative mode) and mass spectrum after in vitro 
enzymatic biotransformation of 16. 
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Figure S32. EIC (m/z = 170.0438-170.0456, negative mode) and mass spectrum of reference 
compound 17. 

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8. Original MALDI Data 
 
 
Figure S33. MALDI-analysis of holo-ACP. 
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Figure S34. MALDI-analyses of ACP-bound products of in vitro biotransformation of 5 (top) and 4 
(bottom). 
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Figure S35. MALDI-analysis after attempted in vitro biotransformation of 8. 
 
 
Figure S36. MALDI-analysis after attempted in vitro biotransformation of 10. 
 
 
Figure S37. MALDI-analysis of ACP-bound product of in vitro biotransformation of 12. 
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Figure S38. MALDI-analysis of ACP-bound product of in vitro biotransformation of 16. 
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Twofold polyketide branching by a stereoselective
enzymatic Michael addition†
Daniel Heine,a Srividhya Sundaram,a Tom Bretschneidera and Christian Hertweck*ab
The versatility of the branching module of the rhizoxin polyketide
synthase was tested in an in vitro enzyme assay with a polyketide
mimic and branched (di)methylmalonyl-CoA extender units. Compar-
ison of the products with synthetic reference compounds revealed that
the module is able to stereoselectively introduce two branches in one
step by aMichael addition–lactonisation sequence, thus expanding the
scope of previously studied PKS systems.
Modular polyketide synthases represent miniaturized assembly
lines that produce many pharmaceutically relevant natural
products with highly diverse structures and biological activities.1
The biosynthesis of the complex polyketides typically involves
simple head-to-tail fusions of activated acyl and malonyl units.
Specifically, a ketosynthase (KS) is primed with an acyl unit, a
malonyl unit is loaded onto the adjacent acyl carrier protein
(ACP) by an acyl transferase (AT), and the KS catalyzes the
Claisen condensation of the bound thioesters to give a b-keto
thioester.2 The variety of polyketide structures result from
several levels of polyketide diversification, including the size
of the chain, the type of building blocks incorporated, the
degree of b-keto processing, and diverse enzymatic tailoring
reactions during or downstream of chain assembly.3 Yet, the
range of realized metabolite structures is limited by the cano-
nical KS-catalyzed Claisen condensation, which exclusively
yields linear polyketide backbones. Deviations from this
scheme are extremely rare, but can have a major impact on
the polyketide structures and their binding to biological tar-
gets. One of these examples is the phytotoxic rhizoxin complex,
which comprises some of the strongest antimitotic agents
known to date.4 Rhizoxin is produced in an unusual symbiosis
of the bacterium Burkholderia rhizoxinica that lives in the
cytosol of the plant-pathogenic fungus Rhizopus microsporus.5
The bacterial endosymbionts assemble the macrolactone core,4
and the fungus increases phytotoxicity of the macrolide by
oxidative tailoring.5b Most importantly, the structure of this
highly active antiproliferative agent features an internal d-lactone
residue that proved to be crucial for the eﬀective interaction
of the polyketide with its biological target, b-tubulin.6 The small
lactone ring branches oﬀ the polyketide backbone in the
b-position of a former acetate unit.7 In general, branches in
polyketide backbones may be introduced by the utilization
of branched starter units,8 chain elongation by substituted
malonyl groups,9 or a-methylation by S-adenosylmethionine
(SAM)-dependent methyltransferases, in particular in modular
trans-AT PKS.10 The polyketide can also be alkylated at the
b-keto group by a mechanism known from mevalonate bio-
synthesis.11 However, none of these mechanisms could ratio-
nalize the formation of the d-lactone in rhizoxin, in particular
since the rhizoxin-producing symbiont lacks genes for isoprenoid-
type branching enzymes.12 Dissection of the modular rhizoxin
(rhi) PKS13 and structural analysis of all pathway intermediates14
suggested that the branch resulted from the vinylogous addition
of a malonyl-unit to an a,b-unsaturated thioester. The architecture
of the modular PKS, which is colinear with the rhizoxin struc-
ture,13a,15 suggested that an unprecedented module consisting of
KS, B (branching) and ACP domains is involved in the chain
branching reaction (Fig. 1).
The in vitro reconstitution of the ‘branching module’ was
succeeded by mixing heterologously produced, soluble KS-B
didomain, ACP and trans-AT.16 By using synthetic pathway
surrogates, mutational analyses and elucidation of the KS-B
protein structure we gained first insight into the course of the
reaction.16 Accordingly, the C–C bond is formed by Michael
addition of the C-2 of the ACP-bound malonyl, and nucleophilic
attack of the d-hydroxyl group at the thioester-bound polyketide
yields the lactone ring.16 We also found that the branching
module tolerates alternative substrates with amine and amide
substituents in lieu of the alcohol, giving rise to d-lactam and
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glutarimide residues, respectively.17 An open question remained
whether or not the branching module would also allow the
incorporation of a substituted extender unit, which would lead
to two chain branches and two new stereocenters in a single
biotransformation. Here, we report the finding that the KS-B
module is indeed capable of introducing a branched extender
unit and elucidate the mechanistic and stereochemical implica-
tions of this reaction. To test the scope of the vinylogous chain
branching reaction in vitro we interrogated the module with
a surrogate of the growing polyketide chain and substituted
malonyl-CoA thioesters. The functional module was success-
fully reconstituted using His-tagged KS-B didomain, holo-ACP
and trans-AT (Fig. 2). As surrogate, an a,b-unsaturated thioester
was designed that contains an S-configured hydroxyl group in
d-position, as in the natural substrate produced upstream of the
b-branching module.16,17 The N-acetyl cysteamine (SNAC) thio-
ester mimics the phosphopantetheinyl linker in the natural ACP,
which allows for the transfer of the acyl onto the KS by trans-
esterification. To monitor product formation in the in vitro assay
the ACP–lactone adduct was measured by matrix-assisted laser
desorption/ionization-time of flight (MALDI-TOF) analysis, and
the detached lactone was analyzed by high-performance liquid
chromatography-high resolution mass spectrometry (HPLC-
HRMS) using synthetic references. The successful transfer of
methylmalonyl-CoA (MMCoA) onto the ACP is a prerequisite for
the biotransformation. In this context it should be noted that the
loading of MMCoA onto ACP by a regular trans-AT is unusual as
trans-AT PKSs typically employ malonyl-CoA (MCoA), but a
degree of flexibility towards MMCoA in vitro has been observed
previously in some systems.18
The successful formation of the desired adduct was verified
by MALDI-TOF. When performing the assay with MMCoA in
place of MCoA, we detected a new signal in the MALDI trace at
m/z = 12738 (Fig. 3). Comparison with the signal of the holo-ACP
indicated a mass shift of 168 Da, which points towards
the eﬀective transfer of the substrate and the incorporation of
a C3H5O unit. Notably, performing the assay with a heat-
inactivated version of the KS or without substrate (substrate
blank) did not give any comparable signals, thus proving that the
reaction is enzyme catalyzed. After workup and extraction of the
new product with methanol, HPLC-HRMS revealed the for-
mation of two new compounds with m/z = 187.0964 [M + H]+,
which correspond to a molecular formula of C9H15O4. The
deduced molecular mass diﬀers from the product obtained with
MCoA by 14 Da, thus indicating that MMCoA was successfully
incorporated. Although MSn fragmentation data already strongly
suggested that d-lactones with methyl branches are produced, a
synthetic reference was required to (a) verify its constitution and
to elucidate (b) the exact position of the methyl group (at the side
chain or attached to the lactone ring) and (c) the configuration of
the substituents. Synthesis of the reference was initiated by a
Z-selective Still–Gennari olefination variant of the Horner–Wads-
worth–Emmons reaction.19 Deprotection of the THP ether 6 by
p-toluenesulfonic acid gave p-sorbic acid (7) in excellent yield.
Michael-addition of diethyl methylmalonate at elevated tempera-
ture proceeded smoothly, but resulted in a mixture of syn-/anti-
diastereoisomers of the product of the Michael addition.
Fig. 1 Structure of rhizoxin (1) and model for Michael-type polyketide
branching to form the d-lactone side chain; (i) Michael addition and
(ii) hydrolysis of the thioester bond at the KS and lactonisation. KS,
ketosynthase; B, branching domain; ACP, acyl carrier protein.
Fig. 2 Experimental setup for the in vitro b-branching assay. SNAC,
N-acetylcysteamine; AT, acyltransferase; MCoA, malonyl-CoA, MMCoA,
methylmalonyl-CoA, DMMCoA, dimethylmalonyl-CoA.
Fig. 3 (A) SIM-LC-HRMS (m/z = 185.0814, negative mode) analysis of
hydrolyzed product and comparison with the synthetic reference (mixture
of diastereoisomers). (B) MALDI analysis of ACP-bound product. SIM,
selected ion monitoring.
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To improve diastereoselectivity, the reaction conditions were
altered, eventually leading to a single product of the vinylogous
addition at room temperature. The syn-configuration of 8 was
proven by NOE spectroscopy. Acidic hydrolysis resulted in
decarboxylation, and yielded the desired lactone reference 3
in 78% yield (Fig. 4). Analysis of 2D NMR data including NOESY
data shed light on the relative configuration of product refer-
ence 3. Substituents at C-3 and C-5 are syn, and since C-5 (S) is
predefined in the d-hydroxy ester 4, position C-3 has an R
configuration. As position C-2 is not defined, reference 3 exists
as a 1 : 1 mixture of the two diastereoisomers, 3a and 3b
(Fig. S1, ESI†). HPLC-HRMS comparison of the synthetic refer-
ence with the product of the enzyme assay showed that the
synthetic diastereoisomers 3a/b are identical with the two
compounds formed in the in vitro assay. Thus, we unequivocally
verified the structures of the reaction products. Since both R- and
S-MMCoA are accepted as substrates for the branching module,
the active site obviously provides suﬃcient space for both enan-
tiomers. Thus, it appeared reasonable to examine whether
dimethylmalonyl-CoA (DMMCoA) would also be accepted as a
branching/elongation unit. Recently, we have shown that a
KS-like enzyme loads DMMCoA onto a sugar residue of the
antibiotic cervimycin.20 Furthermore, DMMCoA is accepted as
an elongation unit by the yersiniabactin and epothilone PKSs.21
To test whether this substrate is also incorporated into the
rhizoxin substructure, we synthetically prepared DMMCoA20
and loaded the dimethylmalonyl moiety onto the holo-ACP by
means of the trans-AT. Since the trans-AT-catalyzed malonyl
transfer could be a potential bottleneck, we verified the success-
ful formation of DMM–ACP byMALDI-TOF analysis. It is remark-
able that the trans-AT is also capable of transferring this unusual
building block. We then applied the ACP adduct to the in vitro
enzyme assay. Monitoring the fate of DMMCoA–ACP in the
in vitro branching reaction by MALDI and HPLC-HRMS did not
show any formation of a dimethylated product. However, we
observed the decarboxylated DMM–ACP, isobutyryl–ACP by
MALDI analyses (Fig. S2, ESI†). Thus, one can conclude that
DMM–ACP is not accepted as substrate for the branching
module. A plausible explanation could be that the space for
the elongation unit is limited and DMM might be orientated
differently in the KS, hampering C–C-bond formation. Our
findings, in particular the results obtained with MMCoA, have
several implications for the reaction mechanism of the rare PKS
branching module. First, the finding that the methyl branch is
exclusively located in the side chain supports the proposed
reaction mechanism in which the d-hydroxy group of the
Michael adduct attacks the thioester carbonyl at the KS. As a
consequence, the initial chain is terminated and the newly
introduced malonyl-derived carbon chain is passed on to the
downstream module for further elongation. Second, we found
that the reaction is highly specific with respect to diastereo-
control of lactone ring formation. MMCoA attacks from the Re
face, resulting in the R-configuration of the b-carbon atom. In
contrast, the configuration of the a-position appears as a mixture
of both configurations. It is well conceivable that an isomerisa-
tion occurs after decarboxylation and formation of the carbon
nucleophile. The proposed mechanism also implies that the
vinylogous attack of an E-enolate would yield a product with the
opposite configuration at the b-carbon (Fig. 5).
In conclusion, we have shown that the KS-B didomain is
capable of performing a twofold chain branching by Michael
addition of a substituted extender unit. Besides the incorpora-
tion of MCoA extender units, the KS-B didomain allows for the
incorporation of MMCoA resulting in a double-branch of the
polyketide backbone. While attack of the methyl malonyl unit
at the a,b-unsaturated thioester and the subsequent lactonisation
take place with marked syn-diastereoselectivity, an R/S-mixture
was observed for the third stereocenter that results from the
incorporation of the substituted malonyl unit. Our results grant
insight into the scope of the unusual PKS module and strongly
support the proposed reaction mechanism. From a synthetic
biology perspective, these findings are important since the use
of the branching module could greatly enhance the current
options for polyketide chain diversification. In particular, the
alteration of complex polyketides that are not easily accessible by
Fig. 4 Chemical synthesis of product reference 3. (a) 3,4-Dihydro-2H-
pyran, PPTS, CH2Cl2, 0 1C then RT, 93% (b) (1) DIBAL, toluene, 78 1C,
(2) methyl P,P-bis(2,2,2-trifluoroethyl)phosphonoacetate, KHMDS, 18-crown-
6, THF, 78 1C, 2 steps 55% (95% cis) (c) TosOH, CH2Cl2, 94% (d) diethyl
methyl-malonate, Cs2CO3, acetonitrile, 0 1C then RT, 69% (e) 2 M HCl,
100 1C, 78%. PPTS = pyridinium p-toluenesulfonate, DIBAL = diisobutylalu-
minium hydride, KHMDS = potassium bis(trimethylsilyl)amide, THF = tetra-
hydrofuran, TosOH = p-toluenesulfonic acid.
Fig. 5 Proposed mechanism of the diastereoselective Michael addition of
the decarboxylated, branched extender unit MMCoA at the polyketide
surrogate 2. The nucleophilic attack exclusively takes place at the Re face,
resulting in an R configured new chiral center. No rigorous stereocontrol
over the second stereocenter formed in this reaction was observed.
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synthetic methods and their sustainable production might come
within reach.
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Twofold Polyketide Branching by a Stereoselective 
Enzymatic Michael Addition 
Daniel Heine,a Srividhya Sundaram,a Tom Bretschneidera and Christian Hertwecka,b*
Instrumentation
NMR spectra were recorded on Bruker AVANCE II 300, AVANCE III 500 or 600 MHz 
spectrometer, equipped with a Bruker Cryo platform. Chemical shifts are reported in parts 
per million (ppm) relative to the solvent residual peak of chloroform-d1 (1H: 7.24 ppm, 
singlet; 13C: 77.00 ppm, triplet) or methanol-d4 (1H: 3.30 ppm, quintet; 13C: 49.00 ppm, 
septet). MALDI measurements were performed with a Bruker UltrafleXtreme machine. 
HRESI-MS was carried out with an Accela UPLC-system (Thermo Scientific) combined with an 
Exactive mass spectrometer (Thermo Scientific) equipped with an electrospray ion source. 
HPLC-MS measurements were performed on a HPLC 1100 System connected to a 1100 
Series LC/MSD Trap using an Zorbax Eclipse XDB-C8, 4.6 x 150 mm column, particle size 5 μm 
(Agilent Technologies). Semi-preparative HPLC was performed on a 1260 Infinity System 
(Agilent Technologies) using the following columns: Zorbax Eclipse XDB-C8, 9.5 x 250 mm, 
particle size 5 μm (Agilent Technologies), Zorbax Eclipse XDB-C18, 9.5 x 250 mm, particle size 
5 μm (Agilent Technologies) and EC 250/4 Nucleodur Sphinx RP, particle size 5 μm 
(Macherey-Nagel). All solvents for analytical and preparative HPLC measurements were 
obtained commercially at least in gradient grade and were filtered prior to use. To avoid 
microbial growth 0.1 % formic acid was added to the water, used for analytical and 
preparative HPLC. IR-spectra were recorded on an FT/IR-4100 ATR spectrometer (Jasco).
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General experimental procedures
All reagents were obtained from commercial suppliers (Sigma Aldrich and Acros Organics) 
and were used without further purification. Chemical solvents were obtained at least in 
HPLC grade and dried prior to use by the following procedures: dichloromethane (DCM) was 
distilled from a calcium hydride suspension. Tetrahydrofurane (THF) was pre-dried over 
potassium hydroxide and then freshly distilled from lithium aluminum hydride. Acetonitrile 
was distilled from P2O5. Toluene was dried over molecular sieve 4A. Methanol, chloroform 
and ethyl acetate were distilled prior to use. Reactions were performed under inert 
atmosphere (Argon) using the Schlenk technique. For thin-layer chromatography TLC 
aluminum sheets silica gel 60 F254 (MERCK) were used. Open column chromatography was 
performed on silica gel 60; particle size 0.015 - 0.04 mm (Macherey-Nagel) and on 
Sephadex® LH-20 (Sigma-Aldrich).
Protein purification 
The proteins used in the assay were purified as described previously.[17] Briefly, 5 mg of 
Escherichia coli BL21 cells containing the expression plasmids (pTB57, pTB41 and pTB39 for 
KS-B, ACP-holo and RhiG respectively) were suspended in 50 mL of equilibration buffer 
(20 mM Tris buffer (pH 7.5) supplemented with 200 mM NaCl and 50 mM imidazole). Cell 
disruption was carried out by sonication (Sonotrode, 20% power) and the cell debris was 
removed by centrifugation at 9,000 g for 20 min at 4 °C. The supernatant was loaded onto a 
5 mL Ni-NTA matrix (Macherey Nagel) connected to a FPLC machine (Akta Explorer, 
Amersham Biosciences). The recombinant protein was eluted using the same buffer with 
500 mM imidazole. The protein was diluted twice with 20 mM Tris (pH 7.5) and purified 
further by an ion-exchange column (5 mL HiTrap Q HP, GE Healthcare). Elution of the protein 
was carried out over 30 column volumes of 20 mM Tris (pH 7.5) and 1 M NaCl and the 
fractions containing target protein were concentrated using a vivaspin column (MWCO 5 and 
10 kDa – Sartorius). All proteins were stored in 4 °C for in vitro assays.
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In vitro biotransformation
In vitro reconstitution of the branching reaction was performed as reported previously.[16] In 
a total of 40 μL reaction, 167 μM ACP, 3 μM KS-B, 0.2 μM RhiG, 750 μM MMCoA and 
1,000 μM (R,S)-(E)-S-(2-acetamidoethyl) 5-hydroxyhex-2-enethioate were incubated in 
20 mM Tris buffer (pH 7.0) at 23 °C with shaking at 400 rpm. After 2 h, 2 μL of the sample 
was mixed with 2 μL of 100 mM 2’,5’-dihydroxyacetophenone (containing 2.5 mM 
diammonium hydrogen citrate) and spotted onto an anchor chip 800/384 T F target (Bruker) 
to analyse the product attached to ACP-holo. For mass measurements, the enzyme reaction 
was stopped by adding an equal volume of methanol. After a brief spin to precipitate the 
proteins, the supernatant was directly analyzed by HRMS (Exactive).
Relative configuration of 3
O
O
OH
O O
O
OH
O
H HH H
H H H H
NOESY coupling
235 5 3 2
3a 3b
Figure S1. NMR-based analysis of the product reference and selected NOESY correlations of compounds 3a and 
3b.
3
 
ͨͣ
Figure S2. Analysis of DMM-ACP by MALDI-TOF.  
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Chemical Syntheses
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Ethyl (3S)-3-((tetrahydro-2H-pyran-2-yl)oxy)butanoate (5)
 
OTHP
5
O OEt
Compound 5 was synthesized in analogy to a literature procedure.[1]
1H NMR (300 MHz, CDCl3): δ 1.17 (3H, d, 3J = 6.1 Hz), 1.23 (3H, t, 3J = 7.2 HZ), 1.22 (3H, t, 
3J = 7.2 HZ), 1.27 (3H, d, 3J = 6.2 Hz), 1.42-1.86 (12 H, m), 2.35 (1H, dd, 2J = 11.6 Hz, 
3J = 5.6 Hz), 2.40 (1H, dd, 2J = 11.6 Hz, 3J = 6.3 Hz), 2.54 (1H, dd, 2J = 15.0, 3J = 7.5), 2.65 (1H, 
dd, 2J = 15.0 Hz, 3J = 7.2 Hz), 3.41-3.52 (2H, m), 3.77-3.93 (2H, m), 4.06-4.16 (4H, m), 4.16-
4.28 (2H, m), 4.67 (1H, m), 4.72 (1H, m) ppm; HRMS (ESI+): m/z calculated for C11H20O4Na: 
239.1254, found: 239.1250 [M+Na]+.
5
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Z-Methyl (5S)-5-((tetrahydro-2H-pyran-2-yl)oxy)hex-2-enoate 6
O
THPO O
6
THP ether 5 (216 mg, 1 mmol) was dissolved in dry toluene (10 mL) and cooled to −78 °C 
under argon. DIBAL (1 M in cyclohexane, 2.5 mL) was added dropwise and the solution 
stirred for two hours. A solution of hydrochloric acid and methanol (1:2, 5 mL) was added 
and the mixture allowed to reach room temperature. After filtration over Celite and sodium 
sulfate, the solution was concentrated under reduced pressure and used without further 
purification. Methyl P,P-bis(2,2,2-trifluoroethyl)phosphonoacetate (318 mg, 1 mmol) and 18-
crown-6 (1.32 g, 5 mmol) were dissolved in dry tetrahydrofurane (20 mL) and cooled to 
−78 °C. KHMDS (1 M in toluene, 1 mL) and the crude aldehyde dissolved in dry THF (1 mL) 
were added slowly. The resulting mixture was stirred for 30 min at −78 °C. Saturated NH4Cl 
was added and the aqueous phase was extracted with diethyl ether. The combined organic 
phase was dried over sodium sulfate and concentrated under reduced pressure. The product 
was purified by column chromatography (n-hexane:ethyl acetate, 4:1) using silica gel to give 
125 mg of a clear oil. 
Yield: 55% (95% cis). 1H NMR (300 MHz, CDCl3): δ 1.13 (3H, d, 3J =6.2 Hz), 1.23 (3H, d, 
3J =6.3 Hz), 1.46-1.86 (12H, m), 2.76-2.97 (4H, m), 3.43-3.53 (2H, m), 3.67 (6H, s), 3.82-3.99 
(4 H, m), 4.65-4.69 (2H, m), 5.84 (2H, dt, 3J =11.6 Hz, 4J =1.7 Hz), 6.29 (1H, dt, 3J1 = 11.6 Hz, 
3J2 = 7.4 Hz), 6.43 (1H, dt, 3J1 =11.7 Hz, 3J2 = 7.2 Hz). 13C NMR (75 MHz, CDCl3): δ 19.7, 19.9, 
22.7, 23.5, 25.4, 25.5, 30.7, 31.1, 35.2, 36.6, 51.0, 51.0, 62.7, 62.9, 70.8, 72.4, 96.1, 98.1, 
120.3, 120.8, 146.3, 147.2, 166.7, 166.8 ppm, IR (film): 813, 869, 996, 1020, 1075, 1131, 
1173, 1438, 1650, 1721, 2869, 2942 cm–1, HRMS (ESI+): m/z calculated for C13H21O4: 
241.1445, found: 241.1442 [M+H]+.
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(S)-6-methyl-5,6-dihydro-2H-pyran-2-one (7)
O
O
7
THP-Ether 6 (326 mg, 1.4 mmol) was dissolved in dichloromethane (10 mL) and 
p-toluenesulfonic acid monohydrate (13.3 mg, 0.07 mmol) dissolved in dichloromethane 
(1 mL) was added. After 3 h, the solution was concentrated under reduced pressure and the 
crude product purified by column chromatography over silica gel (dichloromethane) to give 
148 mg of a clear oil. 
Yield: 94%. 1H NMR (300 MHz, CDCl3): δ 1.43 (3H, d, 3J = 6.3 Hz),  2.22-2.41 (1H, m), 4.50-4.62 
(1H, m), 6.00 (1H, ddd, 3J1 = 9.8 Hz, 3J2 = 5.5 Hz, 3J3 = 3.8 Hz), 6.85 (1H, ddd, 3J1 = 9.8 Hz, 
3J2 = 2.5 Hz, 3J3 = 1.2), 13C NMR (75 MHz, CDCl3): δ 20.7, 31.0, 74.3, 121.4, 144.9, 164.5 ppm; 
HRMS (ESI+): m/z calculated for C6H9O2: 113.0597, found: 113.0607 [M+H]+.
Analytical data are in full agreement with the reported data.[2]
7
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Diethyl 2-methyl-2-((2S)-2-methyl-6-oxotetrahydro-2H-pyran-4-yl) malonate 8
O
O
O
O
OO
8
Pyrane 7 (134 mg, 1.2 mmol) and diethyl methylmalonate (417 mg, 2.4 mmol, 2 eq.) were 
dissolved in dry acetonitrile at 0 °C. Cs2CO3 (195 mg, 0.6 mmol, 0.5 eq.) was added, and the 
solution slowly allowed to reach room temperature. After 72 h, the solution was 
concentrated under reduced pressure and the crude product purified by column 
chromatography over silica gel (n-hexane:ethyl acetate 9:1) to give 236 mg of a clear oil.
Yield: 69%. 1H NMR (500 MHz, CDCl3): δ 1.25 (6H, t, 3J = 7.1 Hz), 1.35 (3H, d, 3J = 6.3 Hz), 1.42 
(3H, s), 1.78-1.83 (2H, m) 2.50 (1H, d, 3J = 4.3 Hz), 2.52 (1H, s), 2.65-2.73 (1H, m), 4.16-4.22 
(4H, m), 4.49 (1H, m) 13C NMR (125 MHz, CDCl3): δ 14.0, 17.9, 20.6, 31.1, 31.6, 33.8, 56.7, 
61.7, 61.7, 73.8, 170.8, 172.4 ppm, IR (film): 860, 1021, 1095, 1154, 1329, 1369, 1456, 1731, 
2945, 2983 cm–1, HRMS (ESI+): m/z calculated for C14H23O6: 287.1489, found: 287.1487 
[M+H]+.
8
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(R,S)-2-((2S,4R)-2-methyl-6-oxotetrahydro-2H-pyran-4-yl) propanoic acid 3
O
OH
O
O
3
Compound 8 (55 mg, 0.19 mmol) was dissolved in HCl (2 M, 0.5 mL) and heated in a vial with 
closed-top screw cap to 120 °C for 18 h. Water (1 mL) was added and the aqueous phase was 
extracted with ethyl acetate (3×1 mL) to remove impurities. The aqueous phase was then 
concentrated under reduced pressure and subjected to column chromatography over silica 
gel (chloroform:methanol 98:2) to give a clear oil. 
Yield: 78 % 1H NMR (600 MHz, MeOD): δ 1.13 (3H, d, 3J = 7.1 Hz), 1.17 (3H, d, 3J = 7.0 Hz), 
1.32 (3H, d, 3J = 6.2 Hz), 1.34 (3H, d, 3J = 6.3 Hz), 1.35-1.39 (1H, m), 1.77 (1H, ddd, 2J = 14.4 
Hz, 3J1 = 8.2 Hz, 3J2 = 8.1 Hz), 1.81 (1H, ddd, 2J = 14.4 Hz, 3J1 = 6.6 Hz, 3J 2= 4.5 Hz),  2.01 (1H, 
dd, 3J = 15.5 Hz, 2J = 9.6 Hz), 2.10- 2.15 (1H, m ), 2.21-2.27 (1H, m), 2.36-2.39 (1H, m),  2.40 
(1H, dd, 2J = 9.6 Hz, 3J = 5.4 Hz), 2.59-2.66 (1H, m), 2.92 (1H, qd, 3J 1= 7.1 Hz, 3J 2= 7.0 Hz), 
4.49-4.55 (1H, m), 4.55-4.61 (1H, m) 13C NMR (150 MHz, MeOD): δ 12.6, 15.0, 21.2, 21.5, 
33.0, 33.1, 33.1, 34.2, 35.7, 37.9, 38.6, 45.9, 75.6, 76.3, 174.1, 175.6, 178.1, 178.4 ppm; IR 
(film): 1021, 1112, 1416, 1449, 1653, 2341, 2832, 2945, 3324 cm–1, HRMS (ESI+): m/z 
calculated for C9H15O4: 187.0965, found: 187.0964 [M+H]+.
9
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3. NMR spectra
1H NMR Spectrum (300 MHz, CDCl3) of compound 6.
13C NMR Spectrum (300 MHz, CDCl3) of compound 6.
10
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1H NMR Spectrum (300 MHz, CDCl3) of compound 7.
13C NMR Spectrum (75 MHz, CDCl3) of compound 7.
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1H NMR Spectrum (500 MHz, CDCl3) of compound 8.
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13C NMR Spectrum (125 MHz, CDCl3) of compound 8.
1H NMR Spectrum (600 MHz, MeOD) of compound 3.
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13C NMR Spectrum (150 MHz, MeOD) of compound 3.
H,H COSY NMR Spectrum (600 MHz, MeOD) of compound 3.
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HSQC NMR Spectrum (600 MHz, MeOD) of compound 3.
15
 
ͩͥ
 
HMBC NMR Spectrum (600 MHz, MeOD) of compound 3.
16
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NOESY NMR Spectrum (600 MHz, MeOD) of compound 3.
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Polyketide synthase chimeras reveal key role of ketosynthase domain in chain 
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Some polyketide synthase pathways include branching modules that insert branched 
monomers into polyketide products. In vitro reconstitution using swapped domains shows that 
the mysterious branching (B) domain and the homologous X domain in these modules have 
structural rather than catalytic roles (from Nature Chemical Biology). 
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Biosynthesis of rhizoxin in Burkholderia rhizoxinica affords 
an unusual polyketide synthase module with ketosynthase 
and branching domains that install the d-lactone, conferring 
antimitotic activity. To investigate their functions in chain 
branching, we designed chimeric modules with structurally 
similar domains from a glutarimide-forming module and a 
dehydratase. Biochemical, kinetic and mutational analyses 
reveal a structural role of the accessory domains and 
multifarious catalytic actions of the ketosynthase. 
Polyketides constitute a highly heterogenic family of natural prod-
ucts, many of which are important leads for drug development. Given 
their high structural diversity, it is remarkable that the basis of their 
biosynthesis is the simple head-to-tail Claisen condensation of acyl 
and malonyl units, which exclusively yields linear carbon backbones1. 
Polyketide chain assembly minimally requires a ketosynthase (KS) 
that mediates the attack of the malonyl-derived carbanion at the acyl 
thioester to form the C-C bond. In addition, an acyl carrier protein 
(ACP) is needed as an anchor for the growing polyketide chain; a 
malonyl transacylase-acyltransferase (AT) is needed to load the 
extender units onto the ACP; and the degree of B-keto group process-
ing is controlled by the presence of ketoreductase (KR), dehydratase 
(DH) and enoyl reductase (ER) domains. Considering the uniform 
KS-mediated Claisen condensation biochemistry, it is surprising that 
a specialized polyketide synthase (PKS) module mediates a radically 
different reaction in rhizoxin biosynthesis. Rhizoxin (1; Fig. 1a) is 
a highly potent phytotoxin that is produced in a symbiosis of the 
rice seedling blight fungus Rhizopus microsporus and its bacterial 
endosymbiont, B. rhizoxinica2,3. The bacteria assemble the scaf-
fold of the macrolide, and the fungal host introduces an additional 
epoxide moiety to increase the phytotoxicity4. Notably, the rhizoxin 
congeners assembled by the rhizoxin (rhi) PKSs5 represent some 
of the strongest antimitotic agents known to date6. Binding to the 
B-tubulin subunit critically depends on an unusual chain branch7,8 
that consists of a malonyl-derived C2 unit. Genetic and chemical 
analyses of the rhi PKS9 indicate that the rare pharmacophoric unit 
is introduced by a ‘branching module’ consisting of a KS domain, 
an enigmatic ‘branching domain’ (B) and an ACP10. The successful 
in vitro reconstitution of the entire branching module shows that 
the chain branch is introduced by the vinylogous addition of acetate 
to a KS-bound A,B-unsaturated thioester (Fig. 1a)11. As a result, the 
branched intermediate is bound to both the KS and the ACP, and 
only through nucleophilic attack of the thioester at the KS can the 
side chain be cyclized and the polyketide chain be propagated. In 
the genuine rhi pathway, a D-lactone is formed by cyclization of the 
D-hydroxy–substituted intermediate. However, the branching module 
shows a degree of substrate tolerance and also accepts C3 extenders12 
as well as amino and carboxamide nucleophiles in lieu of the 
D-hydroxy group, thus yielding lactam and glutarimide moieties, 
respectively13. This is a key finding because the glutarimide resi-
due is known to be an important pharmacophoric group in many 
antibiotics, such as cycloheximide14. In fact, genetic analysis of the bio-
synthesis of several glutarimide-containing polyketides—including 
9-methylstreptimidone15, migrastatin16 and cycloheximide17—reveals 
that the PKS genes encode a branching module that is highly similar 
to the one found in the rhi PKS, consisting of an unknown (denoted 
as X) domain flanked by KS and ACP domains (Fig. 1b). Despite the 
elucidation of its crystal structure and numerous attempts to char-
acterize the B domain biochemically11, the role of the mysterious B 
or X domains has remained a riddle. Here we report the successful 
interrogation of the B and X domains from lactone- and glutarimide- 
forming PKS modules in vitro. Through engineered functional 
hybrid modules, kinetic analyses and mutational studies, we provide 
compelling evidence that the linker region and an adjacent domain 
with a double-hotdog fold are essential for the branching module but 
do not have catalytic roles for branching and cyclization. Thus, very 
unexpectedly, the branching KS domain alone mediates the entire 
complex reaction sequence.
To elucidate the exact role of the B and X domains in polyketide 
chain branching, we exchanged the B domain of the rhi branching 
module with the functional equivalent of a glutarimide-forming 
PKS, the X domain from the 9-methylstreptimidone PKS of 
Streptomyces himastatinicus (Fig. 2a)15. To test its ability to mediate 
glutarimide formation, we subjected the heterologously produced 
hybrid didomain (Supplementary Results, Supplementary Note 1) 
to an in vitro biotransformation experiment in the presence of 
phosphopantetheinylated ACP and the trans-acting AT. We used 
malonyl CoA and carboxamide-substituted N-acetylcysteamine 
(SNAC) thioester 2 (ref. 13), a mimic of the natural polyketide inter-
mediate for glutarimide biosynthesis, as substrates. MALDI-TOF 
analysis of the ACP-bound product showed a new peak, indicat-
ing the expected mass of the glutarimide-substituted product 
(Supplementary Fig. 7a). Furthermore, extraction of the assay 
mix with methanol released the free acid 3 (Fig. 2b). Its structural 
identity was unequivocally confirmed by high-resolution MS (HRMS) 
comparing the retention time and mass to that of a synthetic refer-
ence13. This finding proved that the hybrid module is functional and 
enabled a direct comparison of the B and X domains. In addition to 
the natural role as a branching D-lactone synthase, the KS-B dido-
main also mediated glutarimide formation in the presence of a suit-
able carboxamide nucleophile. With the working counterpart from 
a genuine glutarimide pathway at hand, we tested whether the KS-X 
didomain could also produce a D-lactone when using the synthetic 
S-hydroxy–substituted SNAC thioester 4, a substrate that mimics 
the polyketide intermediate produced upstream in the rhi pathway11. 
MALDI-TOF measurements indicated that the ACP-bound lactone 
was formed (Supplementary Fig. 7b), and we confirmed the identity 
of the hydrolyzed product (5) by HRMS analyses using an authentic 
reference (Fig. 2c). Thus, both KS-B and KS-X catalyze the Michael 
addition-cyclization sequence to yield D-lactone– and glutarimide-
substituted polyketides.
Polyketide synthase chimeras reveal key role of 
ketosynthase domain in chain branching
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In addition to the qualitative analysis, which demonstrated the 
functionally equivalent substrate tolerance of the KS-B and KS-X 
didomains, we performed kinetic analyses to gain further insight 
into a potential prevalence for a particular branching reaction. To 
determine the kinetic determinants, we performed the in vitro assay 
with either KS-B or KS-X, with increasing concentrations of 2 or 4. 
In the assay for D-lactone formation, we obtained data indicating 
fairly similar substrate affinities of both constructs. Likewise, the 
rate of lactone formation proved to be similar (Table 1)13. Using 2 
as the substrate, the KM and Vmax values were, again, almost identical 
for KS-B and KS-X. Both branching didomains showed a three- to 
fourfold reduced reaction rate and a threefold lower affinity to 2 com-
pared to 4 (Table 1 and Supplementary Fig. 8a). We thus concluded 
that the B or X domains do not have a major role in the selection and 
turnover of the different substrates, irrespective of the biosynthetic 
context (lactone- or glutarimide-producing PKS).
To interrogate the impact of the B and X domains, we generated 
another chimera in which the branching domain is substituted with 
a domain that has a similar fold. As the double-hotdog fold of the 
B domain is a hallmark of DH domains, we explored the catalytic 
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abilities of an engineered KS-DH didomain (Fig. 2a). Specifically, we 
cloned the gene fragment coding for a DH domain from the down-
stream module 10 of the rhi PKS and fused it with the gene coding for 
the branching KS. In addition to the KS, we found that the KS-to-B 
linker domain was also crucial for protein solubility (Supplementary 
Note 2). We repeated the biotransformation experiments with the 
KS-DH hybrid and found that both the glutarimide (Fig. 2d) and the 
D-lactone (Fig. 2e) were formed in the enzyme assay (Supplementary 
Fig. 7c,d). Furthermore, in all of the kinetic studies using KS-DH and 
2 or 4, we determined KM and Vmax values equivalent to those obtained 
for KS-B and KS-X (Table 1 and Supplementary Fig. 8b,c). Thus, in 
the branching module, a regular DH domain can replace the B and 
X domains without loss of function.
Our findings could be rationalized in two ways: (i) the B and X 
domains support the branching-cyclization sequence by a mechanism 
that can also be catalyzed by a typical DH domain or (ii) the B, X and 
DH domains are catalytically inactive and have a solely structural role. 
To rule out a potential catalytic function of the additional domain in 
the genuine and hybrid branching modules, we performed mutational 
analyses. It is well known that DH catalysis depends on a highly con-
served catalytic histidine-aspartate dyad. A remarkable feature of the 
B domain is the presence of Tyr3697 in place of the active site histi-
dine normally present in DH domains (Supplementary Fig. 9a). This 
mutation clearly ruled out the involvement of a histidine in the chain 
branching–cyclization sequence. The aspartate residue is conserved 
among the B (Asp3876), X (Asp2415) and DH (Asp2488) domains 
(Supplementary Fig. 9a–c). To exclude the possibility that the con-
served aspartate residues in the dyads of the B, X and DH domains are 
essential for the module function, we replaced them with alanine to yield 
B°, X° and DH° domains, respectively (Supplementary Fig. 9d). For all 
aspartate-to-alanine mutants (KS-B°-ACP, KS-X°-ACP and KS-DH°-
ACP), we still observed branching activity in the in vitro enzyme assay 
(Supplementary Fig. 10b,d). Because the point mutations at the active 
sites did not affect the enzyme activity, the dyad is clearly not involved 
in the branching reaction. Thus, the additional domain with the double-
hotdog fold seems to have a structural role. To support this conclusion, 
we designed constructs in which the KS and the requisite linker region 
are fused to the ACP (Supplementary Fig. 9e). However, we could not 
detect any soluble protein (data not shown), again demonstrating the 
pivotal role of the B domain for structural stability.
Taken together, we provide multiple lines of evidence indicating 
that B, X and DH domains solely have a structural role in the native 
and chimeric branching modules. Given their structural similarity, it 
is conceivable that the B and X domains from branching modules have 
evolved from DH domains yet lost their catalytic function. In this con-
text, it is of interest to note that inactive or intact but nonfunctional 
DH domains are sometimes found in PKS modules18–20. Domains with 
a double-hotdog fold could be important as spacers between the KS 
and the ACP. It is also noteworthy that the KS-to-B linker region is 
crucial for the solubility of the KS-B didomain. However, our results 
unequivocally demonstrate that the KS domain alone is in charge of 
mediating the entire catalytic sequence, the stereoselective vinylogous 
addition and the subsequent heterocyclization, which leads to lactone 
or glutarimide rings. This finding has profound implications for eluci-
dating the branching process. The branching KS domains that catalyze 
Michael additions and heterocyclizations represent a functionally 
unique family of ketosynthases that clearly differ from the canonical 
KSs of modular assembly lines that exclusively yield linear chains. 
KS domains promoting Michael additions complement the related 
enzymes that catalyze terpenoid-like alkylations of B-carbonyl 
groups21, which are also found in some type I PKS systems. This func-
tional divergence of the KS domains is notable from an evolutionary 
perspective. In the case of the rhi PKS, the evolutionary advantage 
is clear, because the chain branch is pivotal to the antimitotic activ-
ity of the macrolide. Likewise, the glutarimide residues represent 
pharmacophoric groups in various polyketide antibiotics14,22. Thus, 
the branching KS is an important addition to the currently available 
ketosynthase-like biocatalysts23–25. As the KS-mediated branching 
reaction enhances the structural diversity of polyketides to yield 
potent pharmacophoric groups, insights gained from our functional 
analysis are also valuable from a synthetic biology perspective. 
Received 7 July 2015; accepted 28 August 2015; 
published online 19 October 2015
Methods
Methods and any associated references are available in the online 
version of the paper.
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Table 1 | Kinetic determinants of wild-type and chimeric 
proteins for the production of 5 and 3
KS-B KS-X KS-DH
KM Vmax KM Vmax KM Vmax
5 1,348 o 315 20.9 o 2.4 1,871 o 728 18.4 o 5.7 1,428 o 461 15.2 o 3.7
3 4,082 o 519 4.7 o 0.4 3,707 o 255 4.4 o 1.1 4,878 o 724 5.4 o 0.8
Data are from three independent experiments and represent mean o s.d.
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ONLINE METHODS
General. Chemicals were purchased from Sigma-Aldrich and Roth. MALDI 
measurements were performed using an UltrafleXtreme MALDI TOF/TOF 
(Bruker). HRMS measurements were performed using an Exactive Orbitrap 
High-Performance Benchtop HRMS with an electrospray ion source and an 
Accela HPLC system (Thermo Scientific). All solvents for analytical HPLC 
measurements were obtained commercially at least in gradient grade and were 
filtered before use. To avoid microbial growth, 0.1% formic acid was added to 
the water. CD measurements were performed using a J815 spectropolarimeter 
(Jasco). Site-directed mutagenesis was performed using a Quikchange II XL 
kit (Stratagene). The identity of all recombinant proteins was confirmed using 
SDS-PAGE.
Alignment and threading of KS-X. The structure of KS-X was predicted 
by aligning amino acids corresponding to residues 1614–2525 (GenBank 
CCC21123.1) of KS-B (Protein Data Bank code 4KC5). The prediction was 
done using the Phyre2 server26, and the structure was visualized in Pymol 
(Version 1.5.0.4; 2010).
Cloning experiments. To facilitate cloning of the genes for X and DH 
domains to the C-terminal of KS, two separate constructs were generated: 
(i) the region corresponding to KS spanning residues 3152–3661 (GenBank 
CBW75249.1) was cloned in pHis8-3 by introducing a C-terminal KpnI site, 
using the primer pair KS-BamHI-fw (5`-GGA TCC TCC GGT GAG CGC 
GTC GAG-3`) and KS-KpnI-rv (5`-GGG GTA CCT TCC TCG ACG ATC 
ATA TGG-3`), resulting in pSS31. (ii) For the second construct, the region 
spanning residues 3152–3821 (GenBank CBW75249.1) that corresponds to 
KS and the KS-B linker region was cloned with the insertion of the KpnI 
site using primers KS-BamHI-fw (5`-GGA TCC TCC GGT GAG CGC GTC 
GAG-3`) and KS-KpnI-rv (5`-GGG GTA CCC GAC GAC TCG TAA CCT 
TCC TC-3`), resulting in pSS33. The X-encoding gene from region 2053–2525 
(GenBank CCC21123.1) and the DH-encoding gene corresponding to the 
region 2286–2576 (GenBank CBW75249.1) were amplified from the genomic 
DNA of Streptomyces himastatinicus and Burkholderia rhizoxinica, respectively, 
using the following primer pairs: X-KpnI-fw (5`-GGG GTA CCC ACA TGA 
TTC TGG AGG AGT ACG CGG GA-3`), X-EcoRI-rv (5`-CGG AAT TCC TAC 
AGT TCG TCC ACG ACG AAG G-3`); DH-KpnI-fw (5`-GGG GTA CCC TGC 
ACC CGC TGG TGC ATC-3`) and DH-EcoRI-rv (5`-GAA TTC CTA GGG 
TTC AAC GCC AGT C-3`). The corresponding PCR products were cloned in 
pJET 1.2 (Thermo Scientific) for sequence confirmation and subcloned into 
pHis 8-3 to generate pSS32, pSS34 and pSS42 for KS-DH° (without linker), 
KS-DH (with linker) and KS-X, respectively. All of the recombinant plasmids 
were heterologously expressed in E. coli BL21 (New England BioLabs).
Protein production and purification. The procedures for the production 
and purification of ACP (pTB41), KS-B (pTB57) and RhiG (pTB39) were as 
described previously11. E. coli BL21 transformants containing pSS32, pSS34 
and pSS42 were cultivated in LB medium at 37 °C. After A600nm reached ~0.5, 
the cells were induced with 0.1 mM IPTG at 15 °C for 18 h. The cell pellet was 
dissolved (10 ml buffer per g pellet) in 20 mM Tris buffer, pH 7.5, containing 
0.2 M NaCl and 50 mM imidazole. After disrupting the cells by sonication 
after four 3-min cycles at 20% power (Sonotrode), the cells were centrifuged 
at 9,000g at 4 °C for 30 min. The lysed supernatant was then loaded onto a 
Ni-NTA column (Macherey Nagel) connected to an FPLC machine. Proteins 
were eluted using the same buffer with 0.5 M imidazole. The protein was diluted 
twice with 20 mM Tris (pH 7.5) and purified further by an ion-exchange 
column (5 ml HiTrap Q HP, GE Healthcare). Proteins were eluted over 30 
column volumes of 20 mM Tris (pH 7.5) and 1 M NaCl, and the fractions 
containing target proteins were concentrated using Amicon columns (MWCO 
5 and 10 kDa; Millipore). All of the proteins were stored at 4 °C for in vitro 
assays. Long-term storage of the proteins was possible at −20 °C supplemented 
with 50% glycerol.
In vitro reconstitution of the branching reaction. The in vitro assay for 
the reconstitution of the branching reaction was performed as described 
previously11 with minor modifications. Briefly, in a 40-Ml reaction, 167 MM 
ACP; 3 MM KS-B, KS-X or KS-DH; 0.2 MM RhiG; 750 MM malonyl-CoA; and 
1,000 MM of SNAC thioesters were incubated in 20 mM Tris buffer (pH 7.0) at 
23 °C with shaking at 400 r.p.m. After 2 h, 2 Ml of the sample was mixed with 
2 Ml of 100 mM 2`,5`-dihydroxyacetophenone (containing 2.5 mM diammo-
nium hydrogen citrate) and spotted onto an anchor chip 800/384 T F target 
(Bruker) to analyze the product. The MALDI-TOF was operated in posi-
tive linear mode. Data acquisition was performed using flexControl 3.3 in 
the range of 5–35 kDa with 1,000-Hz laser frequency, 60% laser power and 
500 shots at each spot. Analysis of the data was executed in flexanalyis 3.3. 
For mass measurements, the enzyme reaction was stopped by adding an equal 
volume of methanol. After a brief spin to precipitate the proteins, the superna-
tant was directly analyzed by HRMS (Exactive). HPLC conditions: C18 column 
(Betasil C18 3 Mm, 150 × 2.1 mm) and gradient elution (MeCN/0.1% (v/v) 
HCOOH (H2O) 5/95 for 1 min, gradient up to 98/2 in 15 min and 98/2 for 3 
min; flow rate 0.2 ml min−1; injection volume 3–5 Ml).
Kinetic studies. To determine the kinetic parameters for the KS-X and KS-DH 
didomains, we varied the concentration of the substrate 4 in the range of 
108 MM to 2,164 MM, and the reaction was performed for 75 min. Higher 
concentrations ranging from 435 MM to 6,519 MM were used for 2, and the 
reaction was performed for 250 min. Samples were taken at regular intervals, 
and the peak height/area of the product attached to the ACP was analyzed 
by MALDI-TOF. The mean kinetic parameters were calculated from three 
independent experiments using a Lineweaver-Burk plot. The substrates and 
the reference compounds were synthesized as below.
S-(2-Acetamidoethyl) (E)-5-amino-5-oxopent-2-enethioate (2). Compound 2 
was synthesized according to a synthesis procedure reported before13. All ana-
lytical data are in good agreement with the reported values. 1H NMR (600 MHz, 
CDCl3): D 6.96 (dt, 3J1 = 15.5 Hz, 3J2 = 7.2 Hz, 1H), 6.28 (dt, 3J = 15.5 Hz, 
4J = 1.5 Hz, 1H), 3.34 (t, 3J = 6.7 Hz, 2H), 3.15 (dd, 3J = 7.2 Hz, 4J = 1.5 Hz, 2H), 
3.07 (t, 3J = 6.7 Hz, 2H), 1.91 p.p.m. (s, 3H); HRMS (m/z): [M+H]+ calculated 
for C9H15O3N2S, 231.0798; found, 231.0793.
2-(2,6-Dioxopiperidin-4-yl) acetic acid (3). Compound 3 was obtained from 
Sigma-Aldrich. Analytical data are in full agreement with the literature data27. 
1H NMR (600 MHz, DMSO-d6): D 12.3 (s, 1H), 10.7 (s, 1H), 2.55 (d, 3J = 3.9 Hz, 
1H) 2.53 (d, 3J = 3.9 Hz, 1H) 2.36-2.44, (m, 1H), 2.26-2.36 (m, 4H), HRMS 
(m/z): [M+H]+ calculated for C7H10O4N, 172.0610; found, 172.0610.
S-(2-Acetamidoethyl) (S,E)-5-hydroxyhex-2-enethioate (4). Compound 4 
was synthesized according to a procedure reported before13. All analytical 
data are in good agreement with the reported values13. 1H NMR (600 MHz, 
CDCl3): D 6.92 (dt, 3J = 15.6 Hz, 4J = 7.5 Hz, 1H), 6.20 (dt, 3J = 15.6 Hz, 
4J = 1.4 Hz, 1H), 3.97 (m, 1H), 3.45 (q, 3J = 6.3, 2H), 3.08 (t, 3J = 6.4 Hz, 2H), 
2.36-2.33 (m, 2H), 1.97 (s, 3H), 1.23 p.p.m. (d, 3J = 6.3 Hz, 3H); HRMS (m/z): 
[M+H]+ calculated for C10H18O3NS, 232.1002; found, 232.0998; [ ]B D22  = +8.66 
(c = 1 mg ml−1, MeOH).
2-((2R,4R)-2-Methyl-6-oxotetrahydro-2H-pyran-4-yl) acetic acid (5): 
Compound 5 was synthesized according to a known procedure11. Analytical 
data are in good agreement with the literature data. 1H NMR (300 MHz, 
MeOD): D 4.59-4.68 (m, 1H), 4.43-4.56 (m, 1H), 2.75 (ddd, 3J1 = 17.5 Hz, 
3J2 = 5.9 Hz, 4J = 1.9 Hz, 1H), 2.61 (dd, 3J1 = 15.5 Hz; 3J2 = 5 Hz, 1H), 2.29-2.50 
(m, 8H), 2.17 (dd, 3J1 = 17.5 Hz, 3J2 = 10.2 Hz, 1H), 2.00–2.09 (m, 1H), 1.73-1.87 
(m, 2H), 1.34 p.p.m. (d, 3J = 6.3 Hz, 6H); HRMS (m/z): [M+H]+ calculated for 
C7H13O4, 173.0808; found, 173.0810.
Secondary structure determination by CD. The secondary structures of KS-B, 
KS-X and KS-DH were determined at 23 °C. Wavelength scans were recorded 
for the far-UV region between 250 nm and 190 nm at a speed of 10 nm min−1, 
a bandwidth of 1 nm and with accumulations of 3–5 spectra using a 1-mm 
quartz cuvette (Hellma). For all measurements, a concentration of 0.1 mg ml−1 
protein was used.
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of protein was carried out using the same procedure described above. For 
enzyme assays, the same concentrations as the wild type were used. CD 
(Jasco) measurements confirmed the correct folding of the mutated proteins 
(Supplementary Fig. 10a,c).
Mutational analysis of KS-X and KS-DH. Point mutations on X and DH 
were made using the following primers on plasmids pSS34 and pSS42 
respectively: X-D2415A-fw (5`-CTC GCG GCC CTC GCT CAG GGC 
GCG-3`), X-D2415A-rv (5`-CGC GCC CTG AGC GAG GGC CGC GAG-3`); 
DH-D2488A-fw (5`-CCG CCG GGC GTA CTC GCT AGT GCG CTG 
CAT-3`), DH-D2488A-rv (5`-ATG CAG CGC ACT AGC GAG TAC GCC CGG 
CGG-3`). All mutations were confirmed by sequencing, and the production 
26. Kelley, L.A. & Sternberg, M.J. Nat. Protoc. 4, 363–371 (2009).
27. Ji, X.-Y. et al. Chem. Pharm. Bull. (Tokyo) 58, 1436–1441 (2010).
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SUPPLEMENTARY RESULTS 
Supplementary Notes 
Supplementary Note 1 
Rational design and functional analysis of hybrid branching modules 
To elucidate the exact role of the enzyme domains (B and X) in polyketide chain branching 
we first sought to cross-complement the B domain of the functional rhi branching module 
with the functional equivalent of a glutarimide-forming PKS. On the basis of crystal data for 
KS-B (PDB ID – 4KC5) we performed a structural threading of proteins related to the B 
domain. Alignment and structure prediction showed that the X domain from a trans-AT PKS 
module SmdI1 shares the highest similarity in folding (Supplementary Fig. 1a). Therefore, 
an intergenic exchange of B with a domain designated as unknown (X) from the 9-
methylstreptimidone producer, Streptomyces himastatinicus,1 was performed. Specifically, the 
gene for the X domain (including the linker region) was amplified from the genome of 
Streptomyces himastatinicus and fused to the C-terminus of the rhi KS gene (Supplementary
Fig. 1b and 2a). The hybrid protein in which the linker region and B domain of the rhi PKS 
were replaced with the X domain from the 9-methylstreptimidone pathway, was 
heterologously produced in E. coli BL21 and purified by affinity and ion-exchange 
chromatography. Initially, the solubility of the hybrid KS-X didomain was substantially 
reduced compared to the native protein. However, after changing the induction temperature to 
15 qC we obtained sufficient amounts of soluble protein. The successful construction of the 
desired chimera was proven by SDS-PAGE (Supplementary Fig. 3a), tryptic digestion and 
MALDI analyses (Supplementary Fig. 4), and the correct folding of the protein was verified 
by comparison of circular dichroism (CD) spectra of KS-B and KS-X (Supplementary Fig. 
3b).
Nature Chemical Biology: doi:10.1038/nchembio.1932
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Supplementary Note 2 
Construction of a functional branching module lacking B and X domains 
To construct a module without B or X, as a first step, the KS-to-B linker region and the B 
domain were replaced with the DH domain (Supplementary Fig. 1c and 2b). The resulting 
hybrid protein (KS-DHq), behaved differently compared to wild-type KS-B and showed a 
drastically reduced solubility, which resulted in inclusion bodies when produced at 28 qC
(Supplementary Fig. 5). Since solubility could not be improved, we considered the 
possibility that the linker region is crucial for protein solubility. Therefore, we constructed 
another chimera that comprised the KS-to-B linker domain, and eventually succeeded in the 
production of soluble protein at reduced temperature (15 qC) (Supplementary Fig. 3a). The 
identity of the KS-DH didomain was confirmed by tryptic digest and MALDI-TOF analysis 
(Supplementary Fig. 6), and comparison of the CD spectra showed that its secondary 
structure is similar to KS-B and KS-X (Supplementary Fig. 3b).
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Supplementary figures 
Supplementary Figure 1. Modeling of KS-X and chimera constructs. (a) Modeled KS-X 
didomain from module 2 (SdmI gene) of 9-methylstreptimidone cluster showing high 
similarity to KS-B (left). Modeled KS-X with color codes for the domains is also shown 
(right). (b) Cloning strategy for KS-X chimera encoded on the plasmid pSS42. The gene 
Nature Chemical Biology: doi:10.1038/nchembio.1932
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corresponding to the unknown X domain from 9-methyl streptimidone (9-MS) cluster is 
cloned to the C-terminus of KS domain of rhizoxin (rhi) cluster to generate pSS42. (c)
Cloning strategy for KS-DH chimera encoded on the plasmid pSS34. The gene for DH 
domain from module 10 of rhi gene cluster is fused to the C-terminus of KS and linker 
domain using KpnI and EcoRI restriction sites. Black filled line refers to the KS-B linker 
region.
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Supplementary Figure 2. Cloning strategy of the chimeras. (a) Cloning strategy for 
generation of chimeras using gene fragments coding for domains of the rhizoxin (rhi) and 9-
methyl streptimidone (9-MS) PKSs. (b) Gene fragments corresponding to DH domain of the 
rhizoxin (rhi) was exchanged for B domain. Black filled line refers to the KS-B linker region. 

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Supplementary Figure 3. Protein production with the hybrid didomains. (a) SDS-PAGE 
(12%) of purified KS-B (1), KS-X (2), KS-DH (3). The molecular weights of the proteins are 
104.7, 100 and 99 kDa respectively. M – protein marker. (b) Secondary structure fingerprint 
of the chimeras by far-UV CD. 
Nature Chemical Biology: doi:10.1038/nchembio.1932
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Supplementary Figure 4. KS-X evaluation by MALDI fingerprinting. Tryptic digestion 
and MALDI analysis of the marked band corresponding to histidine-tagged KS-X protein. 
Peptides from KS and X domain were detected. Peptides corresponding to the B domain were 
not present. Lanes: 1 – KS-B; 2 – KS-X; 3 – KS-DH; M – protein marker. 
Nature Chemical Biology: doi:10.1038/nchembio.1932
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Supplementary Figure 5. SDS-PAGE of KS-DHq. In the absence of KS-to-B linker domain, 
soluble protein could not be obtained even at an induction temperature of 12 qC. S – soluble; 
I.S – insoluble. 
Nature Chemical Biology: doi:10.1038/nchembio.1932
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Supplementary Figure 6. KS-DH evaluation by MALDI fingerprinting. Tryptic digestion 
and MALDI analysis of the marked band corresponding to histidine-tagged KS-DH protein. 
Peptides from KS, KS-B-linker and DH domains were detected. Peptides corresponding to the 
B domain were not present. Lanes: 1 – KS-B; 2 – KS-X; 3 – KS-DH; M – protein marker.
Nature Chemical Biology: doi:10.1038/nchembio.1932
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Supplementary Figure 7. In vitro branching assay analysis by MALDI-TOF. (a)
Biotransformation of amide- (2) and (b) hydroxy-substituted SNAC thioester (4) using KS-X 
didomain. (c) Biotransformation of amide- (2) and (d) hydroxy-substituted SNAC thioester 
(4) using KS-DH didomain. MALDI mass spectrum revealed ACP-bound products. Negative 
control refers to the branching reaction without 2 or 4. All examinations were performed in 
duplicates.
Nature Chemical Biology: doi:10.1038/nchembio.1932
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Supplementary Figure 8. Michaelis-Menten kinetics of lactone and glutarimide 
formation. Biocatalysis by (a) KS-X, (b) KS-DH and (c) KS-B. Lactone product turnover is 
atleast 3–5 fold higher than that of glutarimide. The data represent mean ± standard deviation 
resulting from 3 independent experiments. 3D structures of (a) KS-X (modeled), (b) KS-DH 
(modeled) and (c) KS-B are shown. Color codes are consistent with the corresponding 
domains. Modeling of chimeric proteins was done using Phyre 2 server and the structures 
were generated using Pymol. 
Nature Chemical Biology: doi:10.1038/nchembio.1932
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Supplementary Figure 9. Mutational analysis of B, X and DH domains. Comparison of 
active site residues of (a) B, (b) X and (c) DH domains. (d) Mutants with point mutations of 
conserved Asp residue retained the branching activity. (e) KS-ACP fusion resulted in 
insoluble protein production hampering assay conditions.
Nature Chemical Biology: doi:10.1038/nchembio.1932
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Supplementary Figure 10. CD spectra and reaction rate of mutants. (a) CD analysis of 
KS-X in comparison with the mutant KS-X° (D2415A). (b) Kinetic data (mean ± standard 
deviation from 3 independent experiments) of KS-X° in comparison with KS-X. (c) CD 
analysis of KS-DH in comparison with the mutant KS-DH° (D2488A). (d) Kinetic data (mean 
± standard deviation from 3 independent experiments) of KS-DH° in comparison with KS-
DH. 
Nature Chemical Biology: doi:10.1038/nchembio.1932
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On-line enzymatic tailoring of polyketides and peptides
in thiotemplate systems
Srividhya Sundaram1 and Christian Hertweck2
Non-ribosomal peptide synthetases (NRPS) and type I
polyketide synthases (PKS) are versatile thiotemplate systems
for the programmed assembly of biosynthetic building blocks.
Typically, the post-PKS/NRPS enzymes tailor the resulting
chains to yield the bioactive natural product scaffolds.
However, more and more examples have surfaced showing
that important structural modiﬁcations take place while the
intermediates are still bound to the assembly line. A growing
number of enzymatic domains and trans-acting enzymes as
well as their recruiting areas in the modules have been
identiﬁed and characterized. In addition to the widespread on-
line alkylations, hydroxylations and heterocyclizations into
oxazole/thiazole residues, on-line modiﬁcations lead to a
variety of ring systems such as cycloethers, lactones, lactams,
glutarimides, cyclopropanes, decalins and cyclic biaryls.
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Introduction
Thiotemplates are fascinating microbial multienzyme sys-
tems that produce a wealth of polyketide and peptide
natural products, many of which are medicinally important
as antibiotics, anticancer drugs and immunosuppressants.
These versatile molecular assembly lines have a modular
architecture with specialized domains for substrate load-
ing, assembly, modiﬁcation and chain release. Depending
on the type of building blocks and mechanisms employed
for the chain assembly, thiotemplates fall into two groups:
type I polyketide synthases (PKS) and non-ribosomal
peptide synthetases (NRPS), yet there are many hybrids
that generate mixed structures [1–4].
By contrast to biosynthetic pathways where several free-
standing enzymes catalyze the stepwise transformation of
free-ﬂoating, non-covalently bound substrates, in thiotem-
plates the growing polyketide or peptide chains are teth-
ered to the phosphopantetheinyl arms of acyl-carrier
protein (ACP) or peptidyl-carrier protein (PCP) domains
until full maturation of the polyketide or peptide back-
bones. Thus, the thiotemplate systems prevents diffusion
of the substrates and ensures spatial and temporal control
over the many ﬁne-tuned biochemical processes, deﬁning
the choice of building blocks, order of incorporation,
degree of processing and the size of the chains. In addition,
the terminal modules or domains determine the fate of the
product (Figure 1). Typically, thioesterase (TE) domains
liberate the products by either simple hydrolysis or
(macro)cyclizations [5,6], including dimerizations to cre-
ate macrodiolides [7,8]. Alternatively, reductive chain re-
lease, aminolysis as well as various more sophisticated off-
loading mechanisms are known, which may lead to tetro-
nates and several other ring systems (Figure 1b) [9,10].
Despite these variations governed by chain-termination
processes, according to text-book knowledge thiotem-
plates are mainly in charge of assembling the basic peptide
and polyketide scaffolds, whereas so-called post-PKS and
post-NRPS enzymes are responsible for tailoring reactions
such as oxygenations, glycosylations and cyclizations,
which are often crucial for the biological activities of the
ﬁnal products. As the names post-PKS and post-NRPS
imply, chain assembly and tailoring reactions would be
time-resolved events. However, with the growing number
of studied biosynthetic pathways involving thiotemplates,
more and more examples surfaced where trans-acting
enzymes or novel PKS/NRPS domains catalyze peptide/
polyketide transformations during chain assembly.
Common on-line modiﬁcations (alkylations,
hydroxylations, and amino acid
heterocyclizations)
In addition to the canonical NRPS and PKS domains for
b-keto processing and amino acid epimerization, domains
for on-line hydroxylation and methyl transfer are wide-
spread. In particular, integral SAM-dependent methyl-
transferase (MT) domains for a-methylation are
frequently found in trans-AT PKSs, a subgroup of bacte-
rial modular PKSs in which the malonyl units are loaded
by a trans-acting acyl transferases (AT) [11]. For the same
type of PKSs, another on-line alkylation mechanism is
prevalent that leads to terpenoid-like alkyl branches at
the b-carbon relative to the thioester. A set of enzymes
encoded by the hydroxymethylglutaryl-CoA synthase
Available online at www.sciencedirect.com
ScienceDirect
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(HCS) gene cassette is in charge of mediating the b-
branching reactions in trans [12]. Specialized motifs in the
PKS warrant the formation of the HCS-ACP complex in
the correct module [13].
Perhaps the best-known on-line cyclization reactions are
the cyclodehydrations of serine and cysteine residues of
peptides into oxazoline and thiazoline rings, respectively,
which are often found in siderophores (Figure 1c). For
this common modiﬁcation, NRPS modules harbor cycli-
zation (CY) domains, which may be paired with oxyge-
nase (OXY) domains for the formation of oxazole and
thiazole heterocycles [6]. Such backbone cyclizations are
often important for the overall architecture of the natural
products and rigidify the scaffold. The following sections
highlight recent discoveries of on-line tailoring reactions
with emphasis on cyclizations (Figure 1d).
Cycloether formation during polyketide
biosynthesis
Cycloethers are often important moieties that confer
biological activity to polyketide metabolites. Prominent
examples are polyether ionophores like monensin and
lasolocid. Most often, the oxacycles are incorporated by
epoxidation followed by intramolecular nucleophilic ep-
oxide ring opening catalyzed by oxygenases and epoxide
hydrolases/cyclases [14–16]. Tetrahydrofuran and tetra-
hydropyran rings may also be formed by vinylogous
addition reactions and cytochrome-mediated C–O-bond
formation, yet until recently all of these reactions were
known as typical post-PKS modiﬁcations.
Recently, speciﬁc PKS domains have been discovered
that mediate polyketide heterocyclization during chain
assembly. One such example is the dehydratase (DH)
domain involved in the biosynthesis of a potent hater-
umalide, oocydin A (5) produced by plant-associated
enterobacteria of the Serratia and Dickeya genera. One
of the two DH domains mediates the attack of a hydroxyl
group to the b-postion of an a, b-unsaturated thioester in
a Michael addition reaction, resulting in a furan ring
(Figure 2a) [17]. A similar reaction is shown to be cata-
lyzed by a pyran synthase-like (PS) domain in the bio-
synthesis of phormidolide A (6), a brominated
macrocyclic polyketide isolated from a marine cyanobac-
terium (Leptolyngbya sp.) (Figure 2b) [18]. In both cases,
the catalytic domains are part of a type I trans-AT PKS.
The PS domain is also identiﬁed in the biosynthesis of
pederin (7), an antimitotic agent produced by a symbiont
(Pseudomonas sp.) of rove beetles (Paederus spp.) [19]. The
catalytic domain, which is part of a type I trans-AT PKS,
exhibits moderate homology to DH domains with mutat-
ed active site residues. The PS domain was shown to
mediate the oxa-conjugate addition in a stereocontrolled
manner. As a stand-alone enzyme the PS domain is
capable of forming 5-membered and 6-membered
cycloethers, thus representing a versatile biocatalyst
(Figure 2c) [20]. Notably, till date no PS-like domains
have been identiﬁed in cis-AT PKS systems. However, a
functionally related DH domain with both dehydratase
and cyclase activities plays a key role in the biosynthesis
of ambruticin (8), an antifungal agent produced by the
myxobacterium Sorangium cellulosum. Analysis of the
ambruticin modular (cis-AT) PKS and in vitro assays using
synthetic substrate analogs showed that the DH3 domain
catalyzes a dehydration-cyclization cascade to yield the
pyran ring (Figure 2d) [21].
A tetrahydropyran ring is also found in the structure of
salinomycin (9), a polyether ionophore from Streptomyces
albus, yet in contrast to the above-mentioned pathways, no
‘PS’ or ‘DH’-like domains can be found in the modular
salinomycin PKS. It was shown that pyran ring formation
requires a novel cyclase, SalBIII, which is similar to the
MonB-type of epoxide hydrolases. By contrast to the
conventional epoxide ring opening reactions typically me-
diated by such enzymes, SalBIII catalyzes an E1cb-like b-
elimination reaction (Figure 2e) [22]. It was proposed that
SalBIII acts in trans to transform the PKS-bound interme-
diate into the oxacycle. The crystal structure of the enzyme
has been solved, which revealed two aspartate residues
(Asp38 and Asp104) in the active site, which are implicated
in the elimination-addition reaction. On the basis of gene
cluster analyses it is conceivable that an integral Cyc11
domain of the indanomycin PKS mediates pyran ring
formation by a similar mechanism [23]. Taken together,
the PS and DH domains of the pederin and ambruticin
PKSs and the novel trans-acting SalBIII cyclase broaden
the range of online polyketide heterocyclizations.
Polyketide branching with lactonization,
glutarimide formation and lactamization
In addition to cycloether biosynthesis, on-line Michael
additions are also involved in the formation of various
other pharmacophoric heterocycles such as d-lactone and
glutarimide moieties that branch off the polyketide back-
bone. Contrary to O-heterocyclization, these additional
ring systems are installed by the vinylogous attack of an
a,b-unsaturated thioester intermediate by a C-nucleo-
phile, produced by decarboxylation of the ACP-bound
malonyl extender unit, followed by cyclization. First
insights into this unusual polyketide branching mechanism
were gleaned from analysis of the modular trans-AT PKS
for the antimitotic phytotoxin rhizoxin (10) (Figure 3a) that
is produced in symbiosis of the fungus Rhizopus microsporus
and its endobacterium Burkholderia rhizoxinica [24,25]
Elucidation of the pathway intermediates and the
assembly line program [26] suggested that a designated
branching module (KS (Ketosynthase)-B (Branching)-
ACP) plays a key role in chain branching. By the successful
in vitro reconstitution of the module it was found that this
set of domains is sufﬁcient to catalyze the entire branching/
cyclization sequence. According to results obtained
from stable-isotope labeling experiments and trapping
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the Michael adduct, the exact course of the reaction could
be deduced [27]. The Michael addition leads to a bridged
KS-ACP intermediate, which is cleaved by attack of the d-
hydroxy group on the KS thioester. In addition to the
regular C2 extender unit, the KS-B didomain also accepts
a methylmalonyl-derived building block to give a two-fold
branched product [28]. The mechanistic study of the
rhizoxin branching module also provided a model for the
formation of glutarimide-substituted polyketides such as
migrastatin (11), 9-methyl streptimidone (12) and cyclo-
heximide (13) (Figure 3b). On the basis of PKS gene
analyses it was proposed that, in analogy to rhizoxin d-
lactone formation, a KS-X-ACP module (X for mystery
domain) would be involved in glutarimide formation [29–
31]. Using the rhizoxin branching module it was shown that
changing the OH group to a carboxamide substituent
yields the glutarimide residue [32]. In light of the
above-mentioned, PS/DH-catalyzed Michael additions it
is remarkable that the B domain has a double hotdog fold
that is a hallmark of DH domains [33]. To clarify the role of
the B and X domains in lactone and glutarimide biosyn-
thesis, chimeras of branching modules were constructed.
Mutational and kinetic studies and the substitution with
functional and mutated DH domains indicated, however,
that these domains do not play a catalytic role [34]. Lastly,
the branching/cyclization sequence works also for amine-
substituted polyketides, thus providing a new biocatalytic
avenue to d-lactams (Figure 3c). Although this route has
not yet been observed for any natural product, it is plausi-
ble that such pathways exist in nature. Intriguingly, only
recently new on-line modiﬁcation reactions leading to b-
lactams and g-lactams have been revealed, as outlined in
the following sections.
b-Lactamization during peptide assembly
b-Lactams are typical motifs of a broad range of anti-
biotics including penicillins and cephalosporins, and are
essential for their biological activity. The strained rings
are typically formed as a post-NRPS reaction by oxidative
bicyclization (for isopenicillin N) or by an additional b-
lactam synthetase (for clavulanic acid) [35]. Recently, a
third route for b-lactam formation has been elucidated in
the course of studying nocardicin G (14) biosynthesis in
Nocardia uniformis [36]. Nocardicin belongs to the fami-
ly of monocyclic b-lactam antibiotics that are not inacti-
vated by b-lactamase, and acts against Gram-negative
bacteria. Nocardicin is synthesized by a non-ribosomal
peptide synthetase (composed of NocA and NocB) that
posed several riddles. Domain analysis suggested that a
pentapeptide would be the product of the pentamodular
NRPS. However, in lieu of the predicted L-pHPG-L-Arg-
D-pHPG-L-Ser-L-pHPG pentapeptide backbone (pHPG,
para-hydroxyphenylglycine), naturally occurring nocardi-
cins show only a tripeptide backbone with a b-lactam core
and an epimerized C-terminus. By a series of studies at
the genetic and biochemical levels it was found that the
immediate product of the NRPS is indeed a pentapep-
tide, and that the L-pHPG-L-Arg terminus is important for
the processing of the peptide. With help of synthetic
surrogates of pathway intermediates it was found that the
TE domain plays an unusual role. It not only functions as
an epimerase to invert the conﬁguration of the C-terminal
pHPG [37], but also acts as a gate keeper to hold the
peptide backbone until the b-lactam ring had formed.
Thus, compelling evidence existed that b-lactam forma-
tion takes place during, not after peptide assembly.
According to a plausible model, the new route to b-
lactams involves b-elimination at the Ser residue to give
an intermediary dehydroalanyl; b-addition of the incom-
ing C-terminal pHPG residue and aminolysis of the
thioester yields the b-lactam ring [36]. Using synthetic
L-pHPG-L-Arg-D-pHPG-L-Ser-S-PCP4 and puriﬁed holo-
module 5 (Figure 3d), the reaction sequence was recon-
stituted in vitro. The condensation domain in module 5
(C5) was found to be essential for this unprecedented
sequence. In addition to the typical conserved residues,
C5 has a third His residue (His790) in the catalytic motif,
H790HH792XXXDG that plays a central role in the lactam
formation. Since a His790A mutant proved to be non-
functional, it was concluded that this histidine residue
promotes both the dehydration of the Ser residue and the
conjugate addition [36].
Aryl cross-coupling of NRPS-bound
intermediates
As for b-lactams, intramolecular cyclizations of peptide
backbones are indispensible for the antibiotic action of
actinomycete-derived glycopeptide antibiotics, such as
vancomycin, balhimicin and teicoplanin. Speciﬁcally, aryl
cross-couplings of various aromatic amino acid residues
lead to interconnected lactam rings that stabilize the three-
dimensional heptapeptide structures of these valuable
antibacterial agents [38,39]. For a long time it has been
known that the cross-coupling is catalyzed by trans-acting
cytochrome monooxygenases (CYPs) in a highly speciﬁc
order [40]. Furthermore, these specialized CYPs fuse their
substrates only when they are bound to the NPRS. For
example, in teicoplanin (15) biosynthesis by Actinoplanes
teichomyceticus, OxyBtei installs the ﬁrst crosslink between
the side chains of aromatic residues [41,42]. In vitro assays
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(Figure 1 Legend) (a) General cyclization patterns. Polyketide or peptide intermediates bound to carrier protein can be (i) released from the
assembly line as linear compounds and cyclized by tailoring enzymes, or (ii) released as a macrocyclized product that may further by cyclized or
(iii) cyclized on-line by assembly line domains or trans-acting enzymes. (b) Examples of off-loading mechanisms in the formation of a
macrocyclized narbonolide 1 and the spirotetronate versipelostatin 2. (c) Examples of well-known on-line cyclizations that involves the Cy domain
for the formation of oxazole/thiazole moieties (vibriobactin 3 and yersiniabactin 4). (d) Ring structures formed by on-line tailoring as discussed in
this review.
www.sciencedirect.com Current Opinion in Chemical Biology 2016, 31:82–94
 
ͤ͢͡
86 Biocatalysis and biotransformation
Figure 2
O
Dehydration
O
OH
Ambruticin S (8)
OH
HOOC
S
O
PS
ACP
O
H
N
OH
O
OOH
OMe
OMe
OMe
MeO
ACP
Pederin (7)
(a)
(b)
(c)
KS
DH
PS
KR
Cyclization
DH3 DH3
S
O
O
R
OH
O
S
OH
ACPKS
AT
DH3
KR
O
S
OH
ACP ACP
S
O
O
0,1
R
OH
0,1
ACPKS
DH
DH
KR
S DH
ACP
S O
HOOC
OH
Oocydin A (5)
ACPKS
ATd
PS
KR
S PS
DH
Phormidolide A (6)
ATd - KS-AT 
adaptor region
OocK or OocM 
(hydroxylase)
PhmG
(hydroxylase)
Br
OMe
O OH OH OH OH OH
O
O
O
O
OH
(d)
O
O
Cl
OAc
O
R
HO
O
O
R
HO
O
HO
OH
R
O
S
ACP
O
O
O
OH
O
O
A
B
C
O
O
HO
D
E
KS AT
KR
Asp38H
SalBIII
O–
S
ACP
Asp38
SalBIII
O
S
ACP
Asp38
HO
(e)
R
OH
O
HO
HO
R
O
HO
HO
OH
Asp104
R
O
OH
HO
Salinomycin (9)
HO
OH
ACP
S
O
O
R
HO
Current Opinion in Chemical Biology
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showed that for this protein, the peptidyl-PCP alone is not
sufﬁcient to mediate the entire crosslinking. Although the
other oxygenase enzymes (OxyA, OxyC) have been iden-
tiﬁed, the mechanism of recruiting these enzymes to the
PCP-bound peptide has remained elusive.
Only recently, it was shown that all glycopeptide-type
NRPS assembly lines feature a specialized domain (named
X) in the last module, which resembles condensation/
epimerization domains but has a mutated active site. By
generating constructs of the entire module or speciﬁc
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Lactone, glutarimide and lactam formation by non-canonical domains. (a) Vinylogous chain branching in rhizoxin 10 biosynthesis catalyzed by KS-
B didomain. (b) Similar branching mechanisms are observed in the synthesis of glutarimide residue seen in migrastatin 11, 9-methyl streptimidone
12 and cycloheximide 13, catalyzed by KS-X didomain; a regular DH domain can replace B or X domains in the module. (c) d-Lactam formation by
the branching module. (d) Mechanism of b-lactam ring formation in nocardicin G 14 by a novel condensation domain (C5).
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domains, it has been demonstrated that the minimal re-
quirement for OxyBtei to interact with the NRPS-bound
peptide is the presence of the X domain, and that the
interaction happens in the last module (7) of the teicopla-
nin or vancomycin NRPS (Figure 4) [43]. This is differ-
ent from the other P450 recruitment systems that rely only
on the carrier protein [44]. In addition to OxyB, the X
domain strongly interacts with OxyA and, to a lesser
degree, with OxyC. This role of a domain to act as a
recruiter of oxygenase enzymes has been unprecedented
and appears to be a hallmark of glycopeptide biosynthesis.
A range of heptapeptide and hexapeptide substrates, when
presented on the PCP-X didomain in vitro, was also shown
to be sequentially cyclized by OxyB and OxyA, indicating
the impressive substrate tolerance of these enzymes [45].
However, one may also conceive that similarly controlled
mechanisms take place in other biosynthetic pathways
leading to aryl-coupled natural products.
Knoevenagel cyclocondensation
In addition to the above-mentioned avenues, yet another
pathway involving an on-line lactam formation has re-
cently been proposed in the biosynthesis of colibactin, a
not yet fully characterized metabolite of the human
commensal Escherichia coli. Through genetic analyses it
has been known that colibactin is produced by a hybrid
PKS-NRPS pathway known as the ‘pks island’. The
enigmatic compound leads to DNA damage, genomic
instability in mammalian cells and thus correlates with
the induction of colorectal cancers [46]. Although the
gene cluster responsible for colibactin has been known for
over 10 years (clb), its structure has been one of the
challenging elements to address because of the low yield,
extreme instability of the intermediates and the contact-
dependent cytopathic activity. Moreover, it appears that
colibactin affords a prodrug strategy as seen in xenocou-
macin biosynthesis [47] with the N-terminal part of the
‘precolibactin’ removed at a later stage by an encoded
peptidase, ClbP. Over the recent years, many groups have
tried to ﬁt the puzzle with the pathway intermediates to
propose the structure of colibactin. A NMR-based struc-
tural network analysis approach targeting the pathway
intermediates had revealed structures of shunt products,
precolibactin. One of the isolated compounds (16) fea-
tures an azaspiro bicyclic ring structure, which probably
functions as a warhead of colibactin. Upon release by the
peptidase ClbP (with the exposed N-terminal primary
amine and a thiazoline-thiazole tail) the electrophilic
moiety can crosslink DNA by alkylation, probably by a
homo-Michael addition [48].
The intriguing cyclic structure, which incorporates a Met-
derived 1-aminocyclopropane-1-carboxylic acid (ACC) ex-
tender unit, is probably formed by an intramolecular Knoe-
venagel cyclocondensation reaction while the peptide-
polyketide intermediate is still tethered to the PKS-NRPS,
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A conserved X domain in glycopeptide biosynthesis recruits oxygenases to form mature aglycone as shown for teicoplanin 15 biosynthesis.
Current Opinion in Chemical Biology 2016, 31:82–94 www.sciencedirect.com
 
ͧ͢͡
followed by thioester cleavage and decarboxylation
(Figure 5, Route i) [48,49]. However, the biochemical
basis of and the timing of the reaction need to be clariﬁed.
It cannot be ruled out that the cyclization occurs spontane-
ously after chain release [50]. Furthermore, a slightly
different structure was elucidated for another isolated
precolibactin candidate (17), which suggested that decar-
boxylation could also precede cyclization to form the pre-
colibactin warhead (Figure 5, Route ii) [51].
On-line cyclopropanations
Whereas the cyclopropyl group of colibactin obviously
derives from an ACC building block, small carbacycles
may form during polyketide assembly. An unexpected
variation of the terpenoid-like polyketide b-branching
reaction [12] leads to the characteristic cyclopropyl
residue of curacin A (18), a PKS-NRPS hybrid produced
by the cyanobacterium Lyngbya majuscula. Dissection
of the pathway and biochemical assays revealed that
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Proposed intramolecular cyclocondensation reaction in colibactin biosynthesis and structures of full-length precolibactin derivatives (16 and 17)
with the spirobicyclic warhead.
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the (S)-3-hydroxy-3-methylglutaryl intermediate under-
goes a chlorination by a ketoglutarate-dependent non-
heme Fe(II) halogenase [52,53]. The halogenation reac-
tion is followed by dehydration and decarboxylation,
catalyzed by ECH1 and ECH2, respectively, to yield
the allylic chloride. Finally, the enoyl reductase domain
of CurF promotes the subsequent cyclization to afford
the strained three-membered ring [52] (Figure 6a). It
should be noted that the chlorination of the early pathway
intermediate does not lead to a chloro-substituted
ﬁnal product, but sets the stage for the cyclization, thus
representing another rare case of a cryptic halogenation
en route to cyclopropyl rings [54].
A different biosynthetic strategy for on-line cyclopropa-
nations has evolved for the structurally intriguing poly-
cyclopropyl natural product jawsamycin (19) (initially
termed FR-900848) [55]. Heterologous expression and
mutational experiments indicated that the small rings are
introduced stepwise into the growing polyunsaturated
polyketide chain. An enzyme with homology to radical
S-adenosylmethionine (SAM) enzymes (Jaw5) plays a key
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Formation of cyclopropyl rings by (a) NADPH-mediated ER domain (curacin A 18), (b) SAM-dependent cycloproponase Jaw5 (jawsamycin 19) and
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role in the polycyclopropanation (Figure 6b). In the
current biosynthetic model, ﬁrst a SAM ylide is formed
by homolytic C–H cleavage of a SAM methyl and subse-
quent electron transfer from the Fe–S cluster, which
reacts with the enoyl group. Alternatively, a reaction with
a SAM methyl radical would also be possible. The exact
mechanism and the biosynthetic program for these highly
selective reactions remain to be elucidated. Nonetheless,
the Jaw5-mediated reactions are an important addition to
the known on-line alkylation reactions, which may open
new possibilities for pathway engineering.
A route to cyclopropanes that is probably independent of
both halogenation and alkylation has been realized in the
biosynthetic pathway to ambruticin (8), an antifungal
agent from S. cellulosum [56]. On the basis of the deduced
biosynthetic program of the multimodular PKS it was
proposed that a Favorskii-like rearrangement takes place
on an ACP-bound polyene intermediate (Figure 6c). This
reaction would afford the loss of one carbon of an inter-
mediary cyclopropanone residue. Still the putative
Favorskiiase component is elusive and the exact reaction
mechanism needs to be clariﬁed.
Intramolecular [4 + 2] cycloadditions
By contrast to the numerous well-deﬁned domains for
intermediate modiﬁcation or recruitment of trans-acting
enzymes, on-line modiﬁcation processes involving cycload-
ditions are rather cryptic. This applies in particular to the
large number of natural products that derive from intramo-
lecular [4 + 2] cycloadditions. A growing, heterogeneous
family of enzymes have been implicated as mediators of
Diels–Alder reactions, including lovastatin synthase
(LovB) [57], SpnF in spinosyn biosynthesis [58], and VstJ
in the biosynthesis of the spirotetronate versipelostatin
[59]. Similarly, in the biosynthesis of a spirotetramate-
containing pyrroindomycins, two distinct [4 + 2] cycloaddi-
tions have been shown to form the spiroconjugate [60]. The
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Diels–Alder reaction in lovastatin (20) biosynthesis has
long been the text-book example for an on-line cycloaddi-
tion (Figure 7a), yet no distinct domain or enzymatic
feature could be attributed to the [4 + 2] cycloaddition.
Recently, in the biosynthesis of a potential anti-HIV agent
Sch 210972 (21), produced by the fungus Chaetomium
globosum, the decalin core has been proposed to form
through a similar Diels–Alder reaction, but in the presence
of a lipocalin-like enzyme, CghA (Figure 7b) [61]. This
tetramic-acid containing natural product is by a PKS-NRPS
hybrid pathway. It has been proposed that CghA-like
proteins might help bind to speciﬁc conformation of the
polyketide intermediate to perform stereoselective cyclo-
addition reaction.
For modular PKS systems, cases are known where inter-
mediates seem to spontaneously undergo Diels–Alder
reactions. Chlorotonil A (22) from the myxobacterium
S. cellulosum So ce 1525 [62] and anthracimycin (23)
produced by Streptomyces sp. CNH365 [63] are related
complex polyketides that differ in inverted stereocenters
and in the geminal dichloro moiety at C4. In both deduced
pathways, the ACP-tethered elongated a,b-unsaturated
nonaketides have trans-dienophiles that favor an endo-
transition state, thus leading to the trans-decalin geome-
try observed in the molecules (Figure 7c). This Diels–
Alder-like [4 + 2] cycloaddition probably occurs sponta-
neously as the diene and dienophile moieties are in close
proximities to promote ring closure. The inverted stereo-
centers could be rationalized by the stereoinduction of
the C16 methyl group and the R-conﬁgured hydroxyl
group in anthracimycin [62]. Even in cases where inter-
mediates cyclize spontaneously, it is the thiotemplate
program that generates structures with inherent reactivi-
ty, such as diene and dienophile moieties.
Conclusions
This brief overview illustrates that in addition to the
manifold post-PKS and post-NRPS modiﬁcations cata-
lyzed by diverse enzymes, more and more examples of
on-line reactions have emerged. Although the number of
these thiotemplate-related processes is still comparably
low, it should be highlighted that the mentioned reactions
are of eminent importance for the bioactivity of the ﬁnal
products. On-line cyclizations not only lead to pharma-
cophoric groups that are crucial for the binding to the
targets by introducing critical residues or arresting an
otherwise ﬂexible molecule in a preferred conformation,
but may also yield residues that function as warhead. The
novel PKS and NRPS domains as well as the trans-acting
enzymes and their recruiting domains are important addi-
tions to the biosynthetic toolbox. Knowledge of the
assembly line logic will open new possibilities to engineer
biosynthetic pathway to create structural diversity. In
addition, elucidation of the biosynthetic code will aid
in genome mining approaches for the discovery of hith-
erto unknown enzymes and natural products.
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SUMMARY 
Ketosynthase (KS) domains of modular type I polyketide synthases (PKSs) typically catalyze 
Claisen condensation of simple acyl and malonyl units to form linear chains that eventually 
make bioactive polyketides. The KS domain of the branching module of rhizoxin PKS installs 
a β-branch in the otherwise linear polyketide intermediate which is then cyclized to form the 
pharmacophoric δ-lactone moiety. To know the exact role of KS domain in the branching-
cyclization sequence, we performed targeted mutagenesis of 10 of the conserved amino acids. 
Biochemical and kinetic analysis revealed that the C3228A and T3290Y mutations 
completely abolished the β-branch formation. The H3364A, H3404A S3141D, I3478F and 
S3409A mutants exhibited low turnover activity with attenuated rate for lactonization.
Complementing the mutational analyses, we generated chimeras of the branching-KS domain 
with elongating-KSs and show that a canonical linear chain is formed. These results reveal the 
mechanistic details of a complex branching reaction catalyzed solely by a KS domain. 
Keywords 
Trans-AT PKSs, β-branching, KS domain, domain exchange, site-directed mutagenesis, 
biotransformation, enzyme kinetics 
Highlights  
x Polyketide β-branching as well as lactonization is catalyzed by the rhi KS domain. 
x Site-specific mutagenesis of the KS reveals roles of critical conserved residues. 
x A regular linear polyketide chain results from swapping branching-KS with 
elongating KSs. 
x The results reveal complex interplay of the active site residues in the branching-
cyclization reactions.
In Brief  
Sundaram et al., investigates the mechanism of a branching-KS domain of the rhizoxin PKS 
and reports the role of critical conserved residues. The catalytic role of KS is also studied by 
whole domain exchange experiments. 
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INTRODUCTION  
The extremely complex bioactive polyketides are assembled from simple acyl-CoA building 
blocks by giant multienzyme polyketide synthases (PKSs). Bacterial type I modular PKSs 
recruit domains to perform chain elongation followed by ketoreduction, dehydration, and 
enoylreduction that yield structurally diverse polyketides (Chan et al., 2009; Khosla et al., 
2009). Typically, each domain within a module performs a single reaction. Therefore the 
number of modules can directly be translated to the expected product, a principle defined as 
colinearity (Hertweck, 2009). Trans-AT PKSs differ from this regular paradigm. These PKSs 
possess trans-acting acyltransferase (AT) and may contain skipped modules, irregular domain 
orders, inactive as well as dual functional domains and novel domains generating branches 
and rings (Helfrich and Piel, 2016; Piel, 2010). A single trans-AT PKS module minimally 
contains an acyl carrier protein (ACP) domain that shuttles starter/extender acyl-CoA units or 
intermediates and a ketosynthase (KS) domain that decarboxylates the extender unit and 
condenses with the intermediate. The KS domain is the most highly conserved of all the 
domains and contains a thiolase fold with α/β/α/β/α design. The active center of the KS 
domain comprises of a well conserved Cys-His-His catalytic triad. Crystal structures of KSs 
from cis- as well as trans-AT PKSs revealed clues about the reaction mechanism (Gay et al., 
2014; Gay et al., 2016; Keatinge-Clay, 2012). Typically, the reactive Cys is the main 
nucleophile involved in the reaction and is first acylated by attack of the upstream acyl-ACP 
thioester intermediate. The nucleophilicity of Cys is enhanced by one of the histidines which 
might be important in activating the carboxylate of the extender unit attached to a downstream 
ACP. The other histidine recruits a well-placed water molecule to attack the activated 
carboxylate. This yields an enolate that attacks the acyl-KS thioester to elongate the 
polyketide chain. The reaction thus happens in two steps: decarboxylation of extender unit 
attached to ACP and carbon-carbon bond formation – both catalyzed by the KS domain 
(Keatinge-Clay, 2012). The mechanism of a typical KS domain is exemplified by the module 
10 of thailandamide PKS (Figure 1A) (Ishida et al., 2012). 
Some of the KS domains from trans-AT PKSs perform novel activities such as β-branching 
(Hertweck, 2015). One example for such a non-canonical KS domain from the phytotoxic 
rhizoxin trans-AT PKS is part of a branching module that also contains B and ACP domains. 
This module installs the pharmacophoric δ-lactone moiety of the rhizoxin that is vital for its 
antimitotic activity (Kusebauch et al., 2009; Schmitt et al., 2008). The δ-lactone is formed by 
the addition of an ACP-bound malonyl unit to the α,β-unsaturated, unbranched thioester 
polyketide intermediate. As a result of this Michael addition, a β-branch is generated, which is 
then cyclized (Figure 1B) (Bretschneider et al., 2013). Analogous to this, the glutarimide 
moiety of 9-methyl streptimidone, isomigrastatin and cycloheximide (Ju et al., 2005; Wang et 
al., 2013; Yin et al., 2014) is also proposed to be generated by a similar KS domain.  
Although the cryptic B domain shares structural homology with dehydratase (DH) domains, it 
has a distorted active site with a His to Tyr mutation. Mutational analysis of the conserved 
Asp of the B domain revealed that this domain might only have a structural role in the 
branching reaction (Bretschneider et al., 2013). Retaining of the branching activity in the B
domain substitution experiments with structurally related X (Wang et al., 2013) and DH
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domains confirmed that B and X domains maintains the structural integrity while the KS 
domain solely catalyzes the branching-cyclization sequence (Sundaram et al., 2015). Point 
mutations of the active site Cys-His-His residues of KS domain resulted in no branching 
activity confirming the direct role played by these residues (Bretschneider et al., 2013). 
Earlier mutational analyses on the canonical KS domains demonstrated that additional 
residues might be important for the substrate selectivity and specificity (Brautaset et al., 2003; 
Gay et al., 2014). It remains obscure how the branching KS have evolved to catalyze the 
novel β-branching despite the presence of a well conserved catalytic triad.
In this study, we expand the knowledge of the active site residues of the branching-KS as well 
as sought for other residues that might be important for either Michael addition or 
lactonization or both. We also generated chimeric KS domains and show that elongating KSs 
appended to B domain form a regular linear product.  
RESULTS  
Site-specific mutational analysis of KS domain 
To decipher the exact role and mechanism of KS domain in chain branching, we probed into 
the primary sequence of the KS domain. The KS domain in the rhizoxin PKS branching 
module (Rhi-KS14) falls in clade IX category in the cladogram that corresponds to olefinic 
substrates (Nguyen et al., 2008). We compared the amino acid sequence of Rhi-KS14 with 
other KSs (both branching and elongating) from clade IX. 10 positions in the branching KSs 
differ considerably when compared against other KSs that mediate Claisen condensation 
(Figure 2A and S1). Site-directed mutagenesis was performed on these residues where they 
were changed to those that correspond in the other KSs. In case of S3232, it was changed to 
Leu as well as Ala. Figure 2B shows the conserved residues of the Rhi-KS14 (PDB code: 
4kc5) superimposed on the bacillaene KS5 structure (PDB code: 5erb) (Gay et al., 2016). In 
total, 11 single mutations were introduced in the plasmid pTB57 (Bretschneider et al., 2013).
To know the cumulative effect of all the selected amino acids, a synthetic gene (KS’-B) 
(MWG Eurofins) where all the 9 residues were mutated (except T3290). All the proteins were 
heterologously produced in E. coli BL21 (DE3). Figure 2C shows the purified proteins 
together with the active site mutants (C3228A, H3364A, H3404A) on a 10% SDS gel. The 
secondary structure of all the recombinant proteins when compared against the KS-B showed 
that there are no significant differences (except for KS’-B) (Figure 2D and 2E).
In vitro biotransformation with KS mutants 
In the previous study, to decipher the course of the reaction, a SNAC thioester that lacks the 
δ-hydroxy group 1 was used to trap the KSB and ACP domains in place (Figure 3A). This 
resulted in a covalent intermediate bound to both the domains (2) which was then visualized 
on the SDS gel (Bretschneider et al., 2013). To identify any additional residues that might be 
involved in Michael addition, the in vitro assay was initially performed with 1. The assays 
were performed at 23 °C for 16 h. All the mutants except C3228A, T3290Y and the KS’-B, 
retained the vinylogous activity (Figure 3B). It is intriguing that both the histidine residues 
are still capable of undergoing the vinylogous addition, contrary to the previous report 
(Bretschneider et al., 2013). In the previous study, the standard assay timing was only 60 min. 
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It is plausible that the C-C bond formation takes place at a much slower rate when histidines 
are mutated. 
The in vitro reconstitution of the branching reaction was then performed with the native 
substrate mimic 3 to monitor the formation of the lactone 4 (Figure 4A). H3097A, S3117G, 
S3141D, S3232L, S3232A, C3234A, T3267L, L3406E, S3409A and I3478F (Figure 4B, 4C, 
4D, 4F, 4G, 4H, 4I, 4M, 4N and 4O) mutations did not significantly affect the branching 
activity. In all these cases, the δ-lactone 4 was observed in comparable amounts to KS-B 
(Figure 4Q). Corroborating the SDS gel-shift experiments, the mutants C3228A, T3290Y and 
KS’-B did not result in 4 even when the corresponding enzymes were tested at 10 times the 
normal concentration for prolonged timing (16 h) (Figure 4E, 4J and 4P). Both C3228A and 
T3290Y mutants however still retained malonyl-CoA decarboxylation activity (data not 
shown). For the mutants H3364A and H3404A, increasing the enzyme concentration and the 
duration of the assay also increased the amount of product formed (Figure 4K and 4L). It is 
possible that both these residues complement each other in the branching reaction. The KS’B
with 9 mutations had attenuated malonyl CoA decarboxylation activity and the product was 
not observed. During protein production and purification, unlike other mutants, KS’-B
resulted mostly in the formation of inclusion bodies. Even after several rounds of optimization 
during protein purification, it was only possible to get very low amount of soluble protein. 
The CD data of KS-B’ also exhibited slight differences in the near-UV region (Figure 2D). It 
is possible that the introduction of several mutations rendered the protein inactive. Therefore, 
it is difficult to conclude whether the inactivity of KS-B’ is due to structural or functional 
differences.  
LC-ESI-MS of intact proteins 
To complement the LC-MS analysis, LC-ESI-MS of the intact ACP-bound proteins was also 
performed for KS-B, H3364A and H3404A. For the ease of comparison, the assays were 
performed at 10x enzyme concentration for 16 h. The PPant-ejected product was analyzed in 
the first quadrapole. The lactone-bound PPant arm was observed for all the samples tested. 
However, compared to the wild type KS-B (Figure S2), the intensities of the mass fragments 
were approximately 10-fold lower in H3364A and H3404A (Figure S3 and S4).
Kinetic analysis of lactone formation 
The preference of the mutants for the native substrate mimic 3 was further analyzed by 
performing kinetic experiments. The mutants C3228A and T3290Y did not exhibit any 
turnover activity in the in vitro biotransformation and therefore were excluded from the 
kinetic analysis. The assay was performed at saturating concentration of 3 (1 mM) and 
increased enzyme concentrations. Increasing the concentrations of KSB and ACP to 4.5 μM 
and 300 μM respectively aided in comparing the activities of the mutants. Figure 5 shows the 
cumulative data from three independent experiments. The mutants colored in black all have 
comparable activities and reached product saturation from approximately 45 min. S3141D, 
I3478F and S3409A resulted in the accumulation of decarboxylated malonyl-ACP (data not 
shown) whereas the lactonization was less pronounced. The H3364A, H3404A and KS’-B
mutants exhibited negligible activities within the time limit specified (75 min). It is worth 
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mentioning that the decarboxylation activity of H3404 is still affected even after 16 h assay, 
suggesting that this residue is very important for the decarboxylation of malonyl-ACP. A
double mutant (H3364A and H3404A) did not result in 4 proving that they are indispensable 
for decarboxylation.  
   
Construction of KS-B chimeric modules 
Even though the mutational studies shed some information on the kinetics of the branching 
reaction, it was difficult to assign specific roles to individual residues. It is possible that two 
or more residues work together in the branching reaction. To complement this study, KS 
whole domain exchange experiments were performed. The branching KS when exchanged 
with a non-branching KS should ideally lead to a linear product in place of the branched one. 
The KSs, KS5 from bacillaene (Bae) PKS (Butcher et al., 2007), KS4, KS5 and KS9 from 
macrolactin (Mln) PKS (Chen et al., 2007), and KS3, KS12 from thailandamide (Tha) PKS 
(Ishida et al., 2012) belong to clade IX similar to the Rhi-KS14. These KSs accept α, β-
unbranched, unsaturated substrates (Figure 6A) (Nguyen et al., 2008) and yield linear 
polyketide intermediates. Of the 6 KSs, the Bae-KS5 has been reported to show tolerance 
towards shorter acyl-thioesters (Jenner et al., 2013). The genes corresponding to these KSs 
were amplified from the genomic DNA of Bacillus amyloliquefacians (for BaeKS5, MlnKS4, 
MlnKS5 and MlnKS9) and Burkholderia thailandensis (for ThaKS3 and ThaKS12). The 
linker region between the Rhi–KS14 and the B domain in the native KS-B didomain was kept 
intact since this region is also important for structural stability (Sundaram et al., 2015). After 
DNA sequence confirmation, the KS genes were fused to the N-terminus of the linker and the 
B domain and expressed in E. coli BL21 (DE3). All the chimeric proteins were produced as 
KS-B didomains (Figure 6B). Owing to the high GC content of B. amyloliquefacians, except 
for MlnKS4-B, the solubility of the chimeric proteins drastically reduced. To avoid further 
sample loss, only a single step of affinity purification was done for all the proteins (Figure 
6C). However, except MlnKS4-B, none of the enzymes were stable when stored at 4 °C. 
Domain swapping usually results in insoluble or inactive proteins as the interdomain 
communication is compromised (Weissman, 2014).  
A recent study reported the presence of a three-helix LINKS (Laterally-INteracting 
Ketosynthase Sequence) motif located C-terminal to some of the trans-AT KSs. This ~40 
residue region contains a mixture of charged and hydrophobic residues that zip together 
additional copies of KSs within the assembly line (Gay et al., 2016). Some of the KSs do not 
contain LINKS region (for example, Rhi-KS14) whereas in some, the conservation of the 
LINKS region is poor. In the BaeKS5, the LINKS region is well established whereas in 
ThaKS3, ThaKS12, structurally uncharacterized mode of interactions have been proposed to 
occur (Gay et al., 2016). We reasoned that including the LINKS in the chimeric constructs 
would improve the KS dimer stability. Therefore, a new cloning strategy was planned to 
substitute this LINKS region for the linker region that is originally present between Rhi-KS14 
and the B domain (Figure 6B). The resulting hybrids are shown as BaeKS5*-B, ThaKS3*-B
and ThaKS12*-B. Including the LINKS region specific to each of the above mentioned KSs 
greatly improved the solubility of the protein (Figure 6C). The constructs were verified by 
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MALDI-TOF followed by tryptic digestion (Figure S5). Owing to poor storage stability, the 
CD spectra were recorded only for MlnKS4-B, BaeKS5*-B and ThaKS3*-B (Figure 6D).
In vitro biotransformation with KS chimeras
The activity of all the chimeric KS-B was checked by in vitro reconstitution of the branching 
reaction with 3. Figure 7A shows the possible reactions from the assay with the hybrids. If 
the incoming malonyl unit is added to the first (route b) rather than the third carbon atom 
(route a) of the polyketide intermediate bound to KS, a regular Claisen condensation would 
occur. This will lead to a linear product 5 in place of the branched one (4). Of all the 9 hybrids 
tested, only 3 (MlnKS4-B, BaeKS5*-B and ThaKS3*-B) resulted in a new compound which 
has the same mass as 4 with a retention time of ~7.2 min. The rest of the hybrids resulted in 
no turnover of 3. Figure 7B, 7C and 7D shows the extracted ion chromatograms of [M+H]+
173.0808 for these three hybrids. Figure 7E shows the difference in retention times of the 
lactone 4 and the probable linear product 5. MS/MS analysis of the new product (with 
MlnKS4-B as an example) was also performed along with the wild type KS-B as the positive 
control (Figure S6). As shown, the mass fragments were different for 4 and 5. 
DISCUSSION 
The modular structure of the multienzyme polyketide synthases (PKSs) is a very efficient 
platform to modify the domains to produce analogues of desired structure as well as to 
decipher the function of enigmatic domains (Weissman, 2016). Domain modifications have 
been successfully performed with specific reductive, KR (Kellenberger et al., 2008) and AT 
domains of DEBS (Walker et al., 2013). The exchanging and engineering experiments are not 
only limited to individual domains but also to the whole modules as in the case of avermectin, 
aureothin, neoaureothin and luteoreticulin PKSs (Marsden et al., 1998; Sugimoto et al., 2014; 
Sugimoto et al., 2015). Modifications on KS domain, which performs the core carbon-carbon 
bond formation is a very challenging feat, mainly because of the inability of the chimeric KS 
to maintain domain-domain interfaces. Many of the silent interfaces have been shown to 
activate by rational replacement of the KS domain of DEBS PKS (Chandran et al., 2006). 
Most of the studies on KS domain were directed towards specific mutations of individual 
residues to broaden the substrate specificity (Gay et al., 2014; Jenner et al., 2013; Murphy et 
al., 2016) as well as to understand the role of active site residues (in case of cis-AT PKS) 
(Robbins et al., 2016). 
This study analyses the impact of individual amino acid residues of a non-canonical branching 
KS on the decarboxylation of malonyl-ACP, Michael addition and the subsequent 
lactonization. Although the versatility of the KS cannot be assigned to any specific residue, 
this study revealed insights into the conserved residues. The inactivity of C3228A mutation is 
not surprising (Figure 4E), which is expected by the absence of exceptionally nucleophilic 
C3228 residue needed for binding the polyketide intermediate. The H3364 enhances 
decarboxylation of malonyl-ACP by deprotonating a water molecule to attack the malonate. 
The H3364A mutant exhibited slow turnover in terms of the formation of a decarboxylated 
malonate as well as the subsequent lactone (4) formation (Figure 4K). A previous report on 
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FabF also suggested that this histidine functions to enhance the overall rate of the reaction 
(Zhang et al., 2006) and thus may not an absolute necessity for the chain branching. The 
H3404 activates the malonyl carboxylate by stabilising the enolate. Reduction in the carbon-
carbon bond formation as well as the lactone (4) (Figure 3B and 4L) supports that H3404 
plays a major role in all the steps of the reaction. Neither of the histidines has marked 
influence on the ionization of C3228 residue. Similar to C3228A, the completely inactive 
T3290Y mutant (Figure 4J) suggests that this residue might interact with one of the histidines 
to promote C-C bond formation. The analogous Phe residue in FabB and FabF enzymes is 
reported to promote decarboxylation and the formation of C2 carbanion (Huang et al., 1998; 
Olsen et al., 1999; Price et al., 2003). We propose that the presence of T3290 promotes attack 
of the malonyl extender unit to the β-carbon of the polyketide intermediate and provides space 
for the formation of a lactone moiety. However, both C3228A and T3290Y mutants still 
functioned as an effective malonyl-CoA decarboxylase (data not shown). The reduction in the 
activity of S3409A mutant is intriguing (Figure 5) and we propose that this residue might 
promote the final lactonization step.  
In this study, we also analyze the role of the entire KS domain by constructing chimeric KS*-
B didomains. Insolubility of chimeric domains has been a major challenge in domain or 
module swapping experiments mainly due to the disruption of the interdomain linkers (Sun et 
al., 2015; Weissman, 2016). Interdomain contacts are critical for maintaining the functional 
state of the module as revealed by the cryo-electron microscopy of module 5 of pikromycin 
PKS (Dutta et al., 2014). Here, although the LINKS region is not conserved among the KSs 
(Gay et al., 2016), we exploited this region to generate soluble and active KS-B chimeras 
(Figure 6C). Although the turnover rate is slow, production of a canonical linear product 5
with the KS-B chimeras establishes the complex role of the Rhi KS in the Michael 
addition/cyclization sequence.   
To summarize, from a series of functional analyses, we provide multiple evidences that the 
KS domain alone catalyzes the Michael addition and cyclization. We also verified the 
residues that play critical role at each step of the branching reaction. This KS-mediated 
branching reaction is very significant from a synthetic biology perspective.  
SIGNIFICANCE 
Novel domains/modules from polyketide synthases are emerging as effective biocatalysts to 
produce non-natural variants. The KS domain of the rhizoxin PKS is highly versatile for it 
produces the pharmacophoric δ-lactone moiety by a non-canonical polyketide β-branching 
followed by lactonization. Similar β-branching-KS domains are observed to take part in the 
formation of glutarimide group in cycloheximide-type of antibiotics. Understanding the 
mechanism of such KS domains is imperative towards extended synthetic biology approaches.
In this study, the minimally invasive site-specific mutational analyses of the residues 
conserved in branching KSs but different in elongating-KSs reveal that the branching-
lactonization reaction is more complex than expected. Insights gained from the mutational 
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analyses and KS domain exchange experiments might enlighten the mechanistic details of the 
branching reaction.   
EXPERIMENTAL PROCEDURES 
General 
Chemicals were purchased from Roth and Sigma-Aldrich. MALDI measurements were done
using an UltrafleXtreme MALDI TOF/TOF (Bruker). High resolution mass measurements 
were performed using an Exactive Orbitrap High Performance Benchtop HRMS with an 
electrospray ion source and an Accela HPLC system (Thermo Scientific). LC-MS/MS 
experiments were performed using a QExactive equipment with Accela HPLC system 
(Thermo Scientific). LC-ESI-MS analysis of intact proteins was performed using ZORBAX 
300SB-CN column in a ThermoFinnigan Surveyor LC equipment with a LTQ velos MS 
attached running on an electrospray ion source. The spectra from LC-ESI-MS measurements 
were deconvoluted using ProMass software (Thermo Scientific). NMR measurements were 
performed on a Bruker AVANCE II 300, AVANCE III 500 or 600 MHz spectrometer, with a 
Bruker cryo platform. Cicular dichroism (CD) measurements were performed using a J815 
spectropolarimeter (Jasco). Site-directed mutagenesis was performed using Quikchange II XL 
kit (Stratagene). Identity of all recombinant proteins was confirmed using SDS-PAGE and 
tryptic fingerprinting followed by MALDI. Crystal structures were visualized using Pymol. 
Cloning experiments 
Mutational procedures 
Primers for point mutations were designed based on the Quikchange II XL mutagenesis kit 
manual (Stratagene) and a previous report (Zheng et al., 2004). The plasmid pTB57 that 
expresses RhiE KS-B under the control of T7 promoter (Bretschneider et al., 2013) was used 
as template. For GC-rich primers, up to 6% DMSO was used to prevent non-specific primer 
annealing. The primers used for generating all the point mutations are listed in table 1. After 
PCR amplification and inactivation of any template DNA by DpnI, 1/10th the sample volume 
of 3 M sodium acetate (pH 5.2) was added to precipitate the amplified product. The 
precipitate was washed with 2.5 volumes of 100% ice-cold ethanol. After a brief 
centrifugation, the DNA pellet was further washed with 70% ethanol. The enriched plasmid 
was then directly used for transformation of E. coli Top10 cells by electroporation. After 
confirming the mutants by DNA sequencing (MWG Eurofins), the plasmids were introduced 
into E. coli BL21 (DE3) (New England Biolabs). The double mutant (H3364A and H3404A) 
was generated using the primers already reported (Bretschneider et al., 2013). The synthetic 
gene with 9 mutations (H3097A, S3117G, S3141D, S3232L, C3234A, T3267L, L3406E, 
S3409A and I3478F) was purchased from MWG Eurofins. The gene was directly cloned in 
the vector pHis8-3 and expressed in E. coli BL21 (DE3) (New England Biolabs). 
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Primers Sequence
H3097A_fw GCGACTTTCCGGCAGACCGGTGGGACGCCAGCAAAATCTATTAC
H3097A_rv GTAATAGATTTTGCTGGCGTCCCACCGGTCTGCCGGAAAGTCGC
S3117G_fw GTGCTAGGCAAGACCACCTGCATCAATGGCGGGTTCATCAAGGAC
S3117G_rv GTCCTTGATGAACCCGCCATTGATGCAGGTGGTCTTGCCTAGCAC
S3141D_fw GCCCAAGGTCTATGCCGACCATATGGACCCAGAGGTCAGACTG
S3141D_rv CAGTCTGACCTCTGGGTCCATATGGTCGGCATAGACCTTGGGC
S3232L_fw CGATACCATGTGCTCGTCGTCCCTCACCTGTATCCACACCGCTTG
S3232L_rv CAAGCGGTGTGGATACAGGTGAGGGACGACGAGCACATGGTATCG
S3232A_fw CGATACCATGTGCTCGTCGTCCGCTACCTGTATCCACACCGCTTG
S3232A_rv CAAGCGGTGTGGATACAGGTAGCGGACGACGAGCACATGGTATCG
C3234A_fw GCTCGTCGTCCTCGACCGCCATCCACACCGCTTGTC
C3234A_rv GACAAGCGGTGTGGATGGCGGTCGAGGACGACGAGC
T3267L_fw CACCCGTACACCACGGTGAATCTCTCCCAAGGCAATTTCACATCG
T3267L_rv CGATGTGAAATTGCCTTGGGAGAGATTCACCGTGGTGTACGGGTG
T3290Y_fw CTACGGGGTGGGTGCTGATGGTTACGTGATTGGTGAAGGCATCGG
T3290Y_rv CCGATGCCTTCACCAATCACGTAACCATCAGCACCCACCCCGTAG
L3406E_fw TCGAATATCGGCCACCTAGAGGCGGCTTCGGGCATTGGC
L3406E_rv GCCAATGCCCGAAGCCGCCTCTAGGTGGCCGATATTCGA
S3409A_fw GCGGCTGCCGGCATTGCCGGCTTGACTAAAACCTTGCTG
S3409A_rv CAAGCCGGCAATGCCGGCAGCCGCCAATAGGTGGC
I3478F_fw GGGGCTTACCTCGTTCGCTGCCGGCGGCATGAAC
I3478F_rv GTTCATGCCGCCGGCAGCGAACGAGGTAAGCCCC
Table 1 Primers for generating point mutations in pTB57. 
Cloning of KS-B chimeras 
To facilitate cloning of the genes for KSs, either KpnI or NdeI site was introduced in the N-
terminus by PCR amplification of region corresponding to linker-to-B and B domains. This 
region was cloned in pHis 8-3. Separately, for cloning KSs with its corresponding LINKS 
motif, a standalone B domain (without the KS to B linker region) was cloned in pHis 8-3
vector. The genes for corresponding KSs were amplified from the genomic DNA of Bacillus 
amyloliquefacians (DSMZ) (for BaeKS5, BaeKS5*, MlnKS4, MlnKS5, MlnKS9) or 
Burkholderia thailandensis (for ThaKS3, ThaKS3*, ThaKS12, ThaKS12*). The primers and 
the region used for amplification are listed in table 2. The corresponding BamHI - KpnI, 
BamHI – NdeI or NcoI – NdeI digested KS fragments were cloned to the N-terminus of 
linker-to-B (without LINKS) or B domain (with LINKS). After sequence confirmation 
(MWG Eurofins), all recombinant plasmids were heterologously expressed in E. coli BL21 
(DE3). 
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Primers Sequence
Accession 
code
Protein 
region
Linker B_KpnI_fw GGGGTACCTACCCAGAGCCAGCGGAC
CBW75249.1 3658 - 4133Linker B_NdeI_fw GGAATTCCATATGTACCCAGAGCCAGCGGAC
Linker B_EcoRI_rv CGGAATTCCTATGTCCCAGTCAGTAAGG
B_KpnI_fw GGGGTACCATCGTCAATCCGCTGATG CBW75249.1 3822 - 4133
Bae KS5_BamHI_fw CGGGATCCGAAGATATCGCGATAATCGG
YP_001421293.1 1893 - 2333Bae KS5_KpnI_rv GGGGTACCGGAATATTCTTCGATGACG
Mln KS4_BamHI_fw CGGGATCCGAGGATATTGCCATTATCGG
YP_001421029.1 660 - 1086
Mln KS4_NdeI_rv
GGAATTCCATATGTTGATATTCTTCCAC
AATGACATGG
Mln KS5_BamHI_fw CGGGATCCAATGATATCGCGATTATCGG
YP_008420824 665 - 1084
Mln KS5_KpnI_rv
GGGGTACCCGCAAATTCTTCTAAAATAA
CATGGGC
Mln KS9_NcoI_fw CATGCCATGGGAGGACATTGCCATTATCGG
YP_001421032 1018 - 1441
Mln KS9_NdeI_rv
GGAATTCCATATGCTCATACGCTTCCAATA
TAAGATGCGC
Tha KS3_BamHI_fw CGGGATCCGCCGCGACGGCGGACGCGATC
WP_011401356.1 3003 - 3441
Tha KS3_KpnI_rv GGGGTACCGTCGCGGCCGTCGCGCTCGTC
Tha KS12_BamHI_fw CGGGATCCGCGGCCGCGTTCGCGGCG
WP_009900597.1 15 - 464
Tha KS12_KpnI_rv GGGGTACCCGCGCCCCGCTCCGCGC
Bae KS5*_BamHI_fw CGGGATCCGCGCAAGTCCGTCCAGACACGCG
YP_001421293.1 1877 - 2513
Bae KS5*_KpnI_fw GGGGTACCGGCCGGTCTTTTGACAGCT
GCATCAGC
Tha KS3*_BamHI_fw CGGGATCCGCCGCGACGGCGGACGCGATC
WP_011401356.1 3003 - 3631Tha KS3*_KpnI_rv GGGGTACCGAATTCCGAGCGGTTCG
CATCCAGCAT
Tha KS12*_BamHI_fw CGGGATCCGCGGCCGCGTTCGCGGCG
WP_009900597.1 15 - 635Tha KS12*_KpnI_rv GGGGTACCCACACCGGCCGCCTTCGCCAGTTG
Table 2 Primers for generating KS-B chimeras. ORF – open reading frame. The genes 
corresponding to the ORFs were amplified. 
Protein production and purification
E. coli BL21 transformants bearing the genes for KS-B mutants and chimeras were cultivated 
in LB medium at 37 °C or 27 °C. After A600nm reached ~0.4 - 0.5, the cells were induced with 
0.1 mM IPTG at 15 °C for 16 - 20 h. The cell pellet was dissolved (10 mL buffer/g pellet) in 
20 mM Tris buffer pH 7.5 containing 0.2 M NaCl and 50 mM imidazole. After disrupting the 
cells by sonication for 4 cycles for 3 min at 20% power (Sonotrode), the cells were 
centrifuged at 9,000 g at 4 °C for 30 min. The lysed supernatant was then loaded onto a Ni-
NTA column (Macherey Nagel) connected to an FPLC machine. Proteins were eluted using 
the same buffer with 0.5 M imidazole. For KS-B mutants, the resulting protein was diluted 
twice with 20 mM Tris (pH 7.5) and purified further by an ion-exchange column (5 mL 
HiTrap Q HP, GE Healthcare). Proteins were eluted over 30 column volumes of 20 mM Tris 
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(pH 7.5) and 1 M NaCl, and the fractions containing target proteins were concentrated using 
Amicon columns (MWCO 10 kDa – Millipore). For KS-B chimeras, the ion-exchange 
chromatography was not performed to prevent further sample loss. All the purified proteins 
were stored at 4 °C for in vitro assays. The mutants were stable when stored at –20 °C 
supplemented with 50% glycerol while the chimeras regularly needed fresh preparation. The 
procedures for the production of ACP, wild type KS-B and AT were as described previously 
(Bretschneider et al., 2013).
In vitro reconstitution of the branching reaction 
The in vitro assay for the reconstitution of branching reaction was performed as described 
previously (Bretschneider et al., 2013) with minor modifications (specified separately in the 
results section). Briefly, in a 40 μL reaction, 167 μM ACP, 3 μM or ~30 μM KS-B, mutants 
and chimeras, 0.2 μM RhiG, 750 μM malonyl-CoA and 1,000 μM of 1 or 3 were incubated in 
20 mM Tris buffer (pH 7.0) at 23 °C with shaking at 400 rpm for 2 h or 16 h. Analysis of the 
reaction by MALDI (Bruker) was done by spotting 2.5 μL of the assay mix with 1 μL of 100 
μM of 2´, 5´ -dihydroxyacetophenone matrix. The MALDI-TOF was operated in positive 
linear mode. Data acquisition was performed using flexControl 3.3 in the range of 5–35 kDa 
with 1000 Hz laser frequency, 60% laser power and 500 shots at each spot. Analysis of the 
data was executed in flexAnalysis 3.3. For HRMS analysis, the reaction was stopped by 
adding equal volume of methanol. After a brief spin to remove precipitated proteins, the 
supernatant was dried using an upstream N2 flow and the residue suspended in methanol was 
used for LC-HRMS analysis (Exactive). HPLC conditions: C18 column (Betasil C18 3 μm, 
150 x 2.1 mm) and gradient elution (MeCN/0.1% (v/v) HCOOH (H2O) 5/95 for 1 min, 
gradient up to 98/2 in 15 min and 98/2 for 3 min; flow rate – 0.2 mL/min; injection volume –
3–5 μL).
LC-ESI-MS and LC-MS/MS measurements 
The branching reaction was also analyzed by LC-ESI-MS using a ZORBAX 300SB-CN 
column in positive mode. For this, in a 120 μL reaction, 167 μM ACP, ~30 μM KS-B, 
H3364A or H3404A, 0.2 μM RhiG, 750 μM malonyl-CoA and 1,000 μM of 3 were incubated 
in 20 mM Tris buffer (pH 7.0) at 23 °C with shaking at 400 rpm for 16 h. The assay mix was 
then desalted using ZebaTM spin desalting columns (7K MWCO, Thermo Scientific) followed 
by elution of the desalted sample in water. The components were separated using a gradient of 
30 – 98% B for 26 min with a flow rate of 0.6 mL min-1. MS/MS fragmentation of the 
selected ion fragments was also performed with the same instrument. The spectra from LC-
ESI-MS measurements were deconvoluted using ProMass software (Thermo Scientific). For
MS/MS analysis, Accucore C18 column (100 x 2.1 mm) was used in a QExactive operating in 
positive mode.
Kinetic studies 
For the determination of kinetic parameters for KS-B mutants, concentration of the substrate 3
was maintained at 1,000 μM and the reaction was performed from 0–75 min. To warrant 
comparison of the rate of the reaction, higher concentrations of ACP (300 μM) and KS-B
mutants (4.5 μM) were used. Samples were taken at regular intervals and the peak intensity of 
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the product attached to the ACP was analyzed by MALDI-TOF. The molarity of product 
formed was calculated from three independent experiments.  
Secondary structure determination by CD 
The secondary structures of all the proteins were determined at 20 °C. Wavelength scans were 
recorded for the far-UV region between 250 and 190 nm at a speed of 10 nm min–1, a band 
width of 1 nm and accumulations of 5 spectra using a 1 mm quartz cuvette (Hellma). For all 
measurements, a concentration of 0.1 mg mL–1 protein was used. 
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FIGURES LEGENDS 
Figure 1 (A) Mechanism of a typical KS domain exemplified by module 10 of the 
thailandamide A PKS. Acyl-ACP intermediate acylates the active site Cys of the KS domain. 
The KS then decarboxylates malonyl extender units to form enolate which is then attacked by 
the acyl-KS intermediate to form a C2-elongated polyketide chain. (B) Non-canonical β-
branching reaction catalyzed by the branching module of rhizoxin PKS. The malonyl extender 
unit is added to the α, β unsaturated thioester of the KS-bound polyketide intermediate. The δ-
hydroxyl group then attacks the KS carbonyl to form the δ-lactone moiety of rhizoxin. KS –
ketosynthase; B – branching domain; ACP – acyl carrier protein. 
Figure 2 (A) Alignment of the conserved amino acids of branching- and elongating KSs. The 
numbers on top correspond to the residues of Rhi–KS14 (PDB code 4kc5). The entries in bold 
is part of the branching modules. (B) Comparison of the active site residues of KS-B (orange) 
(PDB code – 4kc5) with the bacillaene KS5 (green) (PDB code: 5erb). Residues chosen for 
mutational analysis are colored in black. Residues colored in blue forms the catalytic triad. 
(C) Recombinant proteins purified from E. coli on a 10% SDS gel. M – protein molecular 
weight marker. (D) CD spectrum of mutants used in this study compared with the wild type 
KS-B. (E) CD spectrum of the active site mutants. 
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Figure 3 (A) Chain branching assay setup with the deoxy variant of the substrate 1. (B) SDS-
PAGE analysis of the assay mix with 1. The band corresponding to 100 kDa corresponds to 
the KS-B didomain whereas the band at the top corresponds to the trapped KS-B and ACP 
domains with the intermediate (2). All the proteins were verified by tryptic mass 
fingerprinting followed by MALDI. M – protein molecular weight marker. 
Figure 4 (A) In vitro biotransformation setup of the substrate mimic 3 to generate 4. LC-
HRMS analysis of mutants showing extracted ion chromatograms of 4 (m/z – 173.0808, 
[M+H]+). The EIC in cases of 4e, 4j, 4k, 4l and 4p correspond to assays with increased 
enzyme concentration (10x). All other assays were performed under standard conditions (see 
Methods). 
Figure 5 Rate of lactone (4) formation by the mutants and wild type KS-B. Data represent 
mean ± s.d from three independent experiments. 
Figure 6 (A) Partial bacillaene, macrolactin and thailandamide PKS. KSs highlighted were 
chosen for domain exchange experiments. (B) Cloning strategy for the generation of KS-B 
chimeras. (C) KS-B chimeras on a 10% SDS gel. All the proteins were verified by tryptic 
mass fingerprinting followed by MALDI. M – protein molecular weight marker. Rhi –
Rhizoxin; Bae – bacillaene; Mln – macrolactin; Tha – thailandamide. (D) CD spectrum of 
KS-B chimeras. 
Figure 7 (A) Possible routes for product formation with the KS-B chimeras. (B-D) LC-
HRMS spectra of KS-B chimeras. Extracted ion chromatograms for [M+H]+ 173.0808 is 
shown. (E) Shift in the retention time of 4 and 5. Negative control refers to the assays 
performed with heat-inactivated KS-B chimeras. 
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SUMMARY
In vitro reconstitution of a branching module from the rhizoxin PKS revealed a non-canonical 
β-branching mechanism that forms its pharmacophoric δ-lactone moiety. The branching 
module is tolerant towards substrates with varied δ substituents that yield 6-membered rings 
like lactam and glutarimide structures. Here, we expand the range of products and show that 
that the branching module lactonizes substrates with different chain lengths to yield an array 
of 5- to 10-membered lactones. The ability of KS to promote lactone formation complements 
the thioesterase- (TE) catalyzed cyclizations. It further sets the stage to generate ring-
containing molecular architectures with potential bioactivities, especially when large-
membered rings are challenging to produce by synthetic chemistry. 
Keywords 
Polyketide synthase, branching module, beta branching, lactones, ketosynthase, SNAC 
thioesters
Highlights 
x Branching module of the rhizoxin PKS is tolerant towards substrates with varied chain
lengths.
x Lactones with 5- to 10-membered rings are produced independent of a TE domain.
x The branching module is an excellent candidate for generating novel polyketide
products.
In Brief 
Sundaram et al., demonstrates the ability of branching module of the rhizoxin polyketide 
synthase to form 5- to 10-membered lactones by an atypical Michael addition-cyclization 
sequence.
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INTRODUCTION
Polyketide synthases (PKSs) are efficient biosynthetic machineries that generate highly 
diverse natural products with varied chemical structures and biological activities (Staunton
and Weissman, 2001). These enzymes are evolutionarily related to fatty acid biosynthetic 
enzymes and can be modular in nature (Tsai, 2016). Individual proteins (domains) within each 
module catalyze a single reaction in a sequential manner to generate polyketide intermediates 
that are tethered to the assembly line (Hertweck, 2009). The resulting polyketide can be 
tailored by post-PKS enzymes to yield the bioactive scaffolds (Olano et al., 2010). However, 
structural modifications can also occur while the intermediates are tethered to the assembly 
line (Pang et al., 2016; Sundaram and Hertweck, 2016). One of the on-line modifications is 
the generation of cyclic products or rings. Such ring systems add rigidity to the molecule and 
can be used as intermediates to generate active compounds (Townsend, 2013). Natural 
products containing small-sized lactone motifs are widely distributed in nature and most of 
these compounds are associated with effective antibiotic, antifungal and anti-inflammatory 
activities (Hertweck, 2009). Typically, cyclizations are carried out to offload a polyketide or 
peptide intermediate by the chain terminating thioesterase (TE) domains (Pinto et al., 2012; 
Wang et al., 2009; Xu et al., 2013; Zhou et al., 2015). Figure 1A shows the typical chain 
release by intramolecular condensation of the thioester and alcohol to generate macrolides 
like the 6-deoxyerythronolide B (1) core of the erythromycin (Weissman and Leadlay, 2005).
Some examples of lactone formation independent of a TE domain have been reported, for 
example, the β-lactonization of the polyketide ebelactone A (2) (Wyatt et al., 2013) and the 
pH dependent δ-lactonization of lovastatin (3) (Campbell and Vederas, 2010) (Figure 1B).
Although stand-alone TE domains are effective catalysts for in vitro cyclization (Boddy et al., 
2003; Sharma and Boddy, 2007), unwanted hydrolysis or product inhibition hampers the 
cyclization. In light of the classical cyclization reactions, a non-canonical module of the 
branching module of the rhizoxin (4) PKS catalyzes β-branching and subsequent cyclization
reactions. This module comprises of KS (ketosynthase), B (branching) and ACP (acyl carrier 
protein) domains. In an in vitro reconstitution experiment, the branching module has been 
shown to catalyze the transfer of ACP-bound malonyl unit to the α,β- unsaturated thioester 
mimic bound to the KS, by Michael addition (Bretschneider et al., 2013). Following 
lactonization, a branched product (δ-lactone) is generated (Figure 1C), in place of a canonical 
linear intermediate. This lactone group is pivotal for the antimitotic activity of rhizoxin
(PartidaǦMartinez and Hertweck, 2007).
The ability of the branching module to form 6-membered rings have been well investigated 
(Heine et al., 2014). The branching module accepts SNAC thioester analogues with varied δ-
substituents. Amine-substituted substrate resulted in lactam formation whereas the δ-
carboxamide group resulted in glutarimide formation (Heine et al., 2014). While natural 
products with a δ-lactam group are not yet reported, glutarimide-containing compounds are 
reported in case of antibiotics such as cycloheximide (Yin et al., 2014) and 9-
methylstreptimidone (Wang et al., 2013) in addition to the anticancer agents, iso-migrastatin 
and migrastatin (Ju et al., 2005). In addition to the malonyl extender unit, the KS-B didomain
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also recognizes methyl-malonyl ACP to give a dual-branched δ-lactone product (Heine et al., 
2015).
Natural compounds containing lactone motifs are usually associated with biological activities. 
Compounds with a gamma-lactone motif are widespread in nature that exhibits antibiotic, 
antifungal, cytotoxic and anti-inflammatory activities (Adames et al., 2015; Chianese et al., 
2015; Liu et al., 2013; Seitz and Reiser, 2005). Novel caprolactone alkaloids isolated from a 
marine Streptomyces sp. show moderate phytotoxicity and activity against cancer cells 
(Stritzke et al., 2004). Higher members like penicillide (lactone 8), griseoviridin (lactone 9) 
have also been found in nature (Ferraz et al., 2008).
However, polyketide-derived large-membered lactones (>8) are not very abundant in nature. 
Synthetic and semi-synthetic approaches to generate cyclic products are challenging and the 
complexity increases with an increase in the ring size. In this study, we exploited the substrate 
scope of the branching module to produce medium- and large-membered lactone motifs. We 
show that the branching module is very versatile for it produces 5- to 10-membered lactone 
structures, independent of a TE domain, by β-branching and subsequent cyclization reactions. 
RESULTS & DISCUSSION
In vitro biotransformation to lactones
To test the extent of the ring systems that can be formed by the branching module, thioester 
analogues that have shorter or longer methylene chains (7, 9, 11, 13 and 15) were synthesized 
(Figure 2). Initially, the in vitro assay was performed only for 2 h, the condition that is 
standard for the formation of the 6-membered lactone. The reaction was analyzed by MALDI 
for the detection of the ACP-bound products and by HRMS, for the detection of the 
hydrolyzed product. However, analysis of the assay mix did not show any product formation. 
The assay was then performed for 16 h at 23 °C. After workup of the assay mix with 
methanol, high resolution MS analysis of the hydrolyzed products revealed the formation of 
new compounds in all the cases with the desired mass (Figure 3A-3F). The compounds have
[M+H]+ of 159.0652 (C7H11O4), 173.0808 (C8H13O4) (Bretschneider et al., 2013), 187.0965
(C9H15O4), 201.1121 (C10H17O4), 215.1278 (C11H19O4) and 229.1434 (C12H21O4) for 5-, 6-,
7-, 8-, 9-, and 10-membered rings respectively. When the assay was performed with heat-
inactivated KS-B (negative control), no products were observed thus proving that the reaction 
is enzyme catalyzed. However, the ACP-bound lactones could not be detected by MALDI. 
Figure S1 shows that the MS/MS fragments strongly suggest the formation of lactones. While 
small-sized polyketide-derived lactones are widespread in nature, medium- and large-sized 
lactones are scarce but are associated with effective biological activities (17-20) (Figure 3G)
(Adames et al., 2015; Dräger et al., 1996; Ferraz et al., 2008; Ishigami, 2009; Seipke and 
Hutchings, 2013).
In addition to the thioester analogues mentioned above, substrates that yield 5-membered 
ethyl-substituted- (lactone 5*) or 7-membered lactones (lactone 7*) which has the same m/z as 
the native lactone-6 were also tested (Figure 4A). MALDI analyses of the assay mix resulted 
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in a new peak with the m/z of ~12719.7 which corresponds to the ACP-bound 5- and 7-
membered lactones* (Figure 4B). In contrast to the lactones mentioned before, the products 
were observed after performing the assay for 2 h. However, the intensity of the ACP-bound 7-
membered lactone was lower than that of the 5-membered lactone. However, the hydrolyzed 
products could not be detected by high resolution mass (result not shown), even when the 
assay was done for 16 h. In order to verify the formation of the corresponding lactones, LC-
ESI-MS was also performed directly with the desalted-assay mix to detect the product bound
and thereafter ejected from the PPant arm of ACP by further mass fragmentations. As shown 
in figure 5, the mass spectra were recorded for both the products. The spectra were 
deconvoluted to yield the observed mass of 12726.0 ± 5.0 Da and 12728.2 Da ± 3.2 Da for the 
formation of ACP-bound 5*-membered and 7*-membered lactones, respectively (Figure 5A
and 5B). The ACP species generated ions with m/z 849.28 and m/z 849.41 for lactone 5*
(Figure 5A) and lactone 7* (Figure 5B), respectively, which was then selected for MS/MS 
fragmentation experiments. The MS/MS analysis ejected the PPant-bound lactone fragments
with m/z of ~415 for both the samples (Figure 5A and 5B). For all the lactones resulted, 
synthesis of reference compounds to validate the compounds are in progress.
In conclusion, the branching module is shown to accept SNAC thioesters with varied length to 
give 5- to 10-membered lactones. Although the ACP-bound proteins could not be detected by 
MALDI, evidences based on HRMS/MS and LC-ESI-MS clearly corroborate the results. 
Cyclization by branching module comes as an alternative approach for generating structural 
diversity in polyketide natural products and opens up strong possibilities for combinatorial 
biosynthesis. As the branching module also accepts amino-substituted surrogates, generation 
of different membered lactam rings could also be tested in the future. 
SIGNIFICANCE
Modular PKSs play a major role in the production of therapeutically relevant natural products. 
Understanding the mechanism of the key enzyme components of these megasynthases would 
help in the production of non-natural and potentially bioactive compounds. The branching 
module of the rhizoxin PKS generates a δ-lactone moiety by a non-canonical β-branch 
formation followed by lactonization. The δ-lactone moiety is critical for the antimitotic 
activity of the rhizoxin. The branching module has been utilized for its ability to produce 
existing as well as novel 6-membered rings in vitro. Since the lactone rings represent well-
established pharmacophores, the branching module has been tested for rational production of 
small- to large-sized lactones. The results reveal that the branching module is highly versatile 
and produce lactones of up to 10-membered ring size. Although small-sized lactones are 
observed in nature, it is extremely challenging to synthesize stereospecific medium- and 
large-sized lactones by chemical approaches. Therefore, the branching module comes up as an 
excellent biocatalyst for efficient production of rings. These observations are relevant for 
expanding the novel branching-cyclization reactions to a variety of other ring systems.
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EXPERIMENTAL PROCEDURES
General
Chemicals were purchased from Roth and Sigma-Aldrich. MALDI measurements were done
using an UltrafleXtreme MALDI TOF/TOF (Bruker). High resolution mass measurements 
were performed using an Exactive Orbitrap High Performance Benchtop HRMS with an 
electrospray ion source and an Accela HPLC system (Thermo Scientific). LC-MS/MS 
experiments were performed using a QExactive equipment with Accela HPLC system 
(Thermo Scientific). LC-ESI-MS analysis of intact proteins was performed using ZORBAX 
300SB-CN column in a ThermoFinnigan Surveyor LC equipment with a LTQ velos MS 
attached running on an electrospray ion source. The spectra from LC-ESI-MS measurements 
were deconvoluted using ProMass software (Thermo Scientific). NMR measurements were 
performed on a Bruker AVANCE II 300, AVANCE III 500 or 600 MHz spectrometer, with a 
Bruker cryo platform. 
Protein production and purification
The procedures for the production and purification of ACP (pTB41), KS-B (pTB57) and 
RhiG (pTB39) were as described previously (Sundaram et al., 2015).
In vitro reconstitution of the branching reaction
The in vitro assay for the reconstitution of branching module was performed as described 
previously (Bretschneider et al., 2013) with minor modifications. Briefly, in a 40 μL reaction, 
167 μM ACP, 3 μM KS-B, 0.2 μM RhiG, 750 μM malonyl-CoA and 1,000 μM of SNAC 
thioesters (5, 7, 9, 11, 13 and 15) were incubated in 20 mM Tris buffer (pH 7.0) at 23 °C with 
shaking at 400 rpm for 2 h or 16 h. Analysis of the reaction by MALDI (Bruker) was done by 
spotting 2.5 μL of the assay mix with 1 μL of 100 μM of 2´, 5´ -dihydroxyacetophenone 
matrix. The MALDI-TOF was operated in positive linear mode. Data acquisition was 
performed using flexControl 3.3 in the range of 5–35 kDa with 1000 Hz laser frequency, 60% 
laser power and 500 shots at each spot. Analysis of the data was executed in flexAnalysis 3.3.
For HRMS analysis, the reaction was stopped by adding equal volume of methanol. After a 
brief spin to remove precipitated proteins, the supernatant was dried using an upstream N2
flow and the residue suspended in methanol was used for LC-HRMS analysis (Exactive). 
HPLC conditions: C18 column (Betasil C18 3 μm, 150 x 2.1 mm) and gradient elution 
(MeCN/0.1% (v/v) HCOOH (H2O) 5/95 for 1 min, gradient up to 98/2 in 15 min and 98/2 for 
3 min; flow rate – 0.2 mL/min; injection volume – 3–5 μL).
LC-ESI-MS and LC-MS/MS measurements
The branching reaction was also analyzed by LC-ESI-MS using a ZORBAX 300SB-CN 
column in positive mode. For this, in a 120 μL reaction, 167 μM ACP, 3 μM KS-B, 0.2 μM 
RhiG, 750 μM malonyl-CoA and 1,000 μM of 21 or 22 were incubated in 20 mM Tris buffer 
(pH 7.0) at 23 °C with shaking at 400 rpm for 16 h. The assay mix was then desalted using 
ZebaTM spin desalting columns (7K MWCO, Thermo Scientific) followed by elution of the 
desalted sample in water. The components were separated using a gradient of 30 – 98% B for 
26 min with a flow rate of 0.6 mL min-1. MS/MS fragmentation of the selected ion fragments 
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was also performed with the same instrument. The spectra from LC-ESI-MS measurements 
were deconvoluted using ProMass software (Thermo Scientific). For MS/MS analysis, 
Accucore C18 column (100 x 2.1 mm) was used in a QExactive operating in positive mode.
SUPPLEMENTAL INFORMATION
Supplemental information includes supplemental experimental procedures, synthetic data, 
figures and all relevant spectra.
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FIGURES LEGENDS
Figure 1 (A) Classical cyclization reaction catalyzed by a TE domain. (B) Examples of 
bioactive lactone polyketides. (C) Non-canonical Michael addition and lactonization reactions 
catalyzed by KS-B didomain to generate the δ-lactone moiety of rhizoxin (4). TE –
thioesterase; AT – acyl transferase; KR – ketoreductase; KS – ketosynthase; B – branching 
domain; ACP – acyl carrier protein.
Figure 2 In vitro branching assay set-up. SNAC thioesters (5, 7, 9, 11, 13 and 15) used in the 
study. 5 (boxed) is the substrate mimic that generates the native 6-membered lactone.
Figure 3 (A-F) LC-HRMS analysis of 5-, 6- 7-, 8-, 9- and 10-membered lactones. Negative 
control refers to the assays performed with heat-inactivated KS-B enzyme. (G) Examples of 
less-abundant natural 5-, 8-, 9- and 10-membered lactones.
Figure 4 (A) General scheme of the branching assay with 21 and 22. (B) MALDI analysis of 
the ACP-bound products for the formation of 5- and 7-membered lactones*. Negative control 
– enzyme assay without 21 or 22. * indicates a different ring system compared to figure 3.
Figure 5 Analysis of ACP species by LC-ESI-MS of (A) lactone 5* and ejected PPant arm 
with product attached. (B) Spectrum corresponding to lactone 7* and the ejected fragment. 
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4 Unpublished results 
 
4.1 Crystallization attempts of the entire branching module  
4.1.1 Introduction 
Since the report of the high resolution crystal structure of the porcine FAS in 2008,90, 91 many 
structural biologists endeavored to obtain the structure of an intact module to understand the 
exceptional dynamics of the individual catalytic domains between their chemical states, their 
communication among the cis- and trans-
acting enzymes and to facilitate the 
production of novel compounds.143 Inspired 
by the FAS structure, several models for the 
PKS modular structure have been 
proposed.143 Although a high resolution 
structure of a complete module has not yet 
been obtained, complementary techniques 
such as single-particle cryo-EM and SAXS 
have been used to generate models of cis-
AT PKSs.95-98 However, not a single high 
resolution crystal structure of a complete 
module from a trans-AT PKS is available. 
The KSB didomain of the rhizoxin PKS 
branching module is the first solved X-ray 
structure from a trans-AT PKS family (PDB code: 4kc5),142 closely followed by the bacillaene 
PKS KS2.101 For a branching module that hosts versatile domains with extended substrate 
flexibility, little is known about how the domains interact with the ACP during the complex 
branching reaction. Trapping the highly flexible ACP in a crystal is very challenging. The 
crystal structure of the E. coli AcpP and the fatty acid 3-hydroxyacyl-ACP dehydratase FabA 
complex was obtained only using sulphonyl-3-alkynyl pantetheinamide as a mechanism-based 
crosslinking probe.144 In the case of the rhizoxin PKS branching module, the SNAC thioester 
that lacks the δ-hydroxy group 21 resulted in a natural intermediate where both the KSB and 
ACP domains are covalently crosslinked (Figure 4.1).142 Therefore, we sought to crystallize the 
entire branching module-crosslinked-intermediate complex to visualize the interdomain 
contacts. 
4.1.2 Results and discussion 
Construction and functional analysis of a complete branching module 
Attempts to maintain a stable KSB-ACP covalent intermediate has been very challenging. As 
ACP is very dynamic, it was constantly lost either during purification of the intermediate 
complex or during crystallization trials. Therefore, we planned to produce the KSB-ACP as a 
full-length protein. We reasoned that the additional covalent link between KSB and ACP 
would stabilize the crystal formation. Figure 4.2a shows the ACP of the branching module 
modeled into the KSB didomain (PDB code: 4kc5). Earlier attempts to crystallize the full-
Figure 4.1 Deoxy variant of the SNAC thioester 
(21) promotes Michael addition to give a 
covalent intermediate bound to KS and ACP. 
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length branching module (pRW12 – construct from Robert Winkler) were not successful partly 
due to the flexible linker region between the B domain and ACP (colored red in figure 4.2a). 
The crystal structure of the KS-B didomain is therefore based on a new construct which is 
devoid of the unstable N-terminal part of KS (not shown) and the B-ACP long linker region 
(red).142 In this study, cloning strategies were planned to express KSB-ACP as a full length 
protein, in which the B-ACP linker (red) is excluded and the length of C-terminal part of the 
linker (dark blue) is optimized. 
 
Figure 4.2 (a) ACP of the branching module modeled to the KS-B crystal structure (PDB code: 
4kc5). (b) Domain information of the existing (pRW12 and KSB) and new constructs (KSB-ACP-1, 
KSB-ACP-2, KSB-ACP-3 and KSB-ACP-4). The symbol X in red refers to the insertion of the stop 
codon. The constructs KSB-ACP-4 contains both the N- and C-terminal flanking regions of the 
KS domain. The color codes correspond to the respective regions in a. (c) SDS-PAGE of 
recombinant proteins. (d) LC-HRMS analysis of branching reaction showing extracted m/z 
chromatograms of 173.0808 [M+ H]+. 
 
Three constructs were generated which differ in the length of the linker region between the B 
and ACP domains (dark blue). Although the construct pRW12 was challenging to crystallize, it 
is possible that with the substrate 21, the crosslinking might be established. For all the 
constructs, the region coding for PPTase from B. rhizoxinica  pTB41142 was cloned to the 
downstream of the region for ACP, for in vivo phosphopantetheinylation of apo- to holo-ACP. 
These constructs are named as KSB-ACP1, KSB-ACP2, KSB-ACP3 and KSB-ACP4 (figure 4.2b). 
The protein KSB-ACP-3 lacks the B-ACP linker region. Figure 4.2c shows the SDS-PAGE 
analysis of all the recombinant proteins. In vitro biotransformation of the native substrate 
mimic 18 revealed that KSB-ACP-1, KSB-ACP-2 and KSB-ACP-4 resulted in the lactone product 
20 whereas the turnover activity of KSB-ACP-3 was negligible (figure 4.2d).  
 
The branching reaction was then performed with the deoxy substrate 21. For the initial 
experiments, only KSB-ACP-1 was considered. To confirm the covalent linkage formation, LC-
ESI-MS was performed directly with the assay mix after desalting. The mass spectra were 
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recorded for KSB (figure 4.3a), KSB-ACP-1 (figure 4.3b) and KSB-ACP-1 with 21 (figure 4.3c). 
After several attempts to improve the yield of a homogenous sample, an assay condition with 
controlled addition of KSB-ACP-1 (10 μL/min) was selected for obtaining a crosslinked sample 
for crystallization trials. The initial crystals grew over a period of ~8 weeks (figure 4.3 d) but 
the diffraction of the crystals is not yet suitable for obtaining structural data. The 
crystallization work is being performed under collaboration with Dr. Georg Zocher 
(Universität Tübingen). If the crystallization of the protein KSB-ACP-1 is not successful, the 
assay and the subsequent steps will be optimized with other active proteins. Although X-ray 
crystal structure will not depict the entire mechanism, trapping the branching module in a 
specific state would help understand the conformational changes of the domains. 
 
Figure 4.3 Analysis of KSB-ACP species by LC-ESI-MS. (a) KSB (b) KSB-ACP-1 (c) KSB-ACP-1 
with substrate 21. (d) Initial crystals formed 
 
4.1.3 Methods 
Cloning experiments 
The genes corresponding to the B-ACP linker region, ACP and PPTase were amplified from 
pTB41142 and cloned to the C-terminus of KSB in pTB57.142 The primers used for KSB-ACP 
constructs are listed in table 4.4. KSB-ACP-1, KSB-ACP-2 and KSB-ACP-3 proteins contain the 
truncated KS domain, KS-B linker region, ACP but differ in the length of B-ACP linker region 
(Figure 4.2b).  
 
 
Unpublished results  Crystallization of the branching module 
 
  176 
 
Primers Sequence Accession no. Protein region 
PPTase_SacI_fw CGAGCTCAGTGAATTGAAGGAGAT
ATAATTCATG 
WP_013428913.1 1-253 PPTase_XhoI_rv CTCGAGTCAGCCAGAAGTGGGG 
GCTT 
PPTase_HindIII_rv CCCAAGCTTTCAGCCAGAAGT 
GGGGGCTT 
KSB_EcoRI_rv CGGAATTCGGCCATTTCCTCTGT 
CCCAGTC 
CBW75249.1 
 
 
ACP_EcoRI_fw1 CGGAATTCAAGCAGGAGGCTAA 
GCCGCAG 
4162-4251 
ACP_EcoRI_fw2 ATGAATTCGGCGAAAAAATTCTTG
CTTTTATCCAACAG 
4177-4251 
ACP_EcoRI_fw3 
ATGAATTCATCCAACAGGAGTTAC
A 
GGACAAGC 
4184-4251 
 
Table 4.4 Primers used in the study. 
Protein production and purification 
The constructs were heterologously expressed in E. coli BL21 (DE3). Transformants containing 
the target genes were induced with 0.1 mM IPTG for 16 – 20 h at 15 °C. The proteins were 
purified by affinity and ion-exchange chromatography as described previously.145 As a final 
purification step, size exclusion chromatography was performed in 20 mM HEPES, 150 mM 
NaCl (pH 7.5). At this stage, the aggregates were separated from the native dimer KSB-ACPs. 
The purity and identity of the proteins was checked by SDS-PAGE and tryptic digestion 
followed by MALDI analysis.  
 
In vitro branching assay 
The in vitro reconstitution of the branching reaction was done with 10 μM of the KSB-ACP, 750 
μM malonyl-CoA, 0.2 μM RhiG and 1, 000 μM of the SNAC thioester mimic 18 in 20 mM Tris 
buffer (pH 7.0) at 23 °C at 400 rpm for 2 h. For HRMS analysis, the reaction was stopped by 
adding equal volume of methanol. After a brief spin to remove precipitated proteins, the 
organic phase was dried using an upstream N2 flow and the residue suspended in methanol 
was used for analysis (Exactive).  
 
Crosslinking assay 
To crystallize the KSB-ACP complex together with 21, the in vitro assay was scaled up. The first 
trial was performed in 2 mL scale containing 87 μM KSB-ACP-1, 2 μM RhiG, 1.5 mM malonyl-
CoA and 2.5 mM 21 in 20 mM Tris buffer (pH 7.0) at 23 °C, 400 rpm for 4 h. As the protein 
precipitated when RhiG was used in the assay, two different conditions were performed in the 
next trials. (i) In a 5 mL scale, 25 μM KSB-ACP-1, 1.2 mM malonyl-CoA and 4 mM 21 was used 
in 20 mM Tris buffer (pH 7.0) at 23 °C at 400 rpm for 3 h or (ii) In a 5 mL scale, 1.2 mM 
malonyl-CoA and 4 mM 21 was used in 20 mM Tris buffer (pH 7.0) and KSB-ACP-1 was added 
to the assay mix set at 23 °C, 400 rpm, at the rate of 10 μL/min over a period of 80 min, using a 
syringe pump, to a final concentration of 25 μM. The sample was further incubated for 90 min 
at 23 °C. Slow addition of KSB-ACP-1 improved the yield of homogenous sample. After 
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filtration to remove any residual precipitated proteins, the sample was further purified by size 
exclusion chromatography and used for crystallization trials.  
 
LC-ESI-MS measurements and data analysis 
To check the formation of covalent linkage with 21, the branching reaction was analyzed by 
LC-ESI-MS using a ZORBAX 300SB-CN column in positive mode. For this, the assay mix was 
desalted using ZebaTM spin desalting columns (7K MWCO, Thermo Scientific) followed by 
elution of the desalted sample in water. The components were separated using a gradient of 30 
– 98% B for 26 min with a flow rate of 0.6 mL min-1. The spectra from LC-ESI-MS 
measurements were deconvoluted using ProMass software (Thermo Scientific).  
 
Crystallization condition  
The covalent intermediate was crystallized at 4 °C and 20 °C by mixing 6.5 mg/mL or 4.2 
mg/mL of the protein solution with either 0.2 M magnesium chloride hexahydrate, 0.1 M 
HEPES (pH 7.5), 30% PEG400 or 0.1 M sodium acetate trihydrate (pH 7.0), 12% PEG3350. For 
all the screening experiments, sitting drop vapor diffusion as well as micro seeding techniques 
have been tried. The diffraction experiments were performed at beamline X06DA at the Swiss 
Light Source in Villigen, Switzerland. 
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5 Discussion 
 
5.1 Heterocycles formed by the branching module 
 
Canonical ketosynthases catalyze the formation of linear chains in fatty acid and polyketide 
biosynthesis in a head-to-tail fashion.146 In contrast to these canonical ketosynthase domains, 
rhizoxin biosynthesis utilizes a specialized branching module that catalyzes the nucleophilic 
addition of a malonyl building block to the α,β-unsaturated thioester, a mechanism which is 
distinct from the terpenoid-like β-branching known so far.141 The entire branching reaction has 
been reconstituted in vitro and has been shown to catalyze the vinylogous Michael addition 
and the subsequent lactonization.142 Expanding the substrate scope of this branching module 
has great impact in the synthesis of novel polyketide products.  
The plasmids to express the genes for KS-B, ACP and AT were constructed by Dr. Tom 
Bretschneider. The KS-B could only be produced as a soluble and functional didomain. The 
construct for the production of ACP also contains a downstream PPTase gene from B. 
rhizoxinica to allow the in vivo activation of apo to holo-ACP.142 The in vitro assay involves the 
addition of purified, functional proteins (KS-B, ACP and AT), malonyl-CoA and 5-
hydroxyhexenoic acid SNAC thioester mimic 18. One of the strategies to demonstrate the 
substrate promiscuity of the branching module is by feeding non-cognate synthetic variants of 
the substrate in an in vitro reaction. Such thioesters mimic the phosphopantetheine arm of the 
ACP and are highly suitable for in vitro substrate tolerance analyses.147 Phylogenetic analysis of 
KSs from trans-AT PKSs revealed that the substrate specificity is determined by the first four 
carbons of the intermediate (e.g. branched or unbranched).85 The branching KS belongs to the 
clade that accepts α,β-unsaturated, unbranched polyketide intermediates. We tested the effect 
of the α,β-dihydro derivative and several δ-substituted substrates on the branching reaction. 
The latter is particularly important as the δ-hydroxy group of 18 is pivotal for the lactonization. 
A series of biotransformation experiments with SNAC thioester mimics (synthesized by Dr. 
Daniel Heine) revealed that the branching module is highly versatile in the formation of 
different heterocycles (Manuscript A).148 
Figure 5.1a shows the SNAC thioesters used for in vitro biotransformation. The substrates 18, 
22 and 23 were accepted by the branching module whereas 24-26 were not. The result that the 
KS is incapable of accepting 24 reassures that the enzyme recognizes the α,β double bond to 
perform the Michael addition. The KS5 from bacillaene (Bae) PKS, which shares the same 
phylogenetic clade as the branching KS, however, is tolerant towards both α,β-saturated and 
unsaturated substrates.149 The BaeKS5 catalyzes the typical Claisen condensation and produces 
linear product. Therefore, the result shows that the branching KS is highly specialized and 
cannot be tuned to make linear chains with a saturated substrate. It is difficult to explain why 
the biotransformation does not take place with 25 and 26. It is possible that the use of 25 
resulted in steric clashes in the KS binding pocket. However, the decarboxylated form of 
malonyl-CoA bound to the ACP was observed by MALDI measurement, proving that the 
enzymes used in the assay were functional and that the cyclized product was not observed only 
Discussion Heterocycles formed by the branching module 
 180 
 
because of the δ-substituent. When the assay was performed with 26, due to its acidic nature, 
the assay mix precipitated hampering further analysis. Adjusting the pH conditions of the 
assay also did not result in any product formation. Whether the KS was acylated by these 
substrates remains unclear. It is possible that the KS acylation is reversible that leads to 
unloading of nonproductive substrates.  
One of the significant findings from these biotransformation experiments is the ability of the 
branching module to process a δ-carboxamide-substituted SNAC thioester to form a 
glutarimide moiety. The first report of a natural product with a glutarimide group, 
cycloheximide (27), came in 1949.150 Several glutarimide-containing polyketides followed this 
initial discovery including iso-migrastatin (28),151 migrastatin,152 dorrigocins,153 
lactimidomycin154 and 9-methylstreptimidone155 (29). These compounds have diverse functions 
as antiviral, antifungal, antitumoral agents and function as protein synthesis inhibitors by 
binding to the 60S ribosome unit.156, 157 Owing to the pharmacological role of these compounds, 
studying their biosynthesis has gained attention over the recent years. The enzymatic 
machineries that govern the biosynthesis of these compounds turned out to be trans-AT PKSs 
that have been suggested to employ similar branching module to install the glutarimide 
moieties.158-161 However, the enzymes have not been investigated in vivo or in vitro. The current 
study (Manuscript A) provides the first biochemical proof that the glutarimide is indeed a 
result of a Michael addition-cyclization reaction by the branching module.  
 
Figure 5.1 (a) Substrates used in the study (b) Proposed mechanism of β-branching in the 
biosynthesis of glutarimide unit and the natural products with glutarimide groups critical in 
bioactivity 
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Apart from the glutarimide ring, δ-lactam moieties result when the assay is performed with the 
δ-amine-substituted SNAC thioester. δ-lactam-containing terpenes and alkaloids have been 
reported from marine and soil fungi that exhibit anti-allergic and cytotoxic properties.162-164 
Although no δ-lactam-containing polyketides have been reported so far, it is conceivable that 
such molecules are yet to be discovered.  
Kinetic analyses demonstrated that the KS could accept both S and R enantiomers of 18, albeit 
at different rates. The turnover rate of the reaction was greater for the S enantiomer (vmax – 
20.9 ± 2.4 μM min-1) compared to the non-natural R enantiomer (vmax – 2.1 ± 0.3 μM min-1). 
Although the KS is flexible towards the configuration of the δ-hydroxy or the δ-amine group, 
the branching occurs by a syn-selective nucleophilic addition of the malonyl extender unit. 
HRMS analysis shows that exclusively syn-substituted lactone and lactam are formed. It 
appears that the branching KSs have steric requirements to specifically catalyze syn-specific β-
branching and further yield 6-membered heterocycles. A recent report on the substrate 
specificity of KSs from trans-AT system revealed that the presence of a bulky Met residue 
immediately preceding the active site Cys precludes acceptance of β-branched substrates.149 It 
has also been shown that mutating the Met to a smaller Ala residue provided the necessary 
space in the KS binding pocket to bind a β-branched SNAC derivative. Due to the presence of 
Met residue in the branching KS, the added β-branch likely points in the direction opposite to 
that of Met, providing a possible explanation for the syn-selectivity. Non-canonical enzymes 
that perform dual reactions are scarce from trans-AT PKSs. A dehydratase in the cis-AT-
mediated ambruticin biosynthesis (AmbDH3) has been reported to catalyze stereoselective 
dehydration and pyran ring formation.165, 166 Such heterocycles in natural products are 
important as they represent structural motifs and pharmacophoric units as in the case of 
rhizoxin or cycloheximide. Taken together, the non-canonical Rhi KS is promiscuous in 
processing non-native substrates and is a potential candidate for biosynthetic engineering of 
polyketide structures.  
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5.2 Stereoselective dual polyketide branching  
 
Select cis-acting ATs can load unusual extender units including allylmalonyl-CoA, 
ethylmalonyl-CoA and chloroethylmalonyl-CoA.40 However, characterized ATs from trans-AT 
PKSs have limited selectivity over α-substituted extender units. Very few ATs have been 
reported to incorporate non-malonyl extender units to separate modules (figure 5.2).167-169  
 
Figure 5.2 Extender unit variability in trans-AT derived polyketides: Oxazolomycin 
(methoxymalonyl-); Kirromycin (ethylmalonyl-). The extender units are highlighted. 
 
In this context, the ability of the tandem-AT (RhiG) from the rhizoxin PKS to transfer non-
natural methylmalonyl and dimethylmalonyl units on the ACP is an important step forward 
(Manuscript B).170 The finding is significant especially for the β-branching module, where 
more than one branch could be introduced at the same time in vitro. To detect the 
corresponding products by HRMS, the extraction condition of the assay mix needed to be 
changed slightly. After performing the in vitro assay, the reaction mix was extracted with 
methanol instead of ethyl acetate. The intensity of the released product greatly improved with 
methanol extraction. Reactions conducted with methylmalonyl extender units resulted in the 
production of the expected dually branched product. Notably the methyl-group of the 
extender unit is found in the side chain, proving that the lactonization involves the attack of 
the δ-hydroxy group to the KS-bound thioester. It is important to note that both R and S 
enantiomers of methylmalonyl-CoA are accepted by the branching module, resulting in both 
the diastereoisomers in the final lactone product. Hence, in a single step, two (α and β) 
branches are produced in a vinylogous stereoselective chain branching event (Manuscript B). 
It is conceivable that the binding cleft of KS can accommodate both the R and S configurations 
of the newly added methyl branch in addition to the syn-lactone. A similar example of a 
malonyl-specific AT tolerant towards methylmalonyl-CoA has been observed in an in vitro 
assay with the bryostatin AT.171  
The structures of epothilone and yersiniabactin contain gem-dimethyl groups derived from 
dimethylmalonyl-CoA extender unit.172 However, it is loaded on the ACP by a 
methyltransferase-dependent mechanism. To the best of our knowledge, the trans-AT 
described in this study is the first of its kind to load a dimethylmalonyl extender unit on the 
ACP. The fact that KS could decarboxylate the dimethylmalonyl unit to yield isobutryl-ACP 
shows that only the Michael addition and the subsequent lactonization are hampered. The 
wrong orientation of the additional methyl branch in the KS binding cleft could likely be the 
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reason for this. The extender unit specificity of AT could be determined based on signature 
fingerprint motifs in the sequence.173, 174 According to this, GHSXG and HAFH indicate 
malonyl-CoA specificity whereas GHSQG and YASH motifs indicate methylmalonyl-CoA 
specificity (figure 5.3a). The Phe residue preceding the catalytic His has been predicted to 
sterically clash with α-substituted extender units including methylmalonyl-CoA.59 Considering 
that RhiG contains the unfavored Phe-His sequence, it remains unclear how the enzyme could 
still bind to methylmalonyl- and dimethylmalonyl-CoA. A similar result was obtained for the 
trans-acting disorazol AT, which showed some tolerance towards methylmalonyl-CoA despite 
containing the Phe-His motif.99 One possibility for this unexpected promiscuity is that the 
fingerprint residues are not well established for non-canonical extender units and trans-acting 
ATs. A modeled RhiG based on the available structures of disorazol AT99 and FabD175 shows 
that some of the residues could be oriented differently in the active site (figure 5.3b). A crystal 
structure of extender unit-bound RhiG would reveal insights into the substrate specificity. In 
parallel to this, the AT specificity could also be engineered to incorporate unusual extender 
units via domain swapping or site-specific mutations.54, 176 However, in the current β-branching 
setting, the orientation of these ACP-bound extender units within the KS binding pocket 
should be taken into consideration. It is challenging to incorporate regiospecific methyl groups 
to natural products using synthetic chemistry approaches. In this context, the branching 
module and the trans-AT from the rhizoxin system are excellent candidates for generating 
novel non-natural polyketide derivatives. 
 
Figure 5.3 a) Sequence alignment of the malonyl-transferring ATs. 2G2Z – FabD from E. coli; 
3SBM – AT from trans-AT disorazol synthase (DSZS). Fingerprint motifs are highlighted in red. 
Other active site residues are colored green. Arrows indicate the catalytic residues b) Alignment 
of the active site residues from FabD bound to malonyl-CoA (red), DSZS AT (blue) and RhiG 
(green). The structure of RhiG was modelled using Phyre2 server and the figure was generated in 
Pymol.53, 177 The numbers correspond to the malonyl-transferring part of RhiG.   
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5.3 The structural role of the B domain  
 
Although the inherent mosaic architecture of trans-AT PKSs render them suitable for 
engineering approaches to understand the role of novel domains, such enzymes have not been 
significantly targeted for genetic manipulation.178 This holds particularly true for the cryptic B 
domain in the branching module of the Rhi PKS. Structural analysis of the B domain suggested 
that it has a double hotdog fold reminiscent of DH domains but has a distorted active site.142 In 
DH domains, an active site Asp residue has been proposed to donate a proton to the β-hydroxy 
unit and the catalytic His extracts an α-proton with the concomitant release of water, to yield 
an α,β-double bond.179, 180 Although a non-canonical DH has been reported to catalyze both 
dehydration and cyclization to yield a pyran ring,165 all DH-catalyzed reactions are mediated by 
an invariant active site histidine. The catalytic His is mutated to Tyr in the B domain, which 
precludes the possibility that it might be involved in the branching reaction.142 Although the B 
domain shares a similar fold to DH domains, it lacks conserved motifs that are specific for a 
DH domain. In fact, alignment of the primary sequence of the B domain and the RhiE_DH 
domain of module 10 revealed an identity of only 23%. A BLAST search of the B domain against 
the PDB database resulted in no reliable hits. Domains homologous to the B domain have been 
speculated to be part of similar branching modules in the biosynthesis of glutarimide-
containing antibiotics (9-methylstreptimidone, migrastatin, etc.).158-161 A multiple sequence 
alignment of these homologues showed that the catalytic His mutation to Tyr was also 
observed in the ‘X’ (unknown) domains of 9-methylstreptimidone (SmdI_X) and migrastatin 
(Mgs_X) PKSs (figure 5.4). While the catalytic His is observed in the X domains of dorrigocin 
(Dgn_X) and lactimidomycin (Ltm_X) PKSs, these domains lack the catalytic Asp. The 
catalytic Asp was only conserved in SmdI_X apart from the rhizoxin PKS from P. fluoresecens 
(RzxE_B). None of the Asp residues close to the active site of Mgs_X, Dgn_X, Ltm_X or 
ChxE_X could be rationalized for catalytic activity. In addition, other residues in the active site 
also exhibited significant variations. 
 
Figure 5.4 Multiple sequence alignment of B domain (CAL69893.1) with its homologous B/X 
domains. Arrows indicate the probable position of the catalytic residues. Active site residues are 
highlighted in green. The numbering on top corresponds to the B domain. Rzx – Rhizoxin 
pathway from Pseudomonas fluorescens (AAY92265.1); Smd – 9-Methylstreptimidone pathway 
from Streptomyces himastatinicus (CCC21123); Mgs – Migrastatin pathway from S. platensis 
subsp. rosaceus (ACY01390.1); Dgn – Dorrigocin pathway from S. platensis subsp. rosaceus 
(ACY01392.1); lactimidomycin pathway from S. amphibiosporus (ACY01400.1) and cycloheximide 
pathway from Streptomyces sp. YIM 56141 (AFO59866.1). 
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In addition to these discrepancies in the amino acid sequence, the crystal structure of the KS-B 
didomain showed that the active centers of KS and the B domain are separated by > 40 Å,142 a 
distance that might be too far to shuttle the intermediates. Also, point mutation of the 
conserved Asp3876 to Ala did not affect the branching activity. Based on these results, it was 
suggested that the B domain has a structural rather than a functional role in the branching 
reaction.142 The current study provides a direct biochemical proof that the B domain can be 
substituted by the SmdI_X or a regular DH domain (RhiE_DH10) with no influence on the 
substrate selectivity or turnover (Manuscript C).145  
Based on the sequence comparison results (figure 5.4), it seemed logical that the B domain 
substitution experiments should be based on the overall fold of the protein (figure 5.5a). The 
structural alignment of the KS-B domain against the KS-X counterparts revealed that although 
B and SmdI_X (or simply X) domains share only 25.8% sequence identity, the overall deviation 
based on the fold was only 1.8 Å. The deviation was mainly observed in the KS-to-B linker 
region and the C-terminal part of the B domain. In assembly line PKSs, the domains are 
connected by linker regions which are not just covalent couplers. These linkers are very 
important for maintaining protein-protein interactions between neighbouring domains. 
Therefore domain substitution experiments should be performed without disrupting this 
interdomain communication.181 The linker region connecting KS-B and KS-X aligned well 
except for an additional α-helix and a β-sheet in KS-to-B linker, which might not be present in 
the KS-to-X linker (figure 5.5b). Therefore, for the B domain substitution experiments with X 
domain, the constructed chimera has the Rhi KS fused with the region spanning both the 
linker and X regions of the SmdI.159 The second chimera was constructed by fusing the Rhi KS 
and KS-to-B linker region with a regular DH domain. For this purpose, the DH domain 
upstream of the branching module (RhiE_DH10) was used.122 When this construct was initially 
constructed without the KS-to-B linker, the protein could not be produced in a soluble form, 
proving that the linker region is also needed to obtain a soluble functional protein. 
 
 
Figure 5.5 a) B domain (orange) aligned to X (SmdI_X – green; modelled) and DH (RhiE_DH10 – 
pink; modelled) shows the typical double hotdog fold where the central helix is wrapped around 
by six-stranded β-sheets.182 RMSD – 11.398 Å. b) Alignment of the linker regions between the KS 
and the B/X domains from RhiE and SmdI. RMSD – 3.362 Å. The figures are generated using 
Pymol 53 
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Even after careful consideration of the specific domain boundaries in the cloning experiments, 
the solubility of the chimeric proteins drastically reduced compared to the wild type KS-B. 
Therefore, to maximise the production of a soluble KS-X and KS-B hybrids, the fermentation 
condition had to be optimized. Therefore, gene induction experiments were performed at low 
temperature (15 °C) for 16 – 18 h. The proteins were also not suitable for long term storage and 
demanded frequent fresh preparations.  
In the in vitro biotransformation experiments, the fact that both the chimeras could produce 
the lactone and glutarimide structures proves that, irrespective of B, X or DH domains, the 
branching reaction was not affected. These results suggest that the KS domain exclusively 
catalyzes the stereoselective β-branching and lactonization reactions. Since KS-ACP 
architectures are present in other PKS machineries,183 attempts to produce a soluble Rhi KS-
ACP didomain were made. However, owing to poor solubility, the protein could not be tested 
further. Taken together, our data indicate that the B domain as well as the adjacent KS-to-B 
linker region is needed to maintain the structural integrity of the KS-B didomain. Based on 
bioinformatic analysis, the linker regions C-terminal to the KS of trans-AT PKSs were 
hypothesized to be AT-docking domains (ATds) that might be structurally similar to the KS-
AT adapter regions of cis-AT PKSs.174, 184 However, because of the lack of functional 
characterization, this region was renamed to ‘flanking subdomain’.101 Although the current 
result suggests that the linker region is needed to produce a soluble protein, whether it binds 
to AT remains to be determined. In addition to the mutation of the key catalytic histidine, the 
structure of the B domain suggests that the Tyr3738 residue is positioned such that it might 
block the substrate tunnel entrance found in characterized DH domains. This would imply 
that the substrates are unable to even enter the active site of the B domain. This observation is 
consistent with the ability of the KS domain to catalyse both steps of the branching reaction by 
itself. Considering all these results, the B domain appears to be a relic of a DH domain that has 
lost its activity over time. The B domain can possibly control the conformational changes that 
are needed during the interactions of the substrates with the KS domain. Inactive or non-
catalytic domains are often found among PKSs, for example, a DH domain in the FK228 PKS,185 
a DH and a TE domain in the mycolactone PKS186, 187 and a DH, KR and ER domain in the 
rapamycin PKS.188 Such domains might function as mediators to aid in communication 
between the upstream and downstream domains.  
To summarise, the results from the B domain substitution experiments confirm the vital role 
played by the cryptic B and X domains to aid in structural stability and possibly interdomain 
communication. The valuable information gained on the role of B domains and the linker 
regions could prove useful in synthetic biology, helping to generate a functional PKS hybrid 
with the entire branching module in order to synthesize β-branch-containing polyketides.  
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5.4 Investigating the mechanism of the branching KS 
As the B domain substitution experiments reveal that the KS alone is in charge of the 
branching reaction, the sequence of KS was examined to identify potential residues that might 
catalyze Michael addition and lactonization. A detailed phylogenetic analysis revealed that the 
KS of the branching module clustered among KSs (Clade IX) that accept olefinic substrates.85 
While the other KSs in the clade perform a regular Claisen condensation, the Rhi KS alone 
catalyzes a conjugate addition to form the non-canonical β-branch. Phylogenetic analysis of 
the KS domains from cis-AT PKSs, trans-AT PKSs and FASs showed that the known branching 
reliably KSs group together (bootstrap with 1000 replications) (figure 5.6a). Comparison of 
these sequences revealed that there are significant differences in the amino acids that are 
located close to the Cys-His-His catalytic triad. Site-specific mutation of residues in the Rhi 
branching KS to the corresponding residue of an elongating KS was performed in order to 
understand how the β-branching activity evolved. Furthermore, these results might also help 
assign specific roles for the amino acids in the Michael addition and lactonization reactions. 
Such an approach is common to study the PKS enzyme components  and has been employed 
to decipher the reaction mechanism of various PKS domains as well as to alter substrate 
specificity, while still maintaining the protein-protein interactions.178 Based on the mutational 
analysis of the Rhi KS, some of the additional residues that might involve in the reaction have 
been proposed (Manuscript E).  
 
Figure 5.6 a) Phylogeny of KS domains. Ltm-KS2 (ACY01400.1) from Streptomyces 
amphibiosporus, Mgs-KS2 (ACY01390.1); Mgs-KS3 and Mgs-KS4 from Streptomyces platensis, 
ChxE-KS2 (AFO59866.1) from Streptomyces sp., Smd-KS2 (CCC21123) from Streptomyces 
himastatinicus, Rhi-KS14 (CAL69893.1) from Burkholderia rhizoxinica, Rzx-KS2 (AAY92265.1) 
from Pseudomonas fluorescens, Ped-KS12 (AA547562.1) from Pseudomonas sp., Mln-KS5 
(YP_008420824); Mln-KS9 (YP_001421032.1) and Bae-KS5 (YP_001421293.1) from Bacillus 
amyloliquefacians, Tha-KS3 (WP_011401356.1) and Tha-KS12 (WP_009900597.1) from 
Burkholderia thailandensis, Lkc-KS3 (ADN64228.1) from Streptomyces rochei, Ozm-KS2 
(4WKY) from Streptomyces albus, DEBS KSs (2QO3, 2HG4) from Saccharopolyspora erythraea, 
FabB (4XOX) form Vibrio cholerae, FabB (2VB8) from E. coli, FabF (1OX0) from Streptococcus 
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pneumoniae, FabF (2GFW) from E. coli, FabF (2GQD) from Staphylococcus aureus, FabF (4LS5) 
from Bacillus subtilis, FabH (5BNM) from E. coli and FabH (4R8E) from Yersinia pestis. The 
sequences were aligned using Muscle and the phylogenic tree was constructed using Mega6 with 
100 bootstrap replications.189, 190 b) Comparison of active site residues of Rhi-KS14 (green) and 
Tha-KS3 (pink). The structure of Tha-KS3 was modelled using Phyre2 server and the figure was 
generated in Pymol.53, 177 
Mutations of most of the active site residues did not affect the branching reaction 
(Manuscript E). However, for some mutants, the overall rate of the reaction was attenuated 
(Ser3141Asp, Ile3478Phe and Ser3409Ala) while other mutants were completely inactive 
(Cys3228Ala and Thr3290Tyr). The complete inactivity of Thr3290Tyr mutant is intriguing. In 
β-ketoacyl synthase I (FabB) and II (FabF), this position is represented by Phe229 (Phe157 in 
FabH57). Phe229 is one of the highly-conserved residues of the Fab-family of enzymes. This 
residue is located close to the carboxyl group of malonate and has been proposed to promote 
electron movement for decarboxylation and the formation of C2 carbanion.191-195 Although the 
Thr3290Tyr mutant still retained the malonyl-ACP decarboxylation activity, it was not able to 
catalyze β-branch formation. One explanation for the inability to catalyze the conjugate 
addition is that Thr3290 facilitates the attack of the enolate intermediate to the β-position of 
the acyl thioester. In other words, Thr3290 might promote the C-C bond formation.  
The crystal structure of KS-B bound the SNAC thioester substrate analog (18) showed positive 
electron density in the catalytic cysteine but the exact conformation of the substrate could not 
be determined. The bulkier Phe residues that lines the active site tunnel of FabH (Phe213, 
Phe15757) are substituted with smaller Gly or Ala residues in the Rhi KS. Hence it is likely that 
there is more flexibility for processing an α,β-unsaturated substrate. Biotransformation and 
kinetic experiments demonstrated that His3364 and His3404 are critical for substrate turnover. 
While the His3364Ala and His3404Ala mutants retained measurable turnover activity after 16 
hours, the rate of the reaction was slower compared to the wild type. Analogous mutations of 
the catalytic His residues of the KS of DEBS module 1 and E. coli FabB also resulted in 
moderate to very low turnover of the substrate.49, 196 However, a double mutant (His3364Ala 
and His3404Ala) was totally inactive, confirming the role of histidines in catalysis. From the 
mutational analyses, it is not possible to specify a particular residue that might induce 
lactonization by the attack of the δ-hydroxy group at this stage. However, the data provide a 
defined starting point for greater understanding of this unusual KS domain. A high resolution 
co-crystal structure of additional β-branching domains bound to reaction intermediates would 
help in the elucidation of the finer details of substrate binding and catalysis. To this end, 
attempts to obtain a crystal structure of a KS-B-ACP complex together with a crosslinking 
substrate (21) are in progress (Unpublished results).      
To complement the mutational analysis and to strengthen the fact that the KS domain is 
needed for branching, the KS domain was also substituted with 6 other KSs that mediate the 
canonical Claisen condensation. However, as with the B domain substitution experiments, 
soluble protein production was not obtained for most of the KS chimeras. When the 
construction of the chimeras was repeated with KS-specific C-terminal flanking regions named 
LINKS,197 soluble and functional proteins could be produced. Figure 5.6b shows the 
comparison of active site residues of the RhiE beta-branch KS and the canonical ThaKS3.  
Biotransformation assays revealed that the chimeras MlnKS4-B, BaeKS5*-B and ThaKS3*-B 
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produced a product that had the same mass and molecular formula as the native lactone (20 in 
figure 1.8a), albeit with low turnover activity. However, the product eluted at a different time 
(~7.2 min) to that of the lactone 20 (~7.7 min). MS/MS experiments showed that the product 
has a distinct fragmentation pattern to that the lactone (20) suggesting that it might be the 
linear or a cyclized product different from the δ-lactone. These results show that the native KS 
domain is needed to generate a β-branch followed by lactone formation. It also represents a 
successful example of manipulating the substrate specificity of the KS domains by careful 
domain substitution.  
 Over the recent years, ketosynthases that 
perform novel condensation and cyclization 
reactions have been reported. MxnB from 
Myxococcus fulvus Mxf50, CorB from 
Corallococcus coralloides, and PpyS from 
Photorhabdus luminiscens all catalyze the 
Claisen condensation reaction in head-to-
head fusion of two polyketide chains 
followed by lactonization to yield rigid 
pyrone rings (figure 5.7a).198-202 In contrast, 
KSIII-type DarB from Chitinophaga pinensis 
and StlD from Photorhabdus luminescens 
catalyze two distinct C-C bond formations – 
both a Claisen condensation and a Michael 
addition- of a β-ketoacyl substrate and an 
α,β-unsaturated precursor to produce 
cyclohexanediones (figure 5.7b).203, 204 In 
light of these novel reactions, the Rhi KS holds a unique place and represents a new family of 
β-branching cyclase (figure 5.7c).  
 
 
 
 
 
Figure 5.7 Schemes for novel KS-
catalyzed condensation and cyclization 
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5.5 Small- to large-sized lactone formation 
The lactone motifs or related ring structures represent reactive centers for nucleophilic or 
electrophilic reactions in the target biomolecules. The presence of medium-sized rings might 
also provide structural rigidity to natural products which is crucial for their binding to 
biological targets. Typically, TE domains catalyze the lactonization reaction as a means to off-
load a polyketide or a nonribosomal peptide intermediate, to generate medium- to large-sized 
macrocycles.205 Recently, several non-canonical cyclization reactions have been reported to 
occur either on- or off- the PKSs and NRPSs assembly lines, by specialized cis- or trans-acting 
domains and tailoring enzymes (Manuscript D).166, 206, 207 As the branching module of the 
rhizoxin PKS could form 6-membered lactam and glutarimide heterocycles, the ability to 
produce smaller or larger than the 6-membered lactones were tested with SNAC thioester 
mimics of varied acyl chain lengths. HRMS and MS/MS analysis revealed that the branching 
module might form up to 10-membered lactone macrocycles in vitro (Manuscript F). It is 
remarkable that the active site of KS can accommodate large-sized ring lactones. The crystal 
structure of an acyl-enzyme intermediate with the FabF-cerulinin complex revealed extensive 
movement of aromatic residues to aid in directing the acyl chain into the active site pocket. 
The Phe396 residue of the FabF moves away from the active site to leave space for substrate 
binding.49 The substitution of Phe396 to Ala in the Rhi KS probably creates additional space for 
substrate binding as well as the formation of up to 10-membered cycles. Recently, Bae-KS5 has 
been shown to accept and catalyze elongation of shorter-to longer acyl chains. Mutation of a 
bulkier Met residue to Ala led to the elongation of β-methyl branched SNAC thioesters.208 The 
Rhi KS is inherently suitable to accept a wide range of non-natural substrates. Therefore, it 
might also be possible to generate large-sized lactams or other complex products in vitro. 
Medium- to large-sized lactones which show potential bioactivity do occur in nature, but 9- 
and 10-membered lactones are rare.209 The chemical synthesis of stereospecific lactones are 
also extremely challenging. Therefore, the production of a series of lactones by the branching 
module holds vital importance to use its enzyme components to generate complex products. 
This study provides insights into the extended substrate flexibility of the KS domain and opens 
possibilities to expand the range of products formed, for example, by site-specific mutagenesis. 
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6 Summary 
 
 
The diversity of functional groups and stereochemical complexity of natural products 
continues to inspire synthetic chemists and biologists to develop pharmacophore mimics with 
improved bioactivity. Studying polyketide natural product biosynthetic enzymes has opened 
opportunities to engineer the assembly lines or individual modules/domains to generate non-
natural variants. The biosynthesis of the macrolide rhizoxin varies from the archetypal head-
to-tail condensation of acyl building blocks that yield exclusively linear chains. The 
pharmacophoric δ-lactone moiety of rhizoxin is generated by a rare β-branch formed in the 
branching module (KS-B-ACP) of a trans-AT type I PKS. The β-branch is formed as a result of a 
nucleophilic vinylogous addition of a C2 unit to the α,β-unsaturated polyketide intermediate. 
This reaction is further followed by attack of the δ-hydroxy group of the intermediate to the 
KS-bound thioester to yield the δ-lactone. This thesis explains how the branching module of 
the rhizoxin biosynthetic pathway has been utilized for product diversification. It further 
provides a detailed analysis into the individual domains within the module. The results 
obtained from this thesis are summarized as follows. 
 
x To extend the scope of the branching module, chemically synthesized SNAC thioester 
mimics with different δ-substituents have been tested in vitro. An amine-substituted 
substrate resulted in the formation of a δ-lactam whereas the carboxamide-substituted 
substrate yielded a glutarimide ring. These results, together with kinetic assays, showed 
that exclusively syn-substituted products are formed. This study is the first to verify 
that the biosynthesis of the glutarimide in cycloheximide-type of antibiotics follows a 
Michael addition-cyclization sequence catalyzed by the non-canonical KS domain. In 
addition to the formation of 6-membered lactone, lactam and glutarimide rings, this 
thesis also shows that the branching module could form an array of 5- to 10-membered 
lactones. It is intriguing that the active site of KS domain could accommodate rings of 
bigger sizes. It is highly possible that in future, varied ring sizes with substituted 
lactones or lactams could be formed by the branching module. Not only does the 
branching module form lactam, glutarimide and higher order lactones, but, provided 
an appropriate extender unit, can also stereoselectively form a dual branched product. 
These results (Manuscript A, Manuscript B and Manuscript F) provide proof that 
the branching module stereospecifically generates branched rings and is of particular 
interest in the field of synthetic biology to generate potential therapeutics. The work 
was done in collaboration with Dr. Tom Bretschneider, Dr. Daniel Heine, Tawatchai 
Thongkongkaew and Dr. Hak Joong Kim. As part of this study, a detailed review 
discussing novel on-line cyclization reactions of polyketide or nonribosomal peptide 
intermediates catalyzed by assembly line domains and tailoring enzymes has been 
published (Manuscript D). 
 
x The PKSs for the biosynthesis of the glutarimide moiety of the cycloheximide-family of 
antibiotics possess a branching module homologous to the rhizoxin PKS. Prior to the 
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work described in this thesis, the role of the B domain and the homologous X domain 
in the branching modules remained obscure. Since the catalytic Asp to Ala mutant of 
the B domain retained the branching activity, it was proposed that these enigmatic 
domains do not participate directly in catalyzing the branching reaction. To shed light 
on the function of these domains, two different chimeras were constructed. The first 
chimeric didomain constitutes the KS from the branching module fused to the X 
domain from a glutarimide-forming module from 9-methylstreptimidone PKS. 
Biochemical characterization of the chimeric didomain showed that both the KS-B-
ACP and KS-X-ACP modules are functionally equivalent. In addition, kinetic studies of 
the chimeras revealed that the B and X domains do not have any significant impact on 
substrate specificity or the product turnover. Irrespective of their origin, we found that 
the modules containing B or X domains show similar reaction rates and substrate 
affinities. The second chimeric didomain was generated by fusing the KS of the 
branching module with the structurally similar DH domain from the downstream 
module of the rhizoxin PKS. Most surprisingly, the KS-DH-ACP engineered module in 
which the B/X domains were exchanged for the DH domain also catalyzed the Michael 
addition - cyclization sequence with the same efficiency and specificity. The conserved 
Asp residues of the DH and B/X domains were mutated to investigate their potential 
catalytic role. The loss of the typical DH active site residues did not have any impact on 
the chain branching activity, proving that the aspartate-histidine dyad is not required 
for the branching reaction. In an attempt to observe the effect of a complete removal of 
the B domain, the KS and ACP were fused without the linker. However, the KS-ACP 
hybrid could not be produced as a soluble protein, hampering further analysis. The 
results from Manuscript C reveal that the B/X domains and the KS-to-B linker are 
critical for maintenance of the structural integrity of the KS-B didomain. The double 
hotdog fold of the B/X domains could be important for facilitating conformational 
changes between the adjacent domains. Surprisingly, the KS domain alone is capable of 
stereoselectively adding the C2 unit to the β-carbon as well as cyclizing the polyketide 
intermediate to form the δ-lactone. The KS-mediated branching therefore represents a 
unique system to incorporate β-branches in polyketides to yield novel and potentially 
bioactive cyclic moieties. 
 
x The KS domain of the branching module resembles a classical elongating KS with the 
well conserved Cys-His-His catalytic triad and a thiolase fold. Yet, it is solely capable of 
catalyzing the unprecedented β-branching and cyclization reactions. To know if there 
are other potential active site residues that might explain this novel reaction, site-
specific mutagenesis of 10 conserved residues surrounding the active site was 
performed. The residues were chosen based on sequence comparison of KSs that 
catalyze β-branching or elongation. This is the first study reporting an extensive 
mechanistic investigation into the branching KS from a trans-AT PKS. As expected, 
based on previous studies on canonical KS domains, the catalytic Cys is essential for 
transacylation with the polyketide intermediate. Mutation of the catalytic histidines 
decreased the malonyl-CoA decarboxylation activity as well as product turnover. 
Kinetic analysis revealed that mutation of the residues Ser3141, Ser3409 and Ile3478 also 
decreased the rate of product formation. Like the catalytic Cys to Ala mutant, the 
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Thr3290Tyr mutation also rendered the protein inactive. Based on the analogous FAS 
structures, the Thr3290 might be positioned close to the malonyl carboxylate and thus 
aid in β-branch formation. The mutational analysis also indicated that Michael 
addition and the subsequent lactonization could be mediated by two or more residues. 
While elucidation of the mechanism requires further investigation, this study identified 
some key residues for catalysis and created a well-defined starting point to study the 
mechanistic details of the complex branching reaction. In addition to the mutational 
analysis, the KS domain was also substituted with elongating KSs from macrolactin 
(KS4), bacillaene (KS5) and thailandamide (KS3) PKSs. In all the chimeras constructed, 
the B domain and the linker region C-terminal to the KS were kept intact so as not to 
compromise structural integrity. The KS-swapped chimeras were functionally similar to 
a classical KS and catalyzed decarboxylative β-carbon elongation, leading to a proposed 
linear product. These results once again confirm that the active site architecture of the 
branching Rhi KS is very important to perform the Michael addition and lactonization 
(Manuscript E). A crystal structure of the entire branching module would help to 
elucidate the conformational changes occurring within the active site upon substrate 
binding. 
 
To summarize, the results from this thesis validate that the branching module exhibits 
tolerance towards a variety of non-natural substrates to produce novel ring systems. It further 
provides a detailed functional analysis of its key components (KS and B) that could be 
leveraged for synthetic biology. The KS-B-ACP architecture serves as a hallmark to identify 
such non-canonical branching modules in natural product biosynthetic gene clusters.  
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7 Zusammenfassung  
 
 
Die Vielfalt an funktionellen Gruppen und stereochemischer Komplexität von Naturstoffen 
inspiriert synthetische Chemiker und Biologen fortwährend dazu, Wirkstoffderivate mit 
verbesserter Bioaktivität zu entwickeln. Die Erforschung und das daraus folgende Verständnis 
über Polyketidsynthasen eröffnete Möglichkeiten, um Assemblierungslinien oder individuelle 
Module/Domänen zu entwickeln, welche dazu genutzt werden können, nicht natürlich 
vorkommende Polyketid-Varianten zu generieren. Die Biosynthese von Rhizoxin weicht von 
der archetypischen Kopf-Schwanz-Kondensation der Acyl-bildenden Einheiten ab, welche 
ausschließlich zur Produktion von linearen Ketten führt. Die pharmakophore δ-Lacton-Gruppe 
von Rhizoxin wird mittels einer seltenen β-Verzweigung im (KS-B-ACP) einer trans-AT Typ I 
PKS gebildet. Es konnte gezeigt werden, dass die β-Verzweigung aus einer nukleophilen 
vinylogenen Addition einer C2-Einheit an einem α,β-ungesättigten Polyketid-Intermediat 
hervorgeht. An diese Reaktion schließt der Angriff der δ-Hydroxlgruppe des Intermediaten an 
den KS-gebundenem Thioester an, wodurch das δ-Lacton gebildet wird. Die vorliegende Arbeit 
beschreibt die Nutzung des β-Verzweigungs-Moduls in der Rhizoxin-PKS für die Herstellung 
variabler Produkte. Weiterhin wird eine detaillierte Analyse der einzelnen Domänen innerhalb 
des Modules aufgezeigt. Im Folgenden werden die Ergebnisse der vorliegenden Arbeit 
zusammenfassend aufgeführt. 
 
x Um die Substratflexibiltiät des β-Verzweigungs-Moduls zu analysieren wurden chemisch 
synthetisierte SNAC-Thioester-Analoga mit verschiedenen δ-Substituenten in vitro 
getestet. Während aus einem Amin-substituierten Substrat ein δ-Lactam hervorging, 
resultierte ein Carboxamid-substituiertes Substrat in einem Glutarimid-Ring. Diese 
Ergebnisse, zusammen mit den kinetischen Betrachtungen belegen, dass ausschließlich 
syn-substituierte Produkte gebildet werden. Diese Studie verifiziert zum ersten Mal, dass 
die Biosynthese von Glutarimid im Cycloheximid-Typ der Antibiotika einer Michael-
Addition-Zyklisations-Sequenz folgt, welche von einer nicht-kanonischen KS-Domäne 
katalysiert wird. In dieser Arbeit konnte zusätzlich zu der Formation eines 6-gliedrigen 
Lactons, Lactams und Glutarimid-Rings gezeigt werden, dass der β-Verzweigungs-Modul 
weiterhin die Bildung einer Reihe von 5- bis 10-gliedrigen Lactonen katalysiert. Es ist 
erstaunlich, dass das aktive Zentrum der KS-Domäne auch Reaktionen mit größeren 
Ringen unterstützt. Es ist anzunehmen, dass in Zukunft verschiedene Ringgrößen mit 
substituierten Lactonen oder Laktamen durch das Verzweigungs-Modul gebildet werden 
können. Neben der Herstellung von Laktamen, Glutarimiden und Lactonen höherer 
Ordnung ist das Verzweigungs-Modul weiterhin in der Lage, stereoselektiv zweifach 
verzweigte Produkte bei entsprechend bereitgestellten Verlängerungseinheiten zu bilden. 
Diese Ergebnisse (Manuskript A, Manuskript B und Manuskript F) liefern den Beweis, 
dass das Verzweigungs-Modul stereospezifisch verzweigte Ringe bilden kann, was von 
besonderem Interesse für die synthestische Biologie ist, da dies für die Generierung von 
potentiellen Therapeutika genutzt werden könnte. Die Arbeit erfolgte in Kollaboration mit 
Dr. Tom Bretschneider, Dr. Daniel Heine, Tawatchai Thongkongkaew und Dr. Hak Joong 
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Kim. Als Teil dieser Studie wurde ein detaillierter Übersichtsartikel geliefert (Manuskript 
D), welcher neuartige on-line Zyklisierungsreaktionen der Polyketide oder 
nichtribosomalen Peptid-Intermediate beschreibt, die durch Domänen von 
Assemblierungslinien und modifizierende Enzyme katalysiert werden.  
 
x PKS, welche die Biosynthese der Glutarimid-Einheit der Cycloheximid-Familie unter den 
Antibiotika katalysieren, enthalten ein zu den Rhizoxin-PKS homologes Verzweigungs-
Modul. Im Vorfeld dieser Arbeit war die Rolle der B-Domäne des Verzweigungs-Modulen, 
und der homologen X-Domäne unklar. Da die Asp zu Ala-Mutante der B-Domäne die 
katalytische Aktivität der Verzweigungsreaktion bewahrte, wurde angenommen, dass diese 
enigmatische Domäne nicht direkt an der Verzweigungsreaktion teilnimmt. Um die 
Funktion dieser Domänen besser verstehen zu können, wurden zwei verschiedene 
Chimären generiert. Die erste chimäre Bidomäne besteht aus der KS-Domäne der 
Verzweigungs-Module welche mit der X-Domäne des Glutarimid-bildenden Moduls der 9-
Methylstreptimidon-PKS fusioniert wurde. Die biochemische Charakterisierung der 
chimären Bidomänen zeigte auf, dass die Module KS-B-ACP- und KS-X-ACP- funktionell 
äquivalent sind. Kinetische Studien der Chimären zeigten außerdem, dass die B- und X-
Domänen keinen signifikanten Einfluss auf die Substratspezifität oder die 
Produktbildungsrate haben. Ungeachtet derer Herkunft wurde gezeigt, dass die B- oder X-
Domänen enthaltenen Module ähnliche Umsatzraten und Substrataffinitäten aufweisen. 
Die zweite chimäre Bidomäne wurde generiert, indem die KS-Domäne der Verzweigungs-
Module mit der strukturell ähnlichen DH-Domäne aus dem darauffolgenden Modul der 
Rhizoxin-PKS fusioniert wurde. Überraschenderweise konnte gezeigt werden, dass das 
generierte KS-DH-ACP-Modul, indem die B/X-Domänen mit der DH-Domäne 
ausgetauscht wurden, ebenso die Michaelis Addition-Zyklisierungs-Sequenz in selber 
Effizienz und Spezifität katalysiert. Die konservierten Asp-Reste der DH- und B/X-
Domänen wurden mutiert um deren potentiell katalytische Rolle zu untersuchen. Der 
Verlust der typischen aktiven Reste der DH-Domäne hatte keinen Einfluss auf die 
Kettenverzweigungs-Aktivität. Hiermit konnte bewiesen werden, dass die Aspartat-
Histidin-Dyade nicht für die Verzweigungsreaktion benötigt wird. Um den Effekt einer 
kompletten Entfernung der B-Domäne zu untersuchen, wurden KS- und ACP-Domäne 
ohne einen Linker fusioniert. Jedoch konnte der KS-ACP-Hybrid nicht als lösliches Protein 
hergestellt werden, wodurch weitere Analysen nicht möglich waren. Die Ergebnisse des 
Manuskripts C zeigen auf, dass die B/X-Domänen und der Linker zwischen den Domänen 
KS und B essentiell für die Erhaltung der strukturellen Integrität der KS-B-Bidomäne sind. 
Der double hotdog fold der B/X-Domänen könnte bedeutend für eine erleichterte 
Konformationsänderung zwischen den benachbarten Domänen sein. Interessanterweise ist 
die KS-Domäne eigenständig zur stereoselektiven Addition der C2-Einheit an den β-
Kohlenstoff als auch zur Zyklisierung des Polyketid-Intermediates für die Ausbildung des 
δ-Lactons in der Lage. Die KS-vermittelte Verzweigung repräsentiert daher ein 
einzigartiges System für die Inkorporation von β-Verzweigungen in Polyketiden, welche zu 
neuartigen und potentiell bioaktiven zyklischen Einheiten führt.  
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x Die KS-Domäne der Verzweigungs-Module ähnelt mit ihrer konservierten katalytischen 
Triade aus Cystein und zwei Histidinen sowie der Thiolase-Faltung einer klassischen 
Elongations-KS. Dennoch ist sie eigenständig dazu in der Lage, die neuartige β-
Verzweigung und eine Zyklisierungsreaktion zu katalysieren. Um herauszufinden, ob 
weitere potentiell aktive Seitenketten in dieser neuartigen Reaktion involviert sind, wurden 
Punktmutationen bei zehn konservierten Aminosäuren durchgeführt, welche das aktive 
Zentrum umgeben. Die Aminosäuren wurden anhand eines Sequenzvergleiches von KS-
Domänen ausgewählt, welche β-Verzweigungen und β-Elongationen katalysieren. Dies ist 
die erste Studie über eine umfangreiche mechanistische Untersuchung von Verzweigungs -
KS-Domänen einer trans-AT PKS. Entsprechend vorangegangener Studien an kanonischen 
KS-Domänen wurde bestätigt, dass das katalytisch aktive Cys essentiell für die 
Transacylierung mit Polyketid-Intermediaten ist. Die Mutation des katalytischen His 
verringerte sowohl die Malonyl-CoA Decarboxylierungs-Aktivität als auch die 
Produktbildungsrate. Kinetische Analysen zeigten, dass Mutationen an Ser3141, Ser3409 
und Ile3478 ebenso zu einer reduzierten Produktbildungsrate führten. Neben der Mutation 
des katalytischen Cys zu Ala führte auch eine Thr3290Tyr-Mutation zu einem inaktiven 
Protein. Basierend auf der analogen FAS-Struktur, könnte Thr3290 in Nähe zu dem 
Malonylcarboxylat positioniert sein und daher die Formation der β-Verzweigung 
unterstützen. Mutationsanalysen weisen außerdem darauf hin, dass die Michael-Addition 
und die nachfolgende Lactonisierung durch zwei oder mehr Aminosäurereste vermittelt 
werden könnte. Währenddessen die Aufklärung des Mechanismus weiterer 
Untersuchungen bedarf, liefert diese Studie bereits die Identifikation einiger essentieller 
Aminosäurereste für die Katalyse und kreierte einen gut-definierten Startpunkt um 
mechanistische Details der komplexen Verzweigungsreaktion zu untersuchen. Zusätzlich 
zur Mutationsanalyse wurde die KS-Domäne außerdem durch Elongations-Ketosynthasen 
von Macrolactin (KS4)-, Bacillaene (KS5)- und Thailandamid (KS3)-PKS ersetzt. In allen 
konstruierten Chimären wurden die B-Domäne und die Linker-Region C-terminal zur KS 
intakt gehalten, um die strukturelle Integrität nicht zu beeinträchtigen. Diese Chimären 
erwiesen sich funktionell als ähnlich zu einer klassischen KS und katalysierten die 
decarboxylative β-Kohlenstoff-Verlängerung, welche zu dem erwarteten linearen Produkt 
führt. Diese Ergebnisse bestätigen erneut, dass die Architektur des aktiven Zentrums der 
Verzweigungs -Rhi-KS-Domäne von hoher Bedeutung für die Ausführung der Michael-
Addition und Lactonisierung ist (Manuskript E). Die Kristallstruktur der gesamten 
Verzweigungs-Module würde dazu beitragen, die konformationellen Veränderungen 
innerhalb des aktiven Zentrums während der Substratbindung aufzuklären.  
 
Zusammenfassend bestätigen die Ergebnisse der vorliegenden Arbeit, dass das Verzweigungs-
Modul eine Toleranz hinsichtlich einer Variabilität von nicht-natürlichen Substraten aufweist 
und somit die Produktion neuartiger Ringsysteme unterstützt. Die Arbeit liefert weiterhin eine 
detaillierte funktionelle Analyse derer Schlüsselkomponente (KS und B), was für die 
synthetische Biologie von Nutzen sein könnte. Die Architektur von KS-B-ACP dient als 
Kennzeichen für die Identifikation derartiger nicht-kanonischen Verzweigungs-Module in 
biosynthetischen Genclustern von Naturstoffen.  
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
General 
All reagents and 4-penten-2-ol were commercially purchased from Sigma-Aldrich and Roth.
All the solvents used for preparative and analytical measurements were obtained in HPLC 
grade. The chemical synthesis of (E)-(S)-(2-acetamidoethyl) hex-2-enethioate and 2-(2-
methyl-6-oxotetrahydro-2H-pyran-4-yl) acetic acid were performed as described previously 
(Bretschneider, et al., 2013). 
Chemical synthesis of (R,S)-(E)-S-(2-acetamidoethyl) 5-hydroxyhex-2-enethioate (3) 
According to Bretschneider et al. (2013), (R,S)-(E)-S-(2-acetamidoethyl) 5-hydroxyhex-2-
enethioate (3) was synthesized by a reduction-olefination sequence in 6 steps. This method 
has three disadvantages. The reaction sequence is long and time consuming. It also requires a 
protecting group. Moreover, the synthetic route is not flexible for longer and shorter
substrates because the starting materials are not commercially available. Thus, we generated 
the substrates using a new synthetic route. (R,S)-(E)-S-(2-acetamidoethyl) 5-hydroxyhex-2-
enethioate (3) can be synthesized by a cross metathesis reaction between the S-(2-
acetamidoethyl) prop-2-enethiolate and 4-penten-2-ol. The S-(2-acetamidoethyl) prop-2-
enethiolate was synthesized by the method described by (Heine, et al., 2014). Its 
spectroscopic data agrees with the previous report. 
General procedure for a cross metathesis reaction
 0.18 mmole of 4-penten-2-ol (A) and 0.06 mole of S-(2-acetamidoethyl) prop-2-
enethiolate (B) were added into a heat dry 4 ml vial filled with 500 μL of dry CH2Cl2. 1 mg (2 
mole %) of Grubb’s catalyst second generation was added and another portion 1 mg (2 mole 
%) of catalyst was added after 16 hours. The reaction was heated at refluxing for 24 hours. To 
work-up, the reaction was dried under N2 gas and the product was purified by silica gel 
column chromatography using 5% MeOH: CHCl3 as eluent.
 
Molecular formula: C10H17NO3S; HRESIMS: m/z 232.1001 [M+H]+ (calculated 
232.1007, Δm -2.6 ppm) ; IR (film) Q (cm-1): 3289 (O-H and N-H stretching), 3093 (Csp2-H
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stretching), 1652 and 1629 (C=O and C=C stretching) ; 1H (MeOH-d4, 500 MHz): G 6.94 
(1H, dt, J=15.5, 7.6 Hz), 6.22 (1H, dt, J=15.5, 1.3 Hz), 3.80 (1H, sextet, J = 6.2 Hz), 3.33 (2H, 
t, J = 6.8 Hz), 3.06 (2H, t, J = 6.5 Hz), 2.33 (2H, m), 1.91 (3H, s), 1.17 (3H, d, J = 6.0 Hz) 
ppm; 13C (MeOH-d4, 125 MHz): G 190.9, 173.4, 143.9, 131.3, 67.4, 42.5, 40.2, 28.9, 23.3, 
22.5 ppm
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Figure S1, related to figure 2A: Multiple sequence alignment of selected clade IX full-
length KSs. Residues highlighted in red were chosen for mutational analysis in the current 
study. Residues colored in blue constitute the active site. 
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Figure S2, related to ‘‘LC-ESI-MS and LC-MS/MS measurements’’ in the Experimental 
procedures section: ESI-MS of KS-B. (A) Mass spectrum corresponding to ACP-bound 
lactone product. (B) MS2 of m/z 849.28 ejected the PPant arm of ACP with the product 
attached. (C) MS3 fragmentation 
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Figure S3, related to ‘‘LC-ESI-MS and LC-MS/MS measurements’’ in the Experimental 
procedures section: ESI-MS of KSH3364A-B. (A) Mass spectrum corresponding to ACP-
bound lactone product. (B) MS2 of m/z 849.60 ejected the PPant arm of ACP with the product 
attached. (C) MS3 fragmentation 
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Figure S4, related to ‘‘LC-ESI-MS and LC-MS/MS measurements’’ in the Experimental 
procedures section ESI-MS of KSH3404A-B. (A) Mass spectrum corresponding to ACP-bound 
lactone product. (B) MS2 of m/z 849.60 ejected the PPant arm of ACP with the product 
attached. (C) MS3 fragmentation 
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Figure S5, related to figure 6C: MALDI-TOF analysis following tryptic digests of 
recombinant proteins. (A) MlnKS4-B (B) BaeKS5*-B and (C) ThaKS3*-B.  
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Figure S6, related to figure 7: LC-MS/MS of (A) 4 and (B) 5 tested with RhiE KS-B and 
MlnKS4-B respectively.  
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Figure S7, related to figure 4 and figure 7: 1H and 13C NMR spectrum of 3.
1H NMR for 3
13C NMR for 3
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
General 
All reagents, 3-buten-2-ol and 4-penten-2-ol were commercially purchased from Sigma-
Aldrich and Roth. All the solvents used for preparative and analytical measurements were 
obtained in HPLC grade. 
Chemical synthesis of (R,S)-(E)-S-(2-acetamidoethyl) thioate derivatives 
According to (Bretschneider et al., 2013), an (R,S)-(E)-S-(2-acetamidoethyl) 5-hydroxyhex-2-
enethioate was synthesized by a reduction-olefination sequence in 6 steps. This method has 
three disadvantages. The reaction sequence is long and time consuming. It also requires a 
protecting group. Moreover, the synthetic route is not flexible for longer and shorter
substrates because the starting materials are not commercially available. Thus, we generated 
the substrates using a new synthetic route. 
Retrosynthetic analysis 
The (R,S)-(E)-S-(2-acetamidoethyl) thioate derivatives can be synthesized by a cross 
metathesis reaction between the S-(2-acetamidoethyl) prop-2-enethiolate and alken-2-ol
analogues.
Chemical synthesis of alken-2-ol analogues
5-hexen-2-ol 
The 5-hexen-2-ol was synthesized by reduction of 5-hexen-2-one according to a method 
described by (Warner and Bäckvall, 2015). Its spectroscopic data is in agreement with the 
previous report.  
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General procedure for the synthesis of 6-hepten-2-ol, 7-octen-2-ol, and 8-nonen-2-ol
  
6-hepten-2-ol, 7-octen-2-ol, and 8-nonen-2-ol were synthesized by epoxide opening with 
suitable organo cuprates (Leijondahl et al., 2009). Specifically, 7.7 mmole of Mg(s) was 
added into a heat dry schlank flask under Ar. Next, 4 mL of dry THF was added and the 
mixture was stirred overnight. Then 3 drops of 1,2-dibromoethane was added. 1 mL of bromo 
alkene was added slowly and the reaction was stirred at room temperature for 1 hour. 
In another schlank flask, 0.5 ml of epoxypropane and 143 mg of CuI, and 4 mL of dry THF 
were added. The flask was cooled at -78oC. Next, the Grignard reagent was added dropwise. 
The reaction was stirred at -78oC for 1.5 hours and at room temperature for another 1 hour. To 
work-up, 10 mL of saturated aqueous NH4Cl was added. The reaction was extracted 3 times 
with 10 mL Et2O. The organic layer was combined, dried with Na2SO4, and evaporated to 
dryness. The crude reaction was purified by silica gel column chromatography using 20% 
Et2O: hexane as eluent to yield 395.4 mg (46%) of 6-hepten-2-ol, 758.8 mg (78%) of 7-octen-
2-ol, 632.8 mg (60%) of 8-nonen-2-ol.  
6-Hepten-2-ol 
Molecular formula: C7H14O; HRESIMS: m/z 115.1125 [M+H]+ (calculated 115.1123, Δm
+1.7 ppm); IR (film) Q (cm-1): 3337 (O-H stretching), 3076 (Csp2-H stretching), 1641 (C=C 
stretching); 1H (CDCl3, 500 MHz): G 5.79 (1H, m), 4.99 (1H, dq, J = 17.0, 1.6 Hz), 4.93 (1H, 
dd, J = 9.5, 1.5 Hz), 3.78 (1H, m), 2.05 (2H, m), 1.36-1.54 (4H, m), 1.17 (3H, d, J = 6.5 Hz) 
ppm; 13C (CDCl3, 125 MHz): G 138.7, 114.6, 68.0, 38.7, 33.7, 25.0, 23.5 ppm.
7-Octen-2-ol 
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Molecular formula: C8H16O; HRESIMS: m/z 129.1281 [M+H]+ (calculated 129.1279, Δm
+1.5 ppm); IR (film) Q (cm-1): 3356 (O-H stretching), 3077 (Csp2-H stretching), 1641 (C=C 
stretching); 1H (CDCl3, 500 MHz): G 5.78 (1H, m), 5.00 (1H, m), 4.92 (1H, m), 3.77 (1H, m), 
2.04 (2H, m), 1.20-1.50 (6H, m), 1.16 (3H, d, J = 6.0 Hz) ppm; 13C (CDCl3, 125 MHz): G
138.8, 114.4, 68.1, 39.1, 33.7, 28.8, 25.2, 23.5 ppm.
8-Nonen-2-ol 
Molecular formula: C9H18O; HRESIMS:  m/z 143.1432 [M+H]+ (calculated 143.1436, Δm
-2.8 ppm); IR (film) Q (cm-1): 3356 (O-H stretching), 3076 (Csp2-H stretching), 1640 (C=C 
stretching); 1H (CDCl3, 500 MHz): G 5.78 (1H, m), 5.00 (1H, m), 4.91 (1H, m), 3.77 (1H, m), 
2.02 (2H, m), 1.22-1.49 (8H, m), 1.16 (3H, d, J = 6.0 Hz) ppm; 13C (CDCl3, 125 MHz): G
139.0, 114.2, 68.1, 39.2, 33.7, 29.1, 28.8, 25.6, 23.4 ppm
Chemical synthesis of S-(2-acetamidoethyl) prop-2-enethiolate  
The S-(2-acetamidoethyl) prop-2-enethiolate was synthesized according to a method 
described by (Heine et al., 2014). Its spectroscopic data is in agreement with the previous 
report. 
General procedure for a cross metathesis reaction
0.18 mmole of alken-2-ol (A) and 0.06 mole of S-(2-Acetamidoethyl) prop-2-enethiolate (B) 
were added into a heat dry 4 ml vial filled with 500 μL of dry CH2Cl2. 1 mg (2 mole %) of 
Grubb’s catalyst second generation was added and another portion 1 mg (2 mole %) of 
catalyst was added after 16 hours. The reaction was heated at refluxing for 24 hours. To work-
up, the reaction was dried under N2 gas and a product was purified by silica gel column 
chromatography using 5% MeOH: CHCl3 as eluent.
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A general reaction scheme: 
No n
mmole
%yield
recovery of B
(mmole)A B
1 0 0.18 0.06 43* 0.03
2 1 0.18 0.07 36* 0.03
3 2 0.18 0.06 24* 0.02
4 3 0.18 0.06 91* 0.02
5 4 0.18 0.06 58 -
5 5 0.18 0.07 72 -
*The percent yield was calculated based on a recovery of starting material. 
(R,S)-(E)-S-(2-acetamidoethyl) 5-hydroxyhex-2-enethioate (5)
Molecular formula: C10H17NO3S; HRESIMS: m/z 232.1001 [M+H]+ (calculated 232.1007, 
Δm -2.6 ppm) ; IR (film) Q (cm-1): 3289 (O-H and N-H stretching), 3093 (Csp2-H stretching), 
1652 and 1629 (C=O and C=C stretching) ; 1H (MeOH-d4, 500 MHz): G 6.94 (1H, dt, 
J=15.5, 7.6 Hz), 6.22 (1H, dt, J=15.5, 1.3 Hz), 3.80 (1H, sextet, J = 6.2 Hz), 3.33 (2H, t, J = 
6.8 Hz), 3.06 (2H, t, J = 6.5 Hz), 2.33 (2H, m), 1.91 (3H, s), 1.17 (3H, d, J = 6.0 Hz) ppm; 13C
(MeOH-d4, 125 MHz): G 190.9, 173.4, 143.9, 131.3, 67.4, 42.5, 40.2, 28.9, 23.3, 22.5 ppm 
(R,S)-(E)-S-(2-acetamidoethyl) 4-hydroxypent-2-enethioate (7)
Molecular formula: C9H15NO3S; HRESIMS: m/z 218.0847 [M+H]+ (calculated 218.0851, 
Δm -1.8 ppm); IR (film) Q (cm-1): 3284 (O-H and N-H stretching), 3097 (Csp2-H stretching), 
1652 and 1633 (C=O and C=C stretching) ; 1H (MeOH-d4, 300 MHz): G 6.90 (1H, dd, 
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J=15.3, 4.4 Hz), 6.31 (1H, dd, J=15.3, 6.6 Hz), 4.40 (1H, m), 3.34 (2H, t, J = 6.9 Hz), 3.06 
(2H, t, J = 6.6 Hz), 1.91 (3H, s), 1.27 (3H, d, J = 6.6 Hz) ppm; 13C (MeOH-d4, 125 MHz): G
191.2, 173.4, 149.6, 126.9, 67.5, 40.2, 29.0, 22.7, 22.5 ppm 
(R,S)-(E)-S-(2-acetamidoethyl) 6-hydroxyhept-2-enethioate (9)
Molecular formula:  C11H19NO3S; HRESIMS: m/z 246.1159 [M+H]+ (calculated 246.1164, 
Δm -2.0 ppm); IR (film) Q (cm-1): 3289 (O-H and N-H stretching), 3091 (Csp2-H stretching), 
1652 and 1627 (C=O and C=C stretching); 1H (MeOH-d4, 500 MHz): G 6.94 (1H, dt, J=15.5, 
7.0 Hz), 6.18 (1H, dt, J=15.5, 1.4 Hz), 3.72 (1H, sextet, J = 6.2 Hz), 3.34 (2H, t, J = 6.7 Hz), 
3.05 (2H, t, J = 6.7 Hz), 2.30 (2H, m), 1.90 (3H, s), 1.56 (2H, m), 1.16 (3H, d, J = 6.2 Hz) 
ppm; 13C (MeOH-d4, 75 MHz): G 190.9, 173.4, 147.2, 129.5, 67.7, 40.2, 38.2, 29.5, 28.8, 
23.4, 22.4 ppm
(R,S)-(E)-S-(2-acetamidoethyl) 7-hydroxyoct-2-enethioate (11)
Molecular formula: C12H21NO3S; HRESIMS: m/z 260.1314 [M+H]+ (calculated 260.1320, 
Δm -2.3 ppm); IR (film) Q (cm-1): 3494 (O-H and N-H stretching), 3087 (Csp2-H stretching), 
1653 and 1631 (C=O and C=C stretching) ; 1H (MeOH-d4, 300 MHz): G 6.92 (1H, dt, 
J=15.6, 7.4 Hz), 6.17 (1H, dt, J=15.6 Hz), 3.71 (1H, sextet, J = 6.1 Hz), 3.32 (2H, t, J = 6.6 
Hz), 3.04 (2H, t, J = 6.8 Hz), 2.22 (2H, m), 1.90 (3H, s), 1.27-1.69 (4H, m), 1.14 (3H, d, J = 
6.0 Hz) ppm; 133C (MeOH-d4, 75 MHz): G 191.0, 173.5, 147.3, 129.6, 68.2, 40.2, 39.6, 33.1, 
28.9, 25.4, 23.5, 22.5 ppm 
(R,S)-(E)-S-(2-acetamidoethyl) 8-hydroxynon-2-enethioate (13)
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Molecular formula: C13H23NO3S; HRESIMS: m/z 274.1472 [M+H]+ (calculated 274.1477, 
Δm -1.8 ppm) ; IR (film) Q (cm-1): 3286 (O-H and N-H stretching), 1652 and 1629 (C=O and 
C=C stretching); 1H (MeOH-d4, 300 MHz): G 6.92 (1H, dt, J=15.6, 7.0 Hz), 6.17 (1H, dt, 
J=15.3, 1.4 Hz), 3.70 (1H, sextet, J = 5.8 Hz), 3.32 (2H, t, J = 6.6 Hz), 3.04 (2H, t, J = 6.8 
Hz), 2.22 (2H, m), 1.91 (3H, s), 1.28-1.57 (6H, m), 1.13 (3H, d, J = 6.3 Hz) ppm; 13C
(MeOH-d4, 75 MHz): G 191.0, 173.4, 147.4, 129.6, 68.4, 40.2, 39.8, 33.1, 29.2, 28.9, 26.5, 
23.5, 22.6 ppm 
(R,S)-(E)-S-(2-acetamidoethyl) 9-hydroxydec-2-enethioate (15)
Molecular formula: C14H25NO3S; HRESIMS:  m/z 288.1628 [M+H]+ (calculated 
288.1633, Δm -1.7 ppm) ; IR (film) Q (cm-1): 3289 (O-H and N-H stretching), 1652 and 1632 
(C=O and C=C stretching); 1H (MeOH-d4, 300 MHz): G 6.92 (1H, dt, J=15.6, 7.1 Hz), 6.16 
(1H, dt, J=15.3, 1.5 Hz), 3.70 (1H, sextet, J = 5.9 Hz), 3.33 (2H, t, J = 6.6 Hz), 3.05 (2H, t, J = 
6.8 Hz), 2.22 (2H, m), 1.91 (3H, s), 1.28-1.55 (8H, m), 1.13 (3H, d, J = 6.0 Hz) ppm; 13C
(MeOH-d4, 75 MHz): G 191.0, 173.4, 147.5, 129.6, 68.5, 40.2, 40.1, 33.1, 30.3, 29.1, 28.9, 
26.6, 23.5, 22.5 ppm 
Chemical synthesis of (R,S)-E-S-(2-acetamidoethyl)-4-hydroxyhex-2-enethioate (21) and 
(R,S)-E-S-(2-acetamidoethyl)-6-hydroxyhex-2-enethioate (22) 
For synthesis of (R,S)-E-S-(2-acetamidoethyl)-4-hydroxyhex-2-enethioate 21, 1-penten-3-ol 
(0.22 mmol, 17.7 μl) was added to SNAC ester B (0.06 mmol, 10.0 mg). The compound 
(R,S)-E-S-(2-acetamidoethyl)-6-hydroxyhex-2-enethioate 22, was synthesized analogously 
using 4-penten-1-ol (0.22 mmol, 17.7 μl) and SNAC ester B (0.06 mmol, 11.1 mg). The 
mixture was dissolved in dry dichloromethane (0.5 ml) and the mixture was stirred for two 
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days at room temperature. Hoveyda-Grubbs 2nd generation catalyst (10 mol %, 21: 0.01 mmol, 
13 mg; 22: 0.02 mmol, 14 mg) was added in two portions at day one and day two. The solvent 
was removed under a nitrogen stream and the product was purified by open column
chromatography. A gradient of chloroform:methanol (98:2) and chloroform:methanol (95:5) 
was used for elution to give 4.2 mg of 21 and 7.8 mg of 22.
(R,S)-E-S-(2-acetamidoethyl)-4-hydroxyhex-2-enethioate 21 (4.2 mg, yield: 42%). Colorless 
oil; 1H NMR (500 MHz, MeOD): δ 6.88 (1H, dd, 3J1 = 15.5 Hz; 3J2 = 4.7 Hz), 6.32 (1H, dd, 
3J1 = 15.5 Hz; 4J2 = 1.6 Hz), 4.17 (1H, m), 3.34 (2H, t, J = 6.7 Hz), 3.07 (2H, t, J = 6.7 Hz), 
1.91 (3H, s), 1.58 (2H, m), 0.95 (3H, t, J = 7.5 Hz); 13C NMR (600 MHz, MeOD): δ 191.26 
(COS), 173.55 (CON), 148.64 (CH), 127.65 (CHCO), 72.72 (COH), 40.14 (NCH2), 30.40 
(SCH2), 29.05 (CH2), 22.48 (CH3CO), 9.98 (CH3) ppm; HRMS: (ESI+): m/z calculated for 
C10H18O3NS: 232.1005, found 232.1002 [M+H]+.
(R,S)-E-S-(2-acetamidoethyl)-6-hydroxyhex-2-enethioate 22 (7.8 mg, yield: 70%). Colorless 
oil; 1H NMR (500 MHz, MeOD): δ 6.94 (1H, dt, 3J1 = 15.6 Hz; 3J2 = 7.0 Hz), 6.19 (1H, dt, 3J1
= 15.5 Hz; 4J2 = 1.5 Hz), 3.56 (2H, t, J = 6,4 Hz), 3.33 (2H, t, J = 6.7 Hz), 3.05 (2H, t, J = 6.6 
Hz), 2.29 (2H, m), 1.91 (3H, s), 1.68 (2H, m); 13C NMR (600 MHz, MeOD): δ 191.23 (COS), 
173,56 (CON), 147.04 (CH), 129.71 (CHCO), 62.00 (COH), 40.21 (NCH2), 31.90 (SCH2), 
29.56 (CH2), 28.91 (CH2), 22.50 (CH3O) ppm; HRMS: (ESI+): m/z calculated for 
C10H18O3NS: 232.1003, found 232.1002 [M+H]+.
To achieve sufficient purity of the substrate analogues for the vitro branching assay studies, 
the fractions containing the SNAC esters 21 and 22 were purified again by semi-preparative 
HPLC on a 1260 Infinity system using the column Eclipse XDB-C18, 250 x 4.6 mm, particle 
size 5 μm (Agilent Technologies). SNAC esters 21 and 22 were characterized by HRMS, 1H
and 13C NMR measurements. 
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Figure S1 (A-F), related to figure 3: LC-MS/MS of 6, 8, 10, 12, 14 and 16 respectively.
A B
C D
E F
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Figure S2 1H and 13C NMR spectra of 6-hepten-2-ol. 
1H NMR for 6-hepten-2-ol 
13C NMR for 6-hepten-2-ol
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Figure S3 1H and 13C NMR spectra of 7-octen-2-ol.
1H NMR for 7-octen-2-ol
13C NMR for 7-octen-2-ol
 	Ǧ
ͣͨ͢
11
 
Figure S4 1H and 13C NMR spectra of 8-nonen-2-ol.
1H NMR for 8-nonen-2-ol
13C NMR for 8-nonen-2-ol
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Figure S5 1H and 13C NMR spectra of 5. 
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Figure S6 1H and 13C NMR spectra of 7.
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Figure S7 1H and 13C NMR spectra of 9.
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Figure S8 1H and 13C NMR spectra of 11. 
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Figure S9 1H and 13C NMR spectra of 13. 
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Figure S10 1H and 13C NMR spectra of 15.
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Figure S11 1H and 13C NMR spectra of 21.
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Figure S12 1H and 13C NMR spectra of 22.
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The discovery of unprecedented pantetheine conjugates (panphenazines A and B) and 
phenazine-1-carboxylic acid (PCA) from a Kitasatospora sp. shed light on the novel mechanism 
of the phenazines to form radical-based thiol conjugation and crosslinking of proteins.  
 
 
A widespread bacterial phenazine forms S-
conjugates with biogenic thiols and crosslinks
proteins†
D. Heine,a S. Sundaram,a Matthias Beudert,a K. Martina and C. Hertweck*ab
Phenazines are redox-active compounds produced by a range of bacteria, including many pathogens.
Endowed with various biological activities, these ubiquitous N-heterocycles are well known for their
ability to generate reactive oxygen species by redox cycling. Phenazines may lead to an irreversible
depletion of glutathione, but a detailed mechanism has remained elusive. Furthermore, it is not
understood why phenazines have so many protein targets and cause protein misfolding as well as their
aggregation. Here we report the discovery of unprecedented conjugates (panphenazines A, B) of
panthetheine and phenazine-1-carboxylic (PCA) acid from a Kitasatospora sp., which prompted us to
investigate their biogenesis. We found that PCA reacts with diverse biogenic thiols under radical-forming
conditions, which provides a plausible model for irreversible glutathione depletion. To evaluate the
scope of the reaction in cells we designed biotin and rhodamine conjugates for protein labelling and
examined their covalent fusion with model proteins (ketosynthase, carbonic anhydrase III, albumin). Our
results reveal important, yet overlooked biological roles of phenazines and show for the ﬁrst time their
function in protein conjugation and crosslinking.
Introduction
From an evolutionary perspective, it is most remarkable how
small biomolecules have been shaped into privileged structures
that full multiple biological functions. This is particularly true
for the large family of phenazines, ancient N-heterocycles that
are produced by a large variety of bacteria.1 Initially discovered
as colourful bacterial pigments over 150 years ago, to date over
one hundred natural phenazines have been characterised, most
of which are endowed with highly diverse bioactivities.2 These
ndings inspired the chemical synthesis of thousands of
phenazine derivatives and propelled the development of anti-
biotics and anticancer agents.1–3 However, phenazines are
a remarkable example of antibiotic compounds that are actually
crucial for microbial interaction and competitive tness.4–6 They
not only act as signalling molecules in microbial communica-
tion,7–9 mediating biolm formation and morphogenesis of
colonies,10 but also control gene expression11 and inuence the
intracellular redox state10 as well as exocellular electron trans-
fer.12 Owing to their redox properties, phenazines play major
roles in infection processes of pathogens such as Pseudomonas
aeruginosa, especially in cystic brosis patients.13 In particular,
pyocyanin (PYO, 1) and phenazine-1-carboxylic acid (PCA, 2),
the key intermediate in phenazine biosynthesis,14 represent
important virulence factors of P. aeruginosa that damage
infected tissue (Fig. 1).15,16 The primary reason for the delete-
rious eﬀects is phenazine-mediated redox cycling,1 which leads
to high concentrations of reactive oxygen species (ROS). Natu-
rally, ROS is eﬀectively counteracted by reduced glutathione
(GSH) as redox buﬀer, with formation of the oxidised disulde
form (GSSG).17,18 Despite an impressive body of data on phen-
azine functions, there are numerous open questions on their
mode of action. Specically, it was observed that phenazines
Fig. 1 Structures of pyocyanin (1), PCA (2), and panphenazines A (3)
and B (4) discovered in this study.
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may lead to a decrease in GSH levels by conjugation, but the
reaction mechanism has remained elusive.19–22 Moreover, it was
found that ROS formation alone is neither responsible for the
observed cytotoxic eﬀects nor for misfolding and aggregation of
proteins in the model organism C. elegans when exposed to
phenazines.23 Notably, addition of antioxidative agents failed to
rescue the proteotoxic and protein aggregation phenotypes.23 In
this context it is remarkable that phenazine-mediated toxicity
may be attributed to autophagy, which can result from high
titres of misfolded proteins.24 Yet, a link between non-func-
tional proteins and phenazines has been missing. Furthermore,
it is not yet suﬃciently understood why phenazines have such
broad activity proles and highly diverse biological targets.2,25
Here, we report the discovery of unprecedented phenazine–
pantetheine conjugates and the elucidation of their biogenesis,
which revealed an overlooked mode of action of phenazines.
Using two diﬀerent synthetic probes we analysed the ability of
phenazines to form thiol conjugates and crosslink proteins by
a radical mechanism, which may clarify previously inexplicable
disease symptoms and enigmatic phenazine functions.
Results and discussion
Discovery of panphenazines
Through genome mining26 of the rare actinomycete Kitasato-
spora sp. HKI 714 we found that this soil-derived actino-
bacterium has the potential to produce prenylated phenazines.
The genomics-guided search led to the discovery of a series of
new endophenazines along with acylated phenazine deriva-
tives.27 As the strain produced large amounts of PCA (2), the
universal precursor of phenazine derivatives, we expected to
discover more congeners. In fact, metabolic proling of
concentrated culture extracts indicated the presence of unusual
sulfur-containing phenazines. HRMS data (m/z ¼ 501.1807
([M + H]+ for 3), m/z ¼ 501.1808 ([M + H]+ for 4)) and sulfur
isotope pattern analysis suggested a molecular formula of
C24H29O6N4S for both compounds. Because of the extremely low
titres of the new compounds (z5 mg L1) the strain needed to
be grown on a large scale (200 L). By semipreparative HPLC we
eventually succeeded in isolating both compounds, named
panphenazine A (3, 1.4 mg) and B (4, 0.9 mg), in suﬃcient
amounts for NMR analyses. NMR data conrmed the phenazine
core, and the downeld-shi (145.2 ppm) of the substituted
quaternary C-7 of 3 suggested the presence of a thioether-bound
side chain. The adjacent ethylene unit belongs to a cysteamine
residue, and HMBC data pointed towards a peptide bond to the
carboxy terminus of b-alanine. The remaining part of the
molecule represents pantoic acid, which is connected to the b-
alanine by another amide bond. The side chain is therefore
identical to pantetheine, the acyl group carrier of coenzyme A or
acyl carrier proteins during fatty acid and polyketide biosyn-
thesis. The position of the side chain was conrmed by COSY
and HMBC experiments. In an analogous way we elucidated the
structure of compound 4, which diﬀers from 3 only in the
substitution site (C-3 in lieu of C-7) (Fig. S1 and Table S1†).
Thus, panphenazines 3 and 4 are highly unusual pantetheine
adducts of PCA (2).
Biomimetic synthesis of PCA thiol conjugates
Considering the hundreds of known natural phenazines,
reports on sulfur-containing derivatives are scarce. The few re-
ported examples are two N-acetylcysteine conjugates, derma-
cozine J28 and SB 212305,29 and a partially characterised
pyocyanin glutathione adduct.21,22 To date, practically nothing is
known about their formation. Various enzymes have been
described that mediate C–S bond formation in natural product
biosynthetic pathways.30–36 However, inspection of the endo-
phenazine (epa) biosynthesis gene cluster in the Kitasatospora
sp. HKI 714 genome27 did not reveal any candidate genes that
could be involved in the formation of the thioconjugates.
Considering the substitution pattern, it was conceivable that 3
and 4 have resulted from a non-enzymatic reaction. Possible
scenarios are (a) an oxidative aromatic coupling, (b) a Michael
addition followed by reoxidation of the aromatic system, and (c)
a coupling reaction involving radicals.
To elucidate the mechanism of phenazine thioether forma-
tion, we performed a series of experiments using PCA (2) and
N-acetylcysteamine as a simplied surrogate of pantetheine.
Since addition of mild oxidizing agents or bases or incubation
of PCA with disuldes (cysteine, pantethine) did not lead to
S-conjugates, mechanisms involving oxidation or nucleophilic
attack of a deprotonated thiol were ruled out. Instead, we found
that thiol conjugation proceeded smoothly under the inuence
of sunlight. PCA has UV absorption maxima at 250 nm and
370 nm, which could serve for photo-excitation. Irradiation of
the reaction mixture with an UV lamp (370 nm) yielded various
regioisomeric conjugates, 5 (10%), 6 (8%), 7 (5%) and 8 (6%)
(Fig. 2). HPLC-HRMS analysis indicated that, in addition to the
monosubstituted conjugates, various other derivatives con-
taining two or three N-acetyl cysteamine moieties were formed.
Using these reaction conditions, we mimicked the biogenesis of
the panphenazines from pantetheine and PCA. In contrast to
the experiment with N-acetylcysteamine, irradiation of the
solution at 370 nm yielded exclusively two regioisomers. HPLC-
HRMS comparison unequivocally proved that the products are
Fig. 2 Formation of PCA-thiol conjugates. (A) Photo-induced conju-
gate formation of PCA and N-acetylcysteamine (NAC) at 370 nm
(HPLC proﬁle after 24 h); (B) biomimetic synthesis of 3 and 4; (C)
general structure of cysteine–PCA and glutathione–PCA adducts
resulting from irradiation.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 4848–4855 | 4849
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identical with the conjugates 3 and 4 isolated from Kitasatospora
sp. HKI 714 (Fig. S2†). Furthermore, the photoreaction proved to
be a viable route for coupling cysteine and glutathione with PCA,
as evidenced by HRMS and MSn analyses (Fig. S3 and S4†).
The successful photoreactions and the substitution pattern
are highly suggestive for the involvement of resonance-stabi-
lised radicals in thiol conjugation. To interrogate the reaction
mechanism, we conducted the coupling reaction of PCA and N-
acetylcysteamine in the dark, but added azobisisobutyronitrile
(AIBN) as a radical initiator. HPLC-HRMS analyses clearly
indicated the formation of the corresponding adducts. Like-
wise, 3 and 4 were formed aer incubation of PCA with pan-
tetheine and AIBN (Fig. S5†).
Mechanistic considerations
The radical mechanism is supported by two other observations:
rst, addition of an electron source such as triethylamine (TEA)
substantially increases product formation (up to tenfold), which
is in agreement with the reported mechanism of the formation
of the phenazine radical anion.37 Second, addition of the radical
scavenger t-butylhydroxytoluene (TBHT) hampered the photo-
reaction; only traces of conjugates could be detected. Thus, in
addition to the observed substitution pattern of the thio-
conjugates, three lines of experimental evidence support the
radical-based reaction mechanism (Fig. 3).
However, a direct light-induced formation of the thiyl radical
can be ruled out. The homolytic cleavage of the SH bond occurs
at wavelengths below 300 nm,38 yet the PCA-thioconjugates are
readily produced at 370 nm. Alternatively, it is more plausible
that radical formation is initiated by photoexcitation of PCA
into the triplet state. Transferring an electron from TEA (or an
alternative electron source) leads to the phenazine radical anion
(Fig. 3).37 Subsequent protonation generates a neutral radical,
which can react with biogenic thiols (GSH, pantetheine, cyste-
amine, cysteine) to form a thiyl radical while regenerating PCA.
By analogy to the aromatic substitution reaction with thiyl
radicals,39 one may infer that the thiyl radicals readily attack the
electron-rich phenazine core. Aer H abstraction and re-
aromatization, the radical chain reaction continues, which may
also lead to multiple substitutions as observed for N-acetylcys-
teamine. On the contrary, conjugate formation with pan-
tetheine seems to appear more selectively, possibly due to an
increased steric demand of the thiol. Even though various
conjugates could be detected in the HPLC-HRMS trace, only two
isomers (3 and 4) appear in higher amounts. It should be
highlighted that light-independent avenues to the formation of
phenazine radicals have been reported in the biological context.
It is well known that PYO is chemically reduced through radical
intermediates in the cell, and phenazine redox-cycling (intra-
cellular as well as extracellular) may generate PCA radicals,1
which can react with thiols to form conjugates.
Phenazine protein adduct formation and crosslinking
Single-electron redox processes yield phenazine radicals in host
cells; consequently, these reactive species may not only react
with biogenic thiols, but also with SH residues of proteins, an
important target of many small molecules.40,41 Such a process
would be reminiscent of non-enzymatic reactions of sugars with
proteins, yielding advanced glycation end-products (AGEs),
which play important roles in aging and degenerative
diseases.42 Considering the non-selective adduct formation of
phenazines and the multitude of thiols in living cells, it is
obvious that the corresponding conjugates would barely be
detectable in vivo as individual entities. Thus we investigated
whether PCA radicals form conjugates with individual proteins
in vitro. For this, we synthesised a chemical probe (9) (Fig. S6†)
in which the phenazine is fused to biotin via a tetraethylene
glycol (TEG) linker (Fig. 4A).
First, we incubated 9 and AIBN with a cysteine-rich dido-
main (ketosynthase-branching, KS-B, 14 cysteines) of
a modular polyketide synthase (PKS) module.43–45 The reaction
mixture was loaded onto a streptavidin column, and the bio-
tinylated protein was eluted at 60 C in buﬀer with 3 mM
biotin aer multiple washing steps. Subsequent sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
analysis indicated that the protein was indeed linked to the
biotin-labelled probe, unequivocally proving that the phena-
zine was bound to the PKS component (Fig. 4B). To gain
insight into the fate of proteins in the presence of the phen-
azine and UV light, we also prepared a uorescent probe (10).
Although PCA shows uorescence itself, the respective signal
proved to be too weak for the detection of protein conjugates.
Therefore we attached PCA to rhodamine B, a uorophore with
an exceptionally high uorescence quantum yield. The KS-B
didomain was subjected to the rhodamine-based probe 10
with irradiation at 370 nm, and the reaction mixture was
analysed by SDS-PAGE on a 12% gel. Surprisingly, the uo-
rescent bands were substantially larger than expected. Instead
of the predicted band at 100 kDa, we observed a uorescent
signal that corresponds to a molecular weight of over 200 kDa
(Fig. S7†). One possible explanation for this nding is that the
probe might have cross-linked two or more equivalents of the
Fig. 3 Proposed reaction mechanism for the radical-induced conju-
gate addition. Radical formation can proceed via a photochemical
reaction (left) or by redox cycling inside the cell (right). Only one of the
possible intermediates (resonance form) is shown, leading to the
derivative substituted at position 7. ISC ¼ intersystem crossing; HR,
electron donor (triethylamine, thiol or other); HSR, thiol.
4850 | Chem. Sci., 2016, 7, 4848–4855 This journal is © The Royal Society of Chemistry 2016
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protein. When analysing the products on a lower concentrated
gel (10%) for better separation, we detected several protein
aggregates of various sizes (Fig. 5B).
By tryptic digestion and MALDI analyses we corroborated
that all protein complexes resulting from the incubation of KS-B
with 9 and 10 are indeed derived from the KS (Fig. S8.1–S8.6†).
In control experiments where the protein was irradiated in the
presence of rhodamine B alone no aggregation could be
observed (Fig. 5B). MS/MS analysis of the protein (lane a)
revealed one of the peptides where 10 was bound to Cys3559
(Fig. 5C). A model was generated to show the proposed binding
mode of 10 to this cysteine using Pymol (Fig. 5D). These nd-
ings unequivocally showed that the crosslinking activity corre-
lates with the presence of the phenazine moiety and that
multiple linkages are formed. To test the scope of the reaction
we employed two proteins that are completely unrelated to
a PKS, carbonic anhydrase III (5 cysteines) and albumin
(35 cysteines). Aer incubation of carbonic anhydrase III with
probe 10 we monitored the time course of its aggregation.
Bands corresponding to the native protein slowly disappeared
with concomitant formation of extensive protein aggregates
bound to the uorescent probe (Fig. S9†). Using the same
conditions, albumin was functionalised with the rhodamine-
based probe 10, yet formation of higher aggregates was negli-
gible (Fig. S10†). Nonetheless, the monoadduct was ideally
suited to conrm the binding of the probe to a cysteine side
chain by MALDI analysis (Fig. S11 and S12†). Taken together, all
selected proteins are derivatised with the phenazine probe, yet
they diﬀer in their tendency to form higher aggregates, which
may be controlled by steric factors.
Conclusions
Considering the large number of studies on phenazines and
their biological activities, it is surprising that their ability to
capture biogenic thiols and crosslink proteins has so far been
overlooked. The discovery of the panphenazines and the
mechanistic investigations revealed that phenazine radicals
form conjugates with a range of thiols. Thus, we provide
a plausible model for irreversible GSH reduction in human
endothelial cells.19 Furthermore, we report for the rst time that
phenazines form S-conjugates with proteins. Protein modica-
tion and aggregation mediated by small molecules are the focus
of diverse research on biomaterials,46,47 and these processes are
also relevant for protein aging and degenerative diseases.42 Our
ndings are signicant because PCA is an important biosyn-
thetic building block that is produced in large amounts by many
pathogenic pseudomonads during infection processes.2,48 Since
phenazine radicals are readily formed in cells by redox cycling,
PCA and congeners may contribute to protein degeneration
processes. Specically, our ndings may explain the broad
activity proles of phenazines including protein aggregation in
Fig. 4 Evidence for radical-mediated protein conjugation by PCA. (A)
Synthesis of biotin-based probe 9, thio-adduct formation with keto-
synthase (KS-B) and puriﬁcation with streptavidin resin; (a) tetra-
ethylene glycol, EDC, DMAP, DCM, 86% (b) biotin, EDC, DMAP, DCM,
96%. (B) SDS-PAGE (10%) of KS-B after the incubation with the probe 9
for 24 h in the presence of AIBN. (a) Load, (b) ﬂow-through, (c) ﬁrst
wash, (d) second wash, (e) ﬁrst elution, (f) second elution, (g) third
elution, (L) ladder.
Fig. 5 Photo-induced protein crosslinking by PCA. (A) Synthesis of
PCA-rhodamine B conjugate 10 and thio-conjugate formation with
KS-B, (a) tetraethylene glycol, EDC, DMAP, DCM, 86%, (b) rhodamine B,
PyBOP, Hu¨nigs base, DCM, 63%. (B) SDS-PAGE (10%) of KS-B after the
incubation with probe 10 or rhodamine B in water (left picture: under
white light; right picture at 370 nm); (contrast adjusted) (a) 10, 370 nm,
18 h, (b) rhodamine B, 370 nm, 18 h, (c) H2O, 370 nm, 18 h, (d) KS-B
control; (L) ladder. (C) MALDI-MS/MS spectrum of the rhodamine-
based probe (10) linked to a peptide fragment of KS-B and model of
the rhodamine-based probe (10) linked to Cys3559 of KS-B (PDB code
4KC5).
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 4848–4855 | 4851
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C. elegans.23 Radical-based thiol conjugation and protein
crosslinking by phenazines represent novel modes of action
that are an important addition to the body of knowledge on this
widespread group of virulence factors.6
Experimental
General analytical procedures
All NMR experiments were performed on Bruker AVANCE II 300,
AVANCE III 500 or a 600 MHz spectrometer, equipped with
a Bruker Cryo Platform. The chemical shis are reported in parts
per million (ppm) relative to the solvent residual peak of chlo-
roform-d1 (
1H: 7.24 ppm, singlet; 13C: 77.00 ppm, triplet),
methanol-d4 (
1H: 3.30 ppm, quintet; 13C: 49.00 ppm, septet) or
DMSO-D6 (
1H: 2.50 ppm, quintet; 13C: 39.50 ppm, septet). HR
ESI-MS was carried out on an Accela UPLC-system (Thermo
Scientic) combined with an Exactive mass spectrometer
(Thermo Scientic) equipped with an electrospray ion source.
Solid phase extraction was carried out using Chromabond C18 ec
Cartridges lled with 2000 mg of octadecyl-modied silica gel
(Macherey-Nagel). HPLC-MS measurements were performed on
a HPLC 1100 System connected to a 1100 Series LC/MSD Trap
using an Zorbax Eclipse XDB-C8, 4.6 150 mm column, particle
size 5 mm (Agilent Technologies). For thin layer chromatography
TLC aluminium sheets silica gel 60 F254 (MERCK) were used.
Open column chromatography was performed using silica gel
60; particle size 0.015–0.04 mm (Macherey-Nagel) and on
Sephadex® LH-20 (Sigma-Aldrich). Semi preparative HPLC was
performed on an 1260 Innity System (Agilent Technologies)
using the following columns: Zorbax Eclipse XDB-C8, 9.5  250
mm, particle size 5 mm (Agilent Technologies), Zorbax Eclipse
XDB-C18, 9.5  250 mm, particle size 5 mm (Agilent Technolo-
gies) and EC 250/4 Nucleodur Sphinx RP, 10  250 mm, particle
size 5 mm (Macherey-Nagel). All solvents for analytical and
preparative HPLC were obtained commercially in gradient grade
and were ltered prior to use. To avoid microbial growth 0.1%
formic acid was added to the water, used for analytical and
preparative HPLC. UV-spectra were obtained using a UV-spec-
trometer UV-1800 (Shimadzu). IR-spectra were recorded on an
FT/IR-4100 ATR spectrometer (Jasco). For irradiation experi-
ments an UV-lamp TL MINI 6 Watt 33-640 (Philips) and an UV-
lamp F 6W T5 G5 129 3000K 280 lm (Sylvania) were used.
Strain cultivation and isolation of panphenazines
The cultivation of Kitasatospora sp. HKI 714 and the fraction-
ation of the crude extract were performed in exactly the same
way as reported before.27 Compounds 1 and 2 were isolated by
semipreparative HPLC (Zorbax Eclipse XDB-C18, 9.5 250 mm,
5 mm, ow rate 4 mL min1, gradient starting from H2O/MeOH
90/10, in 2.5 min to 50/50, in 15.5 min to 46/54, in 7 min to
42/58, in 5 min to 0/100).
Compound 3. Yellow solid, for a full list of NMR signals see
Table S1† in the SI; IR (lm): 3308, 2923, 2854, 1700, 1652, 1421,
1265, 1053, 759 cm1; UV/vis (MeOH): lmax nm (log 3): 236
(6.22), 274 (6.36), 381 (5.87), 427 (5.78) nm; HR ESI-MS: m/z ¼
501.1807 [M + H]+ (calculated 501.1809 for C24H29O6N4S).
Compound 4. Yellow solid, for a full list of NMR signals see
Table S1† in the SI; IR (lm): 3297, 2929, 1651, 1541, 1410, 1045,
757 cm1; UV/vis (MeOH): lmax nm (log 3): 261 (6.05), 372 (5.52),
408 (5.41) nm; HR ESI-MS: m/z ¼ 501.1808 [M + H]+ (calculated
501.1809 for C24H29O6N4S).
General synthetic procedures
All reagents were obtained from commercial suppliers (Sigma
Aldrich and Acros Organics) and were used without further
purication. Carbonic anhydrase III (29.5 kDa) was obtained
from GE Healthcare UK Limited and albumin (66 kDa) was
obtained from Carl Roth GmbH. Chemical solvents were ob-
tained at least in HPLC grade. Methanol and chloroform were
distilled prior to use. Reactions were performed under inert
atmosphere (Argon) using the Schlenk technique.
Pantetheine
A solution of D-pantethine (200 mg, 0.36 mmol) and dithio-
threitol (100 mg, 0.65 mmol) in a methanolic solution (4 mL;
methanol : water; 1 : 1; v/v) was stirred for 2 days in an inert
atmosphere (argon). The solvent was removed under reduced
pressure and the product puried by column chromatography
using silica gel (chloroform/methanol: 98/2: v/v) to give 195 mg
of a colourless liquid. Yield 97%. 1H NMR (300 MHz, MeOD):
d 0.9 (6H, s), 2.4 (2H, t), 2.6 (2H, t), 3.3–3.6 (6H, m), 3.9 (1H, s)
ppm. 13C NMR (75.5 MHz, MeOD): d 20.9, 21.3, 24.5, 36.4, 40.4,
43.9, 70.3, 77.2, 79.5, 173.9, 176.1 ppm.
Synthesis of panphenazines (3 and 4)
Phenazine-1-carboxylic acid (2, 3 mg, 0.013 mmol) was dissolved
in DMSO (300 mL) and pantetheine (4 mg, 0.013 mmol) was
added. The stirred mixture was incubated at 370 nm for 24 h.
The solvent was removed under reduced pressure and the crude
product dissolved in MeOH. HPLC-HRMS proved the identity of
one product with compound 4. Compound 3 was only produced
in minor amounts under these conditions. The yield of 4 was
quantied by integration of its peak area at a detector wave-
length of 430 nm. Under these conditions yield was determined
to be 2%. Repeating the reaction with the addition of TEA (1.9
mL, 0.014mmol) increased the yield to 24%. In contrast, addition
of TBHT instead of TEA hampered the reaction and no corre-
sponding signal for 4 could be detected in the UV trace.
Synthesis of phenazine N-acetylcysteamine conjugates (5–8)
Phenazine-1-carboxylic acid (2, 10 mg, 0.045 mmol) and N-ace-
tylcysteamine (5 mg, 0.042 mmol) were dissolved in DMSO and
incubated at 370 nm for 24 h. The solvent was removed under
reduced pressure and the residue was subjected to semi-
preparative HPLC (Zorbax Eclipse XDB-C8, 9.5 250 mm, 5 mm,
ow rate 4 mL min1, gradient starting from H2O/ACN 90/10, in
3 min to 80/20, in 25 min to 60/40, in 2 min to 0/100). Yields of
monosubstituted phenazines: 5 (10%), 6 (8%), 7 (5%), 8 (6%)
(yellow solids).
Compound 5. 1H NMR (500 MHz, DMSO-D6): d 1.58 (3H, s),
3.15 (2H, t, 3J ¼ 6.7 Hz), 3.22–3.27 (2H, m), 7.92–7.98 (2H, m),
4852 | Chem. Sci., 2016, 7, 4848–4855 This journal is © The Royal Society of Chemistry 2016
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8.03 (1H, d, 3J ¼ 9.2 Hz), 8.12 (1H, d, 3J¼ 9.2 Hz), 8.16–8.21 (1H,
m), 8.21–8.25 (1H, m) ppm. 13C NMR (125 MHz, DMSO-D6):
d 22.3, 32.7, 38.8, 128.2, 129.3, 131.0, 131.3, 132.4, 139.8, 141.3,
142.3, 142.5, 163.1#, 168.2, 169.3 ppm.
Compound 6. 1H NMR (600 MHz, DMSO-D6): d 1.82 (3H, s),
3.28 (2H, t, 3J¼ 6.8 Hz), 3.36–3.44 (2H,m)*, 7.58 (1H,m), 7.87–7.94
(3H, m), 8.16 (1H, dd, 3J¼ 8.4 Hz, 4J¼ 1.4 Hz), 8.19 (1H, d, 3J¼ 8.4
Hz), 8.23 (1H, t, 3J1 ¼ 5.5 Hz, NH) ppm. 13C NMR (150.9 MHz,
DMSO-D6): d 22.6, 30.4, 37.7, 120.7, 127.0, 128.9, 129.4, 130.2,
131.2, 139.2, 141.2, 141.3, 142.6, 143.2, 164.3, 168.5, 169.6 ppm.
Compound 7. 1H NMR (600 MHz, DMSO-D6): d 1.83 (3H, s),
3.22 (2H, t, 3J ¼ 6.9 Hz), 3.40–3.44 (2H, m), 7.75 (1H, d, 3J ¼ 7.2
Hz), 7.86 (1H, d, 3J ¼ 7.2 Hz), 7.95–8.01 (2H, m), 8.20–8.29 (3H,
m) ppm. 13C NMR (150.9 MHz, DMSO-D6): d 22.6, 29.6, 37.5,
124.0, 128.6, 129.2, 129.6, 131.2, 131.4, 133.6, 140.1, 140.6,
140.7, 142.1, 143.8, 165.4, 169.5 ppm.
Compound 8. 1H NMR (600 MHz, DMSO-D6): d 1.82 (3H, s),
3.30 (2H, t, 3J ¼ 6.9 Hz), 3.39–3.43 (2H, m), 7.73 (1H, d, 3J ¼ 6.6
Hz), 7.77 (1H, dd, 3J¼ 9.2 Hz, 4J¼ 1.5 Hz), 7.80 (1H, dd, 3J1¼ 8.6
Hz, 3J2¼ 6.6 Hz), 7.99 (1H, s), 8.04 (1H, d, 3J¼ 8.6 Hz), 8.09 (1H,
d, 3J ¼ 9.2 Hz), 8.28–8.33 (1H, m, NH) ppm. 13C NMR (150.9
MHz, DMSO-D6): d 22.5, 30.5, 37.6, 121.9, 125.4, 127.0, 127.5,
129.3, 130.3, 130.9, 140.4, 141.1, 142.0, 142.5, 165.5, 169.6, 169.8
ppm. *Signal partly obscured, #signal only detectable from
HMBC data.
Synthesis of phenazine-biotine and -rhodamine probes
Tetraethyleneglycol phenazine-1-carboxylate (11)
Phenazine-1-carboxylic acid 2 (10 mg, 0.044 mmol) was dis-
solved in dichloromethane (5 mL) and cooled to 0 C. Tetra-
ethylene glycol (26 mg, 0.13 mmol, 3 eq.), DMAP (5 mg, 0.04
mmol) and EDC (8.4 mg, 0.05 mmol) were added. Aer 24 h,
water was added and the aqueous phase extracted with
dichloromethane (2  10 mL). The combined organic fractions
were dried over sodium sulfate and concentrated under reduced
pressure. Column chromatography over silica gel (chloroform/
methanol: 98/2, v/v) gave the product (15.3 mg) as yellow oil.
Yield: 86%. 1H NMR (600 MHz, MeOD): d 3.47 (2H, t, 3J ¼ 4.9
Hz), 3.54 (2H, m), 3.58 (2H, t, 3J ¼ 4.9 Hz), 3.61 (2H, m), 3.66
(2H, m), 3.73 (2H, m), 3.93 (2H, t, 3J ¼ 4.7 Hz), 4.65 (2H, t, 3J ¼
4.7 Hz), 7.96–7.99 (3H, m), 8.24–8.27 (1H, m), 8.31 (1H, dd, 3J ¼
6.8 Hz, 4J ¼ 1.3 Hz), 8.33 (1H, m), 8.40 (1H, dd, 3J ¼ 8.8 Hz, 4J ¼
1.3 Hz) ppm. 13C NMR (150.9 MHz, MeOD): d 62.2, 66.0, 70.2,
71.4, 71.6, 71.7, 73.6, 79.5, 130.3, 130.9, 131.0, 132.7, 132.8,
132.9, 133.4, 134.0, 142.0, 143.8, 144.5, 144.9, 168.1 ppm; IR
(lm): 1119, 1214, 1237, 1274, 1350, 1421, 1523, 1727, 2874,
3018 cm1, HRMS: (ESI+): m/z calculated for C21H25O6N2 [M +
H]+ 401.1707, found: 401.1710.
Biotin-labelled phenazine-1-carboxylic acid (9)
Tetraethylene-glycol phenazine-1-carboxylate (7 mg, 0.017
mmol) 11 and biotin (8.5 mg, 0.035 mmol, 2 eq.) were dissolved
in dry dichloromethane (2 mL) and cooled to 0 C. DMAP (2 mg,
0.0.17 mmol) and EDC (8 mg, 0.044 mmol, 2.5 eq.) were added.
Water (5 mL) was added aer 20 h and the aqueous phase
extracted with dichloromethane (2  5 mL). The combined
organic fractions were dried over sodium sulfate and concen-
trated under reduced pressure. Column chromatography over
silica gel (chloroform/methanol: 95/5, v/v) gave 10.5 mg of
a yellow solid. Yield: 96%. 1H NMR (500 MHz, CDCl3): d 1.56–
1.70 (6H, m), 2.28–2.32 (2H, m), 2.67–2.73 (1H, m), 2.81–2.88
(1H, m), 3.06–3.13 (1H, m), 3.57–3.65 (10H, m), 3.72 (2H, dd, 3J1
¼ 5.4 Hz, 3J2 ¼ 4.1 Hz), 3.91 (2H, t, 3J1 ¼ 4.8 Hz), 4.14–4.18 (2H,
m), 4.23–4.28 (1H, m), 4.43–4.48 (1H, m), 4.65 (2H, t, 3J1 ¼ 4.8
Hz), 7.82–7.86 (3H, m), 8.20–8.23 (1H, m), 8.23 (1H, dd, 3J1¼ 7.1
Hz, 4J2 ¼ 1.3 Hz), 8.27–8.30 (1H, m), 8.37 (1H, dd, 3J1 ¼ 8.8 Hz,
4J2¼ 1.3 Hz) ppm. 13C NMR (125 MHz, MeOD): d ppm. 13C NMR
(150.9 MHz, CDCl3): d 24.6, 28.1, 28.2, 33.7, 40.4, 55.4, 60.1,
61.9, 63.3, 64.6, 69.0, 69.1, 70.4, 70.5, 70.6, 70.6, 129.1, 129.3,
130.3, 131.0, 131.2, 131.3, 132.1, 133.2, 141.0, 142.5, 143.1,
143.6, 166.4, 173.5, 174.1 ppm; IR (lm): 747, 1038, 1119, 1179,
1236, 1264, 1455, 1522, 1700, 2867, 2925, 3236 cm1, HRMS:
(ESI+):m/z calculated for C31H39O8N4S [M + H]
+ 627.2483, found:
627.2477.
Rhodamine-labelled phenazine-1-carboxylic acid (10)
To a solution of rhodamine B (1.9 mg, 0.0043 mmol), tetrae-
thyleneglycol phenazine-1-carboxylate 11 (1.7 mg, 0.0043 mmol)
and PyBop (2.7 mg, 0.0052 mmol, 1.2 eq.) in anhydrous
dichloromethane (1 mL) was added Hu¨nigs base (2.9 mL, 4 eq.)
at 0 C. The reaction was allowed to warm to room temperature
and stirred for 24 h. The solution was concentrated under
reduced pressure and the residue was subjected to column
chromatography over silica gel (gradient chloroform/MeOH:
100/0–95/5, v/v). The crude product was subjected to semi-
preparative HPLC using a Zorbax Eclipse XDB-C8 (acetonitrile–
H2O, 0.1% formic acid; starting conditions: 20% acetonitrile,
40% in 4 min, 60% in 12.5 min, 100% in 0.5 min, 100% for 5
min, 20% in 1 min) to give 2.2 mg of a white solid. Yield: 63%.
1H NMR (CDCl3, 600 MHz) d ¼ 1.26–1.37 (12H, m), 3.45–3.49
(3H, m), 3.50–3.59 (9H, m), 3.61–3.64 (2H, m), 3.64–3.68 (1H,
m), 3.69–3.72 (2H, m), 3.73–3.79 (1H, m), 3.90 (2H, t, 3J ¼ 4.8
Hz), 4.12 (2H, t, 3J ¼ 4.7 Hz), 4.63 (2H, t, 3J ¼ 4.8 Hz), 6.78–6.81
(3H, m), 7.02 (1H, s), 7.04 (1H, s), 7.28 (1H, dd, 3J1¼ 7.6 Hz, 4J2¼
0.7 Hz), 7.61–7.82 (3H, m), 7.85–7.91 (3H, m), 8.25 (1H, dd, 3J1¼
6.9 Hz, 4J2 ¼ 1.1 Hz), 8.26 (1H, dd, 3J1 ¼ 8.0 Hz, 4J2 ¼ 1.0 Hz),
8.28–8.32 (2H, m), 8.28 (1H, d, 3J1 ¼ 8.8 Hz) ppm. 13C NMR
(CDCl3, 600MHz) d¼ 12.6, 12.6, 12.6, 13.7, 46.0, 46.0, 46.0, 47.4,
64.7, 64.8, 68.6, 69.2, 70.4, 70.5, 70.6, 70.7, 96.4, 113.6, 114.0,
119.0, 128.7, 129.0, 129.6, 129.8, 130.2, 130.3, 131.2, 131.3,
131.3, 131.4, 131.4, 131.7, 132.3, 132.8, 132.9, 133.0, 133.6,
141.1, 141.9, 142.5, 143.8, 153.8, 155.5, 157.8, 158.8, 165.0, 166.3
ppm. IR (lm): 1077, 1126, 1183, 1342, 1410, 1462, 1590, 1651,
1722, 2353, 2860, 2923, 3318 cm1, HRMS: (ESI+):m/z calculated
for C49H53O8N4 [M]
+ 825.3858, found: 825.3868.
Phenazine-protein binding assays
The biotinylated probe 9 was directly mixed with the protein
(KS-B – 104.7 kDa) in 20 mM Tris–HCl (pH 8.0). Final concen-
trations of the probe and protein were 0.5 mM and 20 mM
respectively. The reaction mixture was incubated for 24 h under
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 4848–4855 | 4853
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the following conditions: (a) at 254 nm (b) at 370 nm or (c) at 22
C in the presence of 0.5 mM azobisisobutyronitrile (AIBN). For
purication of the biotinylated KS-B, the reaction mixture was
diluted twice with 50 mM Tris, 0.2 M NaCl, 0.1% SDS (pH 8.0)
and incubated with 1 mL of streptavidin beads (Thermo
Scientic) at 22 C for 1 h with shaking at 400 rpm. The beads
were washed twice with 50 mM Tris, 0.2 M NaCl, 2% SDS (pH
8.0) aer incubation at 60 C for 10 min. Elution of the bound
protein was achieved by heating the sample thrice at 60 C for
30 min in 50 mM Tris, 0.2 M NaCl, 2% SDS, 3 mM D-biotin
(pH 8.0).
The rhodamine-based probe 10 was incubated with the
protein (KS-B, carbonic anhydrase III, albumin) in water or in
DMSO. Final concentrations of the probe and the protein were
10 mM and 20 mM respectively. The reaction mixture was incu-
bated for varying times between 15 min and 20 h under UV-light
at 254 nm, at 370 nm, at 22 C in the presence of 0.5 mM AIBN
in the dark or at sunlight (specic times and conditions for each
experiment are indicated in the respective gure legend). Aer
the assay the protein samples were analysed by PAGE, on a 10%
or 12% SDS-gel for KS-B. The structures of KS-B and albumin
were visualised using Pymol. The probe 10 was generated as
a fragment and added specically to the Cys residue of the
proteins by replacing the hydrogen atom in Pymol.
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Analytical data of compounds 3 and 4
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Figure S1: Selected 1H,13C HMBC and 1H,1H COSY correlations of panphenazines 3 and 4.
Table S1: NMR spectroscopic data for Compounds 3 and 4 in methanol-d4.
3 4
Position δHa (J in Hz) δCb δHa (J in Hz) δCb
1 - -c - -c
2 8.62, d (7.0) 135.5 8.32, m 134.7
3 8.03, dd (8.7, 7.0) 131.7 - 143.3
4 8.40, dd (8.7, 1.3) 134.8 8.17, d (2.2) 126.6
4a - 144.6 - 144.8
5a - 145.3 - 145.1
6 8.05, d (2.1) 123.2 8.22, dd (7.6, 2.2) 130.2
7 - 145.2 7.96, m 133.0
8 7.87, dd (9.1, 2.1) 134.3 7.96, m 132.8
9 8.18, d (9.1) 129.4 8.28, dd (7.6, 2.2) 129.9
9a - 141.0 - 142.0
10a - 140.8 - 140.4
1` 3.38, m 32.0 3.39, m 32.3
2` 3.59,td (6.90, 1.5) 39.3 3.59, t (6.8) 39.2
3` - 174.1 - 174.1
4` 2.43, t (6.7) 36.5 2.42, t (6.6) 36.5
5` 3.48, m 36.4 3.49, m 36.3
6` - 176.1 - 176.1
7` 3.87, s 77.3 3.87, s 77.3
8` - 40.4 - 40.4
9`/10` 0.89, s 21.3/20.9 0.89, s 21.3/20.9
11` 3.39, m 70.4 3.40, m 70.4
COOH - 169.7 - 170.2
a recorded at 600.3 MHz, b recorded at 150.9 MHz; c signals not detectable.
2
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Binding of phenazine to biogenic thiols
Conjugate formation of PCA with pantetheine following irradiation at 370 nm
Figure S2. SIM-HRMS (m/z = 501.1788–501.1828) analysis of the obtained product after incubation of 
PCA and pantetheine with irradiation at 370 nm; comparison with the isolated reference compounds 
3 and 4. SIM: selected ion monitoring.
Coupling of PCA to cysteine and glutathione
Figure S3. HRMS(/MS) spectrum of PCA-cysteine adduct ([M+H]+) after incubation of PCA with 
cysteine under sunlight.
3
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Figure S4. HRMS(/MS) spectrum of PCA-glutathione-adduct ([M+H]+) after incubation of PCA with 
glutathione under sunlight.
Conjugate formation of PCA with pantetheine in presence of AIBN 
BM083_4B.D: EIC 523 +All MS
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0.0
0.5
1.0
1.5
2.0
2.5
3.0
5x10
2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 Time [min]
364.8
523.4
577.3
652.4 794.3
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Figure S5. SIM-MS spectrum of the product after incubation of PCA with pantetheine in presence of 
AIBN in the dark (top). MS spectrum of PCA-pantetheine-adduct ([M+Na]+) (bottom).
4
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Synthesis of phenazine probes 9 (with biotin) and 10 (with rhodamine).
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Figure S6: Synthesis of biotin- and rhodamine-B-tagged phenazine probes.
Phenazine-protein binding assays with KS-B
Figure S7. SDS-PAGE (12% gel) after incubation of KS-B with rhodamine-B-labelled phenazine 
probe 10 under the following conditions: A) λ = 370 nm, 20 h, in H2O, B) λ = 370 nm, 20 h, 
DMSO, C) sunlight, 8 h, H2O, D) D: sunlight, 8 h, DMSO, E) E: AIBN, 20 h, DMSO, F) F: AIBN, 
20 h, H2O. 
5
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Tryptic mass fingerprinting of labelled KS-B
Figure S8.1. Tryptic mass fingerprinting of KS-B after incubation with 9 and AIBN followed by 
affinity chromatography.
6
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Figure S8.2. Tryptic mass fingerprinting of KS-B after crosslinking with 10 under UV light (1).
7
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Figure S8.3. Tryptic mass fingerprinting of KS-B after crosslinking with 10 under UV light (1).
Figure S8.4. Tryptic mass fingerprinting of KS-B after crosslinking with 10 under UV light (1).
8
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Figure S8.5. Tryptic mass fingerprinting of KS-B after crosslinking with 10 under UV light (1).
Figure S8.6. Tryptic mass fingerprinting of KS-B after crosslinking with 10 under UV light (1).
9
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Phenazine-protein binding assays with carbonic anhydrase III and albumin
    
60 kDa
100 kDa
200 kDa
30 kDa
a  b  c  d  e  f  C   L a  b  c  d  e  f  C   LB)
Figure S9. A) Scheme for the functionalization of carbonic anhydrase III by probe 10 after 
irradiation with UV-light. B) SDS-PAGE (10%) of carbonic anhydrase III after the incubation 
with probe 10 or rhodamine B in water; a) rhodamine B, 370 nm, 10 h; b) 10, 370 nm, 15 
min; c) 10, 370 nm, 30 min; d) 10, 370 nm, 1 h; e) 10, 370 nm, 5 h; f) 10, 370 nm, 10 h, C) 
carbonic anhydrase III control, L: Ladder. The fluorescent bands would correspond to 
potential conjugates of carbonic anhydrase III and 9 with n>5.   
60 kDa
100 kDa
200 kDa
B) L  a  b  c  d  e  f  C L  a  b  c  d  e  f  C
A)
N
N
S
O
N
N
O
370 nm
10
Figure S10. SDS-PAGE (10%) of albumin after the incubation with probe 10 or rhodamine B in 
water (left picture: under white light; right picture at 370 nm); L, Ladder, a) rhodamine B, 
370 nm, 10 h; b) 10, 370 nm, 15 min; c) 10, 370 nm, 30 min; d) 10, 370 nm, 1 h; e) 10, 
10
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370 nm, 5 h; f) 10, 370 nm, 10 h, C) albumin control. The fluorescent band potentially 
corresponds to a 70 kDa monoadduct of 10 and albumin.
Tryptic mass fingerprinting of labelled albumin 
Figure S11. Tryptic mass fingerprinting of albumin after functionalization with 10 under UV 
light (1).
11
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Figure S12. A) Model of the rhodamine-based probe (10) crosslinked to the Cys557 of albumin 
under UV light (PDB code 4F5S) B) MALDI-MS/MS spectrum of the rhodamine-based probe 
(10)-linked peptide of albumin.  
12
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Antimicrobial properties of isolated phenazines 3 and 4
Table S2. Antimicrobial properties of the phenazine-pantetheine conjugates 3 and 4 in 
comparison with PCA (2). B. sub: Bacillus subtilis ATCC 6633; S. aur: Staphylococcus aureus 
SG 511; E. col: Escherichia coli SG 458; P. aer: Pseudomonas aeruginosa SG 137; MRSA: 
Methicillin- and quinolone-resistant Staphylococcus aureus 134/93; VRE: Vancomycin-
resistant Enterococcus faecalis 1528; M. vac: Mycobacterium vaccae IMET 10670; S. sal: 
Sporobolomyces salmonicolor SBUG 549; C. alb: Candida albicans BSMY 212; P. not: 
Penicillium notatum JP36; cpd, compound; PCA: phenazine-1-carboxylic acid (2).
13
Inhibition zone (mm)
Cpd. B. sub S. aur E. col P. aer MRSA VRE M. vac S. sal C. alb P. not
3 0 0 17 0 0 15 13 20 0 0
4 10 0 0 15 0 0 13 0 0 0
PCA (2) 31 25 32 0 20 0 27 20 35 16
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NMR Spectra
1H NMR spectrum (600 MHz, MeOD) of 3.
13C NMR spectrum (150 MHz, MeOD) of 3.
14
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COSY and HSQC spectra of compound 3.
15
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HMBC spectrum of compound 3.
16
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1H NMR spectrum (600 MHz, MeOD) of 4.
13C NMR spectrum (150 MHz, MeOD) of 4.
17
 

ͧͤ͢
COSY and HSQC spectra of compound 4.
18
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HMBC spectrum of compound 4.
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1H NMR spectrum (500 MHz, DMSO-D6) of 5.
20
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13C NMR spectrum (125 MHz, DMSO-D6) of 5.
1H NMR spectrum (600 MHz, DMSO-D6) of 6.
21
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13C NMR spectrum (150 MHz, DMSO-D6) of 6.
1H NMR spectrum (500 MHz, DMSO-D6) of 7.
22
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13C NMR spectrum (125 MHz, DMSO-D6) of 7.
1H NMR spectrum (600 MHz, DMSO-D6) of 8.
23
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13C NMR spectrum (150 MHz, DMSO-D6) of 8.
1H NMR (500 MHz, CDCl3) spectrum of 9.
24
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13C NMR (150 MHz, CDCl3) spectrum of 9.
1H NMR spectrum (600 MHz, CDCl3) of 10. 
25
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13C NMR spectrum (150 MHz, CDCl3) of 10.
1H NMR spectrum (600 MHz, MeOD) of 11.
26
 

ͨͣ͢
13C NMR spectrum (150 MHz, MeOD) of 11.
27
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